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Abstract 
 
Cell division cycle 7-related Ser/Thr (Cdc7) kinase is conserved and essential 
across eukaryotes. When bound to its activator, dumbbell-forming factor 4 (Dbf4) it 
phosphorylates a number of target proteins involved in various aspects of the cell 
cycle, including replication initiation, meiosis, the intra S-phase checkpoint, the 
DNA damage response and mitotic exit. Cdc7 is overexpressed in a number of 
cancers and expression correlates with patient prognosis. Selective inhibition of 
Cdc7 leads to cell death through an aberrant S-phase in transformed cells, while 
healthy fibroblasts are able to survive such treatments. Therefore, Cdc7 is an 
attractive target for cancer therapeutics, and high-resolution structural information 
could be very informative for the development of small molecule inhibitors.  
 
Herein, I present crystal structures of a fully active Cdc7-Dbf4 heterodimeric 
construct bound to a potent Cdc7 inhibitor, a non-hydrolysable ATP analogue and 
an Mcm2-derived substrate peptide. These structures, refined to a high resolution, 
reveal a previously unseen Zn-binding domain that supports a fully open 
conformation of the active site. The structures also reveal features required for 
substrate binding and phosphorylation. In vitro assays have been employed to 
validate the functional significance of these features, and an in cellula system 
developed to investigate their importance in the cell. The new structural and 
functional information gained from this study will inform the design of small 
molecule inhibitors of Cdc7 while the cell-based system opens up new ways of 
addressing the functions of the unique kinase insert sequences of Cdc7. 
 4 
 
Acknowledgement 
 
I would firstly like to thank my supervisor, Dr. Peter Cherepanov for the opportunity 
to spend the last four years working on such a technically diverse and interesting 
project and for his support and guidance throughout. I would also like to thank my 
thesis committee Dr. John Diffley and Dr. Alessandro Costa for their input and 
useful discussion of my work.  A special thanks also goes to John for allowing me 
to use his illustrator files for production of the origin licensing and origin firing 
figures in this thesis. A number of people from the many wonderful core facilities I 
have had at my disposal throughout my PhD have contributed to this thesis, 
including Nicola O’Reilly and the peptide synthesis lab, without whom much of this 
project would not have been possible. I would also like to thank the cell services 
team and the FACS facility for supplying me with cells and advising me on a 
number of experiments that were integral to the outcome of this project. I would 
also like to thank Vesela Encheva of the proteomics facility who helped in the 
design and analysis of a number of mass spectrometry experiments. David Bacon 
and Corella also provided helpful feedback and advice on the content and 
construction of this thesis. I would also like to give a huge thank you to all of the lab 
aids and support staff at Clare Hall and the Crick for supporting me in my work and 
allowing me to purely focus on science. 
 
I have been very fortunate in my time as a PhD student to find myself surrounded 
by a close-knit group of incredibly friendly and talented scientists. I would 
particularly like to thank all members past and present of the Chromatin Structure 
and Mobile DNA lab. Special thanks must go to Siobhan for giving me a crash 
course in all things Cdc7 and making me feel so welcome in my first few months at 
Clare Hall. I would also like to thank Val for her seemingly endless patience when 
teaching me the fundamentals of crystallography and navigating Linux systems. 
Special thanks must also go to Nicola, without whom I’m fairly certain the whole lab 
would fall apart. Paul and Dan also provided endless entertainment and support, 
which kept me sane and made my time in the lab all the more enjoyable. 
 
 5 
 
A special mention must also go to my fellow PhD students Paolo, Aga, Melisa, and 
Kortyna, with whom I survived Chandos Avenue and Clare Hall. I’m pretty sure we 
can now survive anything! I would also like to thank Diana for being a constant 
source of positivity at Clare Hall and for the many lifts home she gave me in her 
frankly terrifying car! 
 
Outside of the lab I have been lucky to meet a number of friends who have grown 
to become family. With them I have done countless things that I would never have 
previously thought possible. Their constant support and friendship have made 
these years some of the best of my life. While there are far too many names to 
mention, special thanks must go to Joe, Colin, Kealan, Jackie and Matthew. As well 
as Brook for organising my social life for several years and making my time in 
London relentlessly fun. I would also like to thank Khalid, not only for his 
encyclopaedic knowledge of DNA replication, but also for introducing me to the 
London Frontrunners and the many friends I have made through the group. If I had 
known joining a running club could have such a positive influence on my life, I 
would have done it years ago! 
 
Most of all I would like to thank my family for their constant love and support.  My 
sisters Kelly and Holy, for keeping me grounded during my time in London. My 
father, Graham, for teaching me to always aim high and experience as much of the 
world as possible and my mother Diane, for her love, support and courage in the 
face of adversity, which has always been a constant source of inspiration. All of my 
achievements, including this PhD, stem from the great start in life and total support 
they have given me.  I cannot say thank you enough! 
 
 6 
 
Table of Contents 
 
Abstract ................................................................................................................ 3	
Acknowledgement ............................................................................................... 4	
Table of Contents ................................................................................................ 6	
Table of figures .................................................................................................. 10	
List of tables ....................................................................................................... 13	
Abbreviations ..................................................................................................... 14	
Chapter 1.	 Introduction ................................................................................... 18	
1.1	 Overview of eukaryotic protein kinases .............................................. 18	
1.1.1	 Kinase function .................................................................................. 20	
1.1.2	 Conserved structural features of kinases .......................................... 21	
1.1.3	 Mechanism of phospho-transfer ........................................................ 25	
1.1.4	 Kinase substrate recognition ............................................................. 27	
1.2	 DNA replication ...................................................................................... 29	
1.2.1	 Regulation of DNA replication ............................................................ 29	
1.2.2	 Origin licensing .................................................................................. 30	
1.2.3	 Origin firing ........................................................................................ 34	
1.2.4	 The role of kinases in the regulation of DNA replication .................... 38	
1.2.5	 Key differences between yeast and human systems in origin loading 
and firing ....................................................................................................... 41	
1.3	 Cdc7-Dbf4 ............................................................................................... 44	
1.3.1	 Regulation of Cdc7-Dbf4 ................................................................... 45	
1.3.2	 Key differences in Cdc7 regulation in yeast and human systems ..... 47	
1.3.3	 Structural organisation of Cdc7-Dbf4 ................................................. 48	
1.4	 Other roles of Cdc7-Dbf4 ....................................................................... 54	
1.4.1	 The role of Cdc7 in replication stress ................................................ 54	
1.4.2	 The role of Cdc7 in Meiosis ............................................................... 56	
1.4.3	 The role of Cdc7 in chromosome cohesion ....................................... 58	
1.4.4	 The role of Cdc7 in mitotic exit .......................................................... 59	
1.4.5	 The role of Cdc7-Drf1 ........................................................................ 59	
1.5	 Cdc7-Dbf4 and cancer ........................................................................... 60	
1.6	 Crystal structure of a minimally active Cdc7-Dbf4 construct ............ 61	
1.7	 Project aims ............................................................................................ 68	
Chapter 2.	 Materials & Methods ..................................................................... 69	
2.1	 General methods for DNA plasmid construction ................................ 69	
2.1.1	 Polymerase chain reaction (PCR) for amplification of DNA ............... 69	
2.1.2	 Overlap-extension (splice) PCR ........................................................ 69	
2.1.3	 DNA purification from agarose gels ................................................... 70	
2.1.4	 DNA digestion for plasmid construction ............................................. 70	
2.1.5	 DNA ligation ....................................................................................... 70	
2.1.6	 Transformation of chemically competent E.coli cells ......................... 71	
2.1.7	 Colony-PCR ....................................................................................... 71	
2.1.8	 Small-scale preparation of plasmid DNA (miniprep) .......................... 72	
2.1.9	 Large-scale preparation of plasmid DNA (maxiprep) ......................... 72	
2.2	 DNA constructs ...................................................................................... 73	
 7 
 
2.2.1	 Constructs for bacterial expression of Cdc7-Dbf4 and Cdc7-Drf1 
heterodimers ................................................................................................. 73	
2.2.2	 Lentiviral and retroviral constructs for expression of Cdc7 in human 
cells 76	
2.3	 Cell lines ................................................................................................. 79	
2.3.1	 Transduction of human cells with lenti- and retroviral vector particles79	
2.3.2	 Disruption of endogenous CDC7 alleles using the CRISPR/Cas9 
system….. ..................................................................................................... 80	
2.3.3	 Transgene excision from the conditional knockout cell line for cell 
cycle assays ................................................................................................. 81	
2.4	 Protein analyses ..................................................................................... 81	
2.4.1	 Sodium dodecyl sulphate – polyacrylamide gel electrophoresis 
(SDS-PAGE) ................................................................................................. 81	
2.4.2	 Coomassie staining ........................................................................... 82	
2.4.3	 Western blotting ................................................................................. 82	
2.4.4	 Production and purification of Cdc7-Dbf4 and Cdc7-Drf1 constructs 84	
2.4.5	 Crystal screens .................................................................................. 86	
2.4.6	 Synthesis of ATPγS conjugated peptides .......................................... 86	
2.4.7	 In vitro kinase assays ........................................................................ 88	
2.5	 Cell cycle analysis using flow cytometry ............................................ 90	
2.6	 X-ray crystallography methods and theory ......................................... 91	
2.6.1	 Production of protein crystals ............................................................ 91	
2.6.2	 Data collection and processing .......................................................... 94	
2.6.3	 Structure refinement and model building ........................................... 98	
Chapter 3.	 Results 1 – Design, production and activity of Cdc7-Dbf4 and 
Cdc7-Drf1 constructs ...................................................................................... 102	
3.1	 Aims ...................................................................................................... 102	
3.2	 Rationale for design of Cdc7 constructs with improved levels of 
activity ........................................................................................................... 102	
3.3	 Expression and purification of Cdc7-Dbf4 and Cdc7-Drf1 
complexes ..................................................................................................... 106	
3.3.1	 Dephosphorylation of recombinant Cdc7-Dbf4 leads to a substantial 
increase in activity ...................................................................................... 108	
3.4	 Optimisation of Cdc7-Dbf4 constructs for crystallography ............. 108	
3.4.1	 Achieving wild type activity by adding residues into KI2 .................. 108	
3.4.2	 Invariant cysteine residues in KI2 are essential for kinase activity in 
vitro 109	
3.4.3	 Zn2+ increases the activity of recombinant Cdc7 .............................. 111	
3.4.4	 Optimisation of KI3 .......................................................................... 111	
3.4.5	 Reducing the MC fragment of Dbf4 drastically reduces Dbf4 
expression .................................................................................................. 112	
3.4.6	 Co-expression of Cdc7 with Drf1 ..................................................... 112	
3.4.7	 Optimisation of bound nucleotide .................................................... 115	
3.5	 Conclusions .......................................................................................... 116	
Chapter 4.	 Results 2 – Crystallisation of a minimal Cdc7-Dbf4 construct 
bound to XL413 and ADP-BeF3- ...................................................................... 118	
4.1	 Aims ...................................................................................................... 118	
 8 
 
4.2	 Crystal screens, optimisation and freezing of Cdc7(ΔN/2aq/3e)-
Dbf4(MC)XL413 ................................................................................................ 119	
4.2.1	 Initial screening of kinase complexes .............................................. 119	
4.2.2	 Crystallisation of Cdc7(ΔN/2o/3e)-Dbf4(MC)AMP-PNP ........................ 120	
4.2.3	 Optimisation of Cdc7(ΔN/2aq/3e)-Dbf4(MC)XL413 crystallisation ...... 120	
4.2.4	 Optimisation of cryo conditions ........................................................ 121	
4.3	 Data collection and structure refinement of Cdc7(ΔN/2aq/3e)-
Dbf4(MC)XL413 ................................................................................................ 122	
4.3.1	 Data collection ................................................................................. 122	
Data processing and structural refinement ..... Error! Bookmark not defined.	
4.4	 The structure of Cdc7(ΔN/2aq/3e)-Dbf4(MC)XL413 .............................. 125	
4.4.1	 A novel zinc binding domain is present in KI2 ................................. 125	
4.4.2	 The Cdc7 KI2 Zn binding domain interacts with motif-M of Dbf4 
resulting in full ordering of the activation segment ..................................... 126	
4.4.3	 Comparison of ΔN/2aq/3e-MC to the previous structure ................. 129	
4.4.4	 Comparison with a peptide bound PKA structure highlights Cdc7 
residues potentially involved in substrate binding ...................................... 131	
4.5	 Crystallisation and crystal screen optimisation of the ADP-BeF3- 
bound Cdc7-Dbf4 complex .......................................................................... 134	
4.5.1	 Crystallisation of Cdc7(ΔN/2aq/3e)-Dbf4(MC)ADP-BeF3 ..................... 134	
4.5.2	 Optimisation of cryo conditions for Cdc7(ΔN/2aq/3e)-Dbf4(MC)ADP-
BeF3 135	
4.6	 X-ray data collection and refinement of the Cdc7(ΔN/2aq/3e)-
Dbf4(MC)ADP-BeF3  structure .......................................................................... 136	
4.6.1	 Data Collection ................................................................................ 136	
4.6.2	 Data processing and structural refinement ...................................... 137	
4.7	 Structure of (ΔN/2aq/3e)-Dbf4 (MC)ADP-BeF3 ........................................ 137	
4.7.1	 Overall architecture of (ΔN/2aq/3e)-Dbf4 (MC)ADP-BeF3 .................... 137	
4.7.2	 Active site of Cdc7 (ΔN/2aq/3e)-Dbf4 (MC)ADP-BeF3 ......................... 138	
4.8	 Conclusions .......................................................................................... 139	
Chapter 5.	 Results 3 – Crystallisation of a Cdc7-Dbf4 heterodimer in 
complex with an ATPγS-conjugated peptide ................................................ 141	
5.1	 Aims ...................................................................................................... 141	
5.2	 Identification and optimisation of Cdc7 substrate peptides ............ 141	
5.2.1	 Peptide arrays of the N-terminal tails of Mcm2, 4 and 6 highlight 
numerous potential Cdc7 phosphorylation sites ......................................... 142	
5.3	 Production of complexes of peptides with Cdc7 (ΔN/2aq/3e)-Dbf4 
(MC) 145	
5.3.1	 Crystal screening of transition complexes using peptides with ADP-
AlF4- and ADP-BeF3- ................................................................................... 145	
5.3.2	 Design and production of ATPγS conjugated peptides. .................. 146	
5.4	 Crystal screens optimisation and freezing of (ΔN/2aq/3e)-Dbf4 (MC) 
ATPγS-Mcm2-S40(15) ............................................................................................... 147	
5.4.1	 Cryo-condition optimisation for data collection ................................ 148	
5.5	 Data collection and structure refinement of Cdc7 (ΔN/2aq/3e)-
Dbf4(MC) ATPγS-Mcm2-S40(15) .............................................................................. 148	
5.5.1	 Data collection for Cdc7 (ΔN/2aq/3e)-Dbf4 (MC) ATγS-Mcm2-S40(15) ..... 148	
5.5.2	 Structure refinement of Cdc7 (ΔN/2aq/3e)-Dbf4 (MC) ATPγS-Mcm2-S40(15)149	
 9 
 
5.6	 Structure of (ΔN/2aq/3e)-Dbf4 (MC) ATPγS-Mcm2-S40(15) .......................... 151	
5.6.1	 Substrate binds in the peptide-binding platform created by the Zn 
binding domain in Cdc7 .............................................................................. 151	
5.6.2	 Arg373 and Arg380 interact with the pre-phosphorylated serine of 
the peptide required for substrate specificity .............................................. 154	
5.6.3	 Cdc7 contains a binding pocket for the P+4 residue of the target 
suggesting a co-evolution with CDK2 ......................................................... 155	
5.6.4	 A possible role for Thr376 in kinase regulation ................................ 157	
5.7	 Conclusions .......................................................................................... 159	
Chapter 6.	 Results 4 - Functional characterisation of Cdc7 mutants in 
cellula using a conditional knockout cell line ............................................... 162	
6.1	 Aims ...................................................................................................... 162	
6.2	 Production of an inducible CDC7 knockout cell line ........................ 162	
6.2.1	 Production of the lentiviral vector containing expressing mCherry-
tagged Cdc7 Cdc7 ...................................................................................... 163	
6.2.2	 Disruption of the endogenous CDC7 alleles in HT1080 mCherry-
Cdc7(LoxP) cells ........................................................................................ 165	
6.2.3	 Expression of FLAG-tagged Cdc7 mutants in CDC7(-/-) mCherry-
Cdc7 cells ................................................................................................... 168	
6.2.4	 Depletion of mCherry-Cdc7 following the treatment of CDC7(-/-) 
mCherry-Cdc7 cells with Ad-GFP-Cre ........................................................ 169	
6.3	 Complementation of cell cycle profiles and Mcm2 phosphorylation 
by mutants of Cdc7 ...................................................................................... 171	
6.3.1	 Cell cycle assay following depletion of mCherry-Cdc7 in the 
conditional knockout cell line ...................................................................... 172	
6.3.2	 Point mutations of the Cdc7 Zn-binding domain, Arg373 or Arg380 
affect Mcm2 phosphorylation and cell cycle progression ........................... 175	
6.3.3	 Deletions in KI2 and KI3 have a minimal affect on Mcm2 
phosphorylation and cell cycle progression ................................................ 179	
6.4	 Conclusions .......................................................................................... 181	
Chapter 7.	 Discussion .................................................................................. 183	
7.1	 Introduction .......................................................................................... 183	
7.2	 Key findings .......................................................................................... 184	
7.2.1	 New insights into the structure of Cdc7-Dbf4 .................................. 184	
7.2.2	 Substrate binding of Cdc7-Dbf4 ....................................................... 184	
7.2.3	 A possible role for Thr376 in kinase regulation ................................ 185	
7.2.4	 Functional importance of Cdc7 KI2 and KI3 .................................... 186	
7.3	 Future directions .................................................................................. 187	
7.3.1	 Structural characterisation of Cdc7-Dbf4 ......................................... 187	
7.3.2	 Phosphorylation as a mechanism of Cdc7-Dbf4 regulation ............. 189	
7.3.3	 Future functional characterisation of Cdc7-Dbf4 ............................. 190	
7.4	 Final conclusions ................................................................................. 191	
Chapter 8.	 Appendix ..................................................................................... 192	
Reference List .................................................................................................. 213	
 10 
 
Table of figures 
 
Figure 1-1 A phylogenetic tree of the protein kinase complement of the human 
genome .................................................................................................................. 19	
Figure 1-2 Main structural features of a protein kinase .......................................... 22	
Figure 1-3 Schematic of the active site of a typcial kinase ..................................... 26	
Figure 1-4 Phases of the cell cycle ........................................................................ 30	
Figure 1-5 A model for the mechanism of origin licensing in S. cerevisiae ............ 32	
Figure 1-6 A model for the mechanism of origin firing in S. Cerevisiae ................. 36	
Figure 1-7 Oscillations of kinase activities during the cell cycle ............................. 38	
Figure 1-8 Schematic of the S. cerevisiae and human Cdc7 and Dbf4 structures . 51	
Figure 1-9 Crystal structure of Cdc7-Dbf4 previously determined in the lab .......... 63	
Figure 1-10 Structure of the Dbf4 motif-C Zn-binding site and its interaction with αC
 ................................................................................................................................ 64	
Figure 1-11 Binding of inhibitors to Cdc7-Dbf4 ...................................................... 67	
Figure 2-1 Plasmids used for expression of Cdc7 and Dbf4/Drf1 constructs for 
expression in bacteria ............................................................................................ 75	
Figure 2-2 Plasmids used for lentivirus and retrovirus production for expression of 
Cdc7 constructs in mammalian cells ...................................................................... 78	
Figure 2-3 Crystallisation by vapour diffusion ........................................................ 92	
Figure 3-1 View of the Cdc7 active  site in the  crystal structure solved by Hughes 
et al. (2012) .......................................................................................................... 104	
Figure 3-2 Example purification of a Cdc7-Dbf4 deletion construct ..................... 107	
Figure 3-3 Comparison of recombinant kinase activity with different KI2 deletions
 .............................................................................................................................. 109	
Figure 3-4 Sequence alignment of metazoan orthologues of Cdc7 ..................... 110	
Figure 3-5 Kinase activity of mutants of invariant cysteine residues .................... 110	
Figure 3-6 Comparison of recombinant kinase activity with different KI2 deletions
 .............................................................................................................................. 112	
Figure 3-7 Example purification of  the Cdc7(ΔN/2aq/3e)-Drf1 (211-345) construct
 .............................................................................................................................. 114	
Figure 3-8 Activities of Cdc7(ΔN/2aq/3e) bound fragments of Drf1 compared to 
Cdc7(ΔN)-Dbf4(MC) and Cdc7(ΔN/2aq/3e)-Dbf4(MC) ........................................ 115	
 11 
 
Figure 4-1 Crystals of Cdc7(ΔN/2o/3e)-Dbf4 (MC) grown in the presence of AMP-
PNP ...................................................................................................................... 120	
Figure 4-2 Crystals of Cdc7(ΔN/2aq/3e)-Dbf4 (MC) grown in the presence of XL413
 .............................................................................................................................. 121	
Figure 4-3 A sample X-ray diffraction pattern from a crystal of Cdc7(ΔN/2aq/3e)-
Dbf4 (MC)XL413 ...................................................................................................... 122	
Figure 4-4 Overall structure of the ΔN/2aq/3e-MC construct of Cdc7-Dbf4 bound to 
XL413 ................................................................................................................... 127	
Figure 4-5 Zinc binding domains in Cdc7 KI2 (A) and Dbf4-C (B) ....................... 128	
Figure 4-6 Overall structure of the ΔN/2aq/3e-MC construct of Cdc7-Dbf4 
superimposed on the previously crystallised structure ......................................... 130	
Figure 4-7 Close up of the active site of Cdc7(ΔN/2aq/3e)-Dbf4(MC) superposed 
on the published structure. ................................................................................... 131	
Figure 4-8 A model for Cdc7-substrate interaction ............................................... 132	
Figure 4-9 Arg373 and Arg380 are essential for Cdc7 activity in vitro ................. 133	
Figure 4-10 Crystals of Cdc7(ΔN/2aq/3e)-Dbf4(MC)ADP-BeF3grown in the presence of 
ADP-BeF3- ............................................................................................................ 135	
Figure 4-11 A sample X-ray diffraction image from a crystal of Cdc7(ΔN/2aq/3e)-
Dbf4 (MC)ADP-BeF3 .................................................................................................. 136	
Figure 4-12 Active site of Cdc7-Dbf4 in complex with ADP-BeF3- ........................ 138	
Figure 5-1 A peptide array kinase assay revealed a number of potential target sites 
for Cdc7-Dbf4 ....................................................................................................... 143	
Figure 5-2 Generalised structure of a bi-substrate inhibitor peptide .................... 146	
Figure 5-3 Optimised crystals of Cdc7 (ΔN/2aq/3e)-Dbf4 (MC) grown in the 
presence of ATPγS-Mcm2-S40(15). ..................................................................... 147	
Figure 5-4 A sample X-ray diffraction pattern collected from a crystal of 
(ΔN/2aq/3e)-Dbf4(MC) ATPΥS-Mcm2-S40(15) ................................................................. 149	
Figure 5-5 Overall structure of Cdc7-Dbf4 bound to ATPγS-Mcm2-S40(15) ....... 152	
Figure 5-6 Electron density reveals successful substrate binding ........................ 153	
Figure 5-7 The structure confirms the recognition of the P+1 residue by Cdc7 
Arg373 and Arg380 and suggests a possible role for Thr376 .............................. 154	
Figure 5-8 An arginine binding pocket allows for favourable interactions between 
the P+4 residue of the peptide and Cdc7-Dbf4. ................................................... 156	
 12 
 
Figure 5-9 Arg44 of Mcm2 is not essential for phosphorylation of Ser41 by Cdc7-
Dbf4 in vitro .......................................................................................................... 157	
Figure 6-1 Expression and depletion of mCherry-Cdc7 in HT1080 cells ............. 164	
Figure 6-2 Identification of a double Cdc7 knockout after transfection of HT1080 
mCherry-Cdc7(LoxP) cells with CRISPR/Cas9 constructs .................................. 167	
Figure 6-4 Expression of FLAG-Cdc7 mutants in CDC7(-/-) mCherry-Cdc7(LoxP) 
cells after infection with pBabe(puro) expression constructs ............................... 169	
Figure 6-5 Removal of mCherry-Cdc7(LoxP) by Cre recombinase ...................... 171	
Figure 6-6 Depletion of mCherry-Cdc7 following infection with Ad-GFP-Cre ....... 172	
Figure 6-7 Cell cycle analysis of CDC7(-/-) mCherry-Cdc7(LoxP) cells  expressing 
WT or kinase dead D196N FLAG-Cdc7 after mCherry-Cdc7 excision ................ 174	
Figure 6-8 Western blot of Mcm2-S40 phosphorylation ....................................... 175	
Figure 6-9 Cell cycle analysis of CDC7(-/-) mCherry-Cdc7(LoxP) cells  expressing 
FLAG-Cdc7 (C353A) infected with Ad-GFP-Cre or Ad-GFP ................................ 177	
Figure 6-10 Cell cycle analysis of CDC7(-/-) mCherry-Cdc7(LoxP) cells expressing 
R380A or R373A/R380A mutants of FLAG-Cdc7 after infection with Ad-GFP-Cre or 
Ad-GFP ................................................................................................................. 178	
Figure 6-11 Cell cycle analysis of CDC7(-/-) mCherry-Cdc7(LoxP) cells  expressing 
Δ2aq orΔ3e deletion mutants of FLAG-Cdc7 after mCherry-Cdc7 excision ........ 180	
Figure 8-2 Amino acid alignments of the motifs-M and C of distal orthologs Dbf4 
orthologs ............................................................................................................... 194	
 
 13 
 
List of tables 
 
Table 2-1 Table of commercially available screens used in this study ................... 86	
Table 3-1 Cdc7, Dbf4 and Drf1 constructs produced for crystallography trials .... 105	
Table 3-2 Table of nucleotide analogues and Cdc7 inhibitors used in 
crystallography trials ............................................................................................. 116	
Table 4-1 Data collection and refinement statistics for Cdc7(ΔN/2aq/3e)-Dbf4(MC) 
bound to XL413 and ADP-BeF3 ............................................................................ 124	
Table 5-1 Table of Cdc7 phosphorylation sites identified using peptide arrays ... 144	
Table 5-2 Table of peptides used for crystallography trials .................................. 144	
Table 5-3 Data collection and refinement statistics for Cdc7(ΔN/2aq/3e)-Dbf4(MC) 
bound to ATPγS-Mcm2-S40(15) .......................................................................... 150	
Table 8-1 Table of plasmids used for protein expression in E.coli. ...................... 196	
Table 8-2 Plasmids used for retrovirus and lentivirus production for expression in 
mammalian cells.. ................................................................................................. 199	
Table 8-3 Cell lines produced and used as part of this study. .............................. 202	
Table 8-4 Oligos used in this study. ..................................................................... 205	
Table 8-5 Peptides used in in vitro kinase assays ............................................... 211	
 
 14 
 
 Abbreviations 
 
ACN   acetonitrile 
ADP   adenosine 5’-diphosphate 
AMP-PCP   β,γ-methyleneadenosine 5′-triphosphate 
AMP-PNP   Adenosine 5′-(β,γ-imido)triphosphate 
APC/C  anaphase promoting complex/ cyclosome 
APS   ammonium persulphate 
ARS    autonomously replicating sequence 
ASK   activator of S-phase kinase   
ATP   adenosine 5’-triphosphate 
ATPγS  adenosine 5’-O-(3-thio)triphosphate 
ATR   ataxia telangiectasia and Rad3 related 
BCA   bicinchoninic acid 
BME             β-mercaptoethanol 
bp   base pairs 
BRCA1                      breast cancer 1 
BRCT   BRCA1 C-terminus 
BSA   bovine serum albumin 
Cas9   CRISP associated endolnuclease  
CCD   charge coupled device 
Cdc   cell division cycle 
CDK   cyclin-dependent kinase 
Cdt   Cdc10 dependent transcript 
Chk1   checkpoint kinase 1 
Clb   cyclin B 
CMG   Cdc45-MCM-GINS complex 
CRISPR  clustered regularly interspaced short palindromic repeats 
Csm3   chromosome segregation in meiosis 3 
Dfp1  Dbf in pombe 1 
DMEM  Dulbecco’ modified Eagle’s medium 
Cryo-EM  cryo-electron microscopy 
Erk                        extracellular signal–regulated kinase 
 15 
 
ES cells        embryonic stem cells 
Dbf   dumbbell former 
DCM   dichloromethane 
DDK   Dbf4-dependent kinase 
DIC   diisopropylcarbodiimide 
DMF                        dimethylformamide 
DNA   deoxyribonucleic acid 
dNTP   deoxynucleoside triphosphate 
Dpb   DNA polymerase B possible subunit 
Drf1   Dbf4-related factor 1 (aka Dbf4B) 
DSB      double strand break 
dsDNA  double stranded DNA 
DTT   dithiothreitol 
EDTA   ethylenediaminetetraacetic acid 
eIF   eukaryotic initiation factor 
EM   electron microscopy 
FACS   fluorescence associated cell sorting 
FBS                         foetal bovine serum 
FL   full-length 
GF   gel filtration 
GFP   green fluorescent protein 
Gwl             greatwall kinase 
GINS   go, ichii, ni, san complex 
Him1   Hsk interacting molecule 1 
His6   hexahistidine tag 
HP1   heterochromatin protein 1 
HRP   horseradish peroxidase 
HRV14   human rhinovirus 14  
HU   hydroxyurea 
IPTG   isopropyl beta-D-1-thiogalactopyranoside 
IRK                           insulin receptor kinase 
Kb   kilobase 
KI   kinase insert 
LC-MS  liquid chromatography-mass spectrometry 
 16 
 
MAPK   mitogen activated protein kinase 
Mcm   minichromosome maintenance 
MEF   mouse embryonic fibroblast  
MEN    mitotic exit network  
Mer2    meiotic recombination protein 2  
mRNA                      messenger ribonucleic acid 
MW   molecular weight 
NCMR   non-conserved middle region 
NES   nuclear export sequence 
NLS   nuclear localisation signal 
NP40   Nonidet P40 
NRS   nuclear retention sequence 
NTP   nucleoside triphosphate 
OCM   ORC-Cdc6-MCM 
OCCM  ORC/Cdc6/Cdt1/MCM 
ORC   origin recognition complex 
PAGE    polyacrylamide gel electrophoresis 
PBD               polo box domain 
PBS   phosphate buffered saline 
PCNA   proliferating cell nuclear antigen 
PCR          polymerase chain reaction 
PEG   polyethylene glycol 
PES   polyethersulfone 
PFU plaque-forming unit 
PK                             protein kinase 
PMSF   phenylmethylsulfonyl fluoride 
Pol   polymerase 
PP1   protein phosphatase 1 
PP2A   protein phosphatase 2A 
pre-IC   pre-initiation complex 
pre-LC  pre-loading complex 
pre-RC  pre-replicative complex 
Psf   partner of Sld5 
PVDF   polyvinylidene fluoride 
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RecQL  RecQ protein-like 
Rfm1    repression factor of MSEs protein 1 
Rif1   Rap-interacting factor 1  
RIPA               radioimmunoprecipitation assay  
RPA   replication protein A 
RPC   replication progression complex 
rpm   revolutions per minute 
Scc2   sister chromatid cohesion protein 2 
SDS         sodium dodecyl sulphate  
Sld   synthetically lethal with dpbb11-1 
ssDNA  single stranded DNA 
Sum1    suppressor of mar 1-1  
TEMED   tetramethylethylenediamine 
TFA    trifluoroacetic acid 
TGS     Tris-glycine-SDS buffer 
TICRR       TopBP1-interacting checkpoint and replication regulator 
TIS                   triisopropylsilane 
TLS   translesion synthesis 
Tof   topoisomerase I associated factor 
TopBP  topoisomerase II binding protein 
WT   wild-type 
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Chapter 1. Introduction 
 
1.1 Overview of eukaryotic protein kinases 
The protein kinase complement of the human genome, also known as the kinome, 
represents a large and functionally diverse collection of proteins. The group 
consists of 538 different genes which corresponds to approximately 1.7% of all 
expressed genes in the genome (Manning et al., 2002). This large group can be 
divided into a number of related groups based upon their sequence similarity with 
478 of these forming a single family with highly conserved sequences required for 
the catalytic activity of the kinase. This group can then be further divided into 7 
groups (Figure 1.1). A further 40 kinases belong to an atypical group which are 
predicted to have similar folding to a typical kinase but are more divergent in their 
sequence (Manning et al., 2002). Cdc7, the focus of this study, belongs to the 
CMGC family of kinases. This group is comprised of 9 highly conserved kinase 
families, most notably the mitogen activated protein kinases (MAPKs) and the 
cyclin dependent kinases (CDKs), which play integral roles in the cells response to 
external stimuli and progression through the cell cycle respectively (Schaeffer and 
Weber, 1999, Malumbres, 2014). Even within the CMGC group, the structure of the 
kinases vary widely with CDKs being characterised by the requirement of a cyclin 
for activation of the kinase while MAPKs such as ERK2 are monomeric and can 
therefore activate without the binding of an accessory protein (Canagarajah et al., 
1997). CMGC kinases are often proline directed, requiring a proline residue in the 
P+1 site of the target sequence, although this feature is not strictly conserved 
across the entire group of kinases (Echalier et al., 2010). This vast number of 
structurally diverse kinases allows them to be involved in nearly all aspects of 
cellular biology including but not limited to cell cycle progression, transcription, 
translation and metabolism despite all catalysing the same reaction. 
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Figure 1-1 A phylogenetic tree of the protein kinase complement of the human 
genome 
(Manning et al, 2002) The position of Cdc7 is circled. 
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1.1.1 Kinase function 
The core catalytic function of a kinase is the transfer of a phosphoryl group (the γ-
phosphate of ATP) to a phosphor-acceptor. In the case of protein kinases this 
acceptor is a serine, threonine or tyrosine residue in a target protein. Typically 
kinases are either serine/threonine specific or tyrosine specific in terms of their 
preferred target sites. A small group of dual specificity kinases have also been 
identified which can phosphorylate any of the possible target residues (Lindberg et 
al., 1992). Phosphorylation represents the most abundant and arguably most 
important post-translational modifications in the cell (Sefton and Shenolikar, 2001). 
Addition of phosphoryl groups to target proteins can lead to a number of outcomes 
including; the activation or inhibition of enzymatic activities, the localisation of 
proteins to specific cellular compartments, the creation of binding sites for protein-
protein interactions as well as the stabilisation of proteins or marking them for 
subsequent degradation. Consequently kinases are involved in almost all aspects 
of cellular function (Cohen, 2002).   
 
In a typical catalytic cycle, the kinase binds to the nucleotide (ATP) and any 
required divalent metal ions before binding the target substrate. The interaction 
between a kinase and its substrate is often fairly transient to facilitate the 
immediate release of the target protein once the phosphoryl transfer has 
successfully taken place. The nucleotide is then released and it is the release of 
the nucleotide which is often the rate limiting step of the reaction (Adams, 2001). 
However, further studies have suggested that the concentration of divalent metals 
utilised for catalysis can also be rate limiting. An example of this is CDK2, for which 
two magnesium ions are required for efficient phosphoryl transfer. However, 
binding of the second magnesium stabilises the binding of ADP after the reaction 
takes place, leading to a slower turnover rate for the reaction (Jacobsen et al., 
2012). It is clear that the various factors that can affect kinase activity have been 
fine tuned throughout evolution to strike a balance between efficiency of phosphoryl 
transfer and the turnover of the kinase. In the final stage of the reaction, ADP is 
released from the active site, allowing the kinase to become competent for a new 
cycle of catalysis. 
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1.1.2 Conserved structural features of kinases 
Despite their diverse structures and targets, kinases all possess a number of core 
structural features required to facilitate catalysis (Figure 1.2). The structural basis 
for the importance of such features was first shown by the crystal structure of PKA 
in complex with a peptide inhibitor and ATP, closely followed two years later by the 
first crystal structure of CDK2 (Knighton et al., 1991a, Knighton et al., 1991b, De 
Bondt et al., 1993). Countless structures of other kinases have since confirmed the 
essential nature of a number of these features, and structures of kinases in various 
active and inactive conformations have revealed the numerous conformational 
changes and post-translational modifications required for successful kinase 
activation (Endicott et al., 2012). Kinases typically appear most similar to each 
other in their ‘on’ state and a greater degree of conformational plasticity is observed 
prior to their activation in which the active site does not have to be correctly formed 
for catalysis (Huse and Kuriyan, 2002). 
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Figure 1-2 Main structural features of a protein kinase 
Schematic of protein kinase A is shown as a carton in pale cyan with key structural 
features highlighted (PDB: 1ATP). ATP is shown as pink sticks and Mn2+ atom are 
shown as grey spheres. Secondary structural elements are labelled from N to C 
terminus. The P-loop is shown in orange, the DFG and APE motifs (which define 
the start and finish of the activation loop) are highlighted in red and purple 
respectively with the activation loop in yellow. The HRD motif is shown in blue. Key 
residues involved in catalysis are shown as sticks including the invariant K72 and 
E91 residues, which form a critical salt bridge and are shown in magenta. D166 
represents the catalytic base for catalysis. All non-carbon atoms are shown in 
standard colouration. 
 
A typical kinase has a bi-lobal architecture with the active site present in a deep 
cleft between the two lobes. The N-terminal lobe is predominantly comprised of a 
5-strand β-sheet and a critical α-helix involved in kinase regulation. The C-lobe 
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tends to be larger than the N-lobe and is comprised predominantly from α-helices. 
The two lobes are connected by a short hinge region which, as well as allowing the 
two lobes to rotate with respect to each other, makes important interactions with 
the adenosine base of ATP during nucleotide binding. The correct orientation of the 
lobes is required for activation of the kinase as this allows for the correct formation 
of the active site at the cleft. This can be achieved through interactions with 
regulatory proteins such as cyclins or even by N-or C-terminal extensions of the 
kinase, as seen with AGC kinases in response to phosphorylation events (Jeffrey 
et al., 1995, Canagarajah et al., 1997, Kannan et al., 2008). 
 
Key features of the N-lobe include the P-loop and the α C-helix. The P-loop is a 
short loop that connects the β1 and β2 strands of the N-lobe. The region is glycine 
rich, typically containing three glycine residues, This loop forms the upper region of 
the ATP binding site and backbone interactions between the P-loop and the α, β 
and γ phosphates positions the phosphates in the correct orientation for phospho-
transfer as well as promoting ADP release and subsequent binding of ATP after 
catalysis (Kornev and Taylor, 2010, Taylor and Kornev, 2011). The conformation of 
this loop is indicative of the activation state of the kinase, as alternative 
conformations prevent the efficient binding of ATP. Phosphorylation of the P-loop 
can also be used to prevent kinase activity as a means of regulation (Morgan, 
1995). The αC-helix is often the only α-helix present in the N-lobe and plays a 
critical role in kinase activation. A key conformational change during kinase 
activation is the movement of this helix towards the active site, facilitating the 
formation of a critical salt bridge between and invariant glutamate residue in the 
helix and a lysine side chain present in the β3 strand. This lysine is also part of a 
conserved motif termed the AxK motif. This not only stabilises the correct 
positioning of a number of structural features required for catalysis, but also allows 
the Glu and Lys residue to coordinate the α and β phosphates of ATP in the correct 
orientation for catalysis. Such movement of the αC-helix as a method of kinase 
activation has been shown in a number of kinase structures (Jeffrey et al., 1995, 
Yang et al., 2002, Bayliss et al., 2003, Sessa et al., 2005, Taylor and Kornev, 2011, 
Hughes et al., 2012). In the inactive conformation, movement of the helix out of the 
active site prevents slat bridge formation and subsequent phospho-transfer. 
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The C-lobe is typically much larger than the N-lobe and is predominantly made up 
of α-helices and 4 short β-strands. Loops between these strands have structural 
significance. The loop between β6 and β7 contains an HRD motif in which the Asp 
residue is the catalytic base which accepts a proton from the target Ser/Thr during 
phospho-transfer. This loop is known as the catalytic loop. The loop between β8 
and β9 of the kinase is called the activation segment, which spans from the 
conserved DFG motif to the APE motif. This region can vary quite significantly 
between kinases in length and sequence. A number of kinases have significant 
insert sequences in this region, the functions of which are poorly understood and 
are difficult to elucidate through structural studies (Nolen et al., 2004, Hughes et al., 
2012, Ocasio et al., 2016). The activation segment is found between the N and C-
lobes of the kinase and despite the extensive differences across kinases, the 
conformation of this region is essential to its efficient activation. The segment often 
contributes to the formation of a substrate-binding platform required for substrate 
recognition. The activation loop is also often the site of phosphorylation events with 
a number of kinases containing a critical threonine residue that must be 
phosphorylated for kinase activation. This phosphorylated residue forms part of a 
charged bond network, which often includes the arginine of the HRD motif and a 
positively charged residue from the αC-helix. This stabilises the correct active site 
conformation for phospho-transfer (Adams, 2003).   Adjacent to the 
phosphorylation site is the P+1 loop, which is thought to stabilise the residue in the 
in P+1 position of the target site to ensure correct orientation of the substrate for 
phospho-transfer. The DFG and APE motifs that flank the activation segment are 
also highly conserved, with the DFG motif playing a particularly important role in 
kinase activity. The aspartate residue of this motif directly coordinates one of the 
metal ions required for catalysis while the phenylalanine binds in a pocket, which 
forms part of one of the hydrophobic spines of the kinase. The location of this 
conserved phenylalanine residue is a reliable indicator of whether the kinase is in 
an active conformation when the kinase has a ‘DFG-in’ conformation (Treiber and 
Shah, 2013).  
 
An important result of conformational changes achieved through kinase activation 
is the formation of the catalytic and regulatory spines of the kinase. These two 
spines are highly conserved across a large number of kinase structures and were 
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identified by local spatial pattern alignment. The spines consist of a number of 
residues that make hydrophobic stacking interactions, which span the N and C 
lobes of the kinase. Both spines are anchored to the αF-helix. In the case of the 
regulatory spine, this is achieved through the formation of a salt bridge between a 
highly conserved aspartate residue and the histidine residue of the HRD motif. A 
number of conserved hydrophobic residues from both the N and C lobes also 
contribute to the spine including the phenylalanine of the DFG motif. The ‘DFG-in’ 
conformation ascribed to active kinases involves the phenylalnine being correctly 
positioned to complete the regulatory spine. Inactive kinases will often adopt a 
‘DFG-out’ conformation in which the spine is not correctly formed (Kornev et al., 
2008, Treiber and Shah, 2013).  The catalytic spine is similarly formed of a number 
of conserved hydrophobic residues anchored to the αF-helix including the alanine 
from the previously described AxK motif. The Catalytic spine also includes the 
adenine ring of the ATP as part of the stacking interactions. The identification of 
these integral spines has shed some light on how mutations far from the active site 
are able to influence nucleotide affinity in kinases (Kornev et al., 2008). 
 
1.1.3 Mechanism of phospho-transfer 
 
The process of phospho-transfer can be achieved through two different 
mechanisms termed associative and dissociative pathways. The most common 
pathway involves the formation of a dissociative transition state in which the bond 
between the β and γ-phosphate of ATP is broken prior to the formation of the bond 
between the phosphoryl group and the target hydroxyl (Adams, 2001). The 
associative pathway involves the formation of a bond between the γ-phosphate and 
the hydroxyl group either prior to, or at the same time as hydrolysis of the β-γ 
phosphate bond.  
 
The critical residues for catalysis can be seen in Figure 1-3 utilising the active site 
of PKA as an example (Adams, 2001). The dissociative reaction involves 
nucleophillic attack of the hydroxyl group of the substrate with aspartate of the HRD 
motif acting as a catalytic base to allow for transfer of the phosphoryl group to the 
Chapter 1 Introduction 
26 
 
target hydroxyl. The catalytic base (Asp166) coordinates the proton of the target 
hydroxyl group orienting the substrate for nucleophillic attack in which its lone pair 
of electrons is directed through the γ-phosphate to the β-γ bond. This breaks the 
bond between the γ phosphorous and the bridging oxygen. The negative charge 
created during this reaction is stabilised by the presence of the divalent metal ions, 
which are coordinated by the aspartate of the DFG motif (Asp184) and (in the case 
of PKA) a conserved asparagine residue (Asn 171). The positive charge of a 
conserved lysine residue (Lys168) also contributes to stabilise the γ-phosphate 
leaving group during transfer. The proton from the attacking hydroxyl group is 
simultaneously transferred to the catalytic base (Asp166), which will later be 
removed to facilitate another round of catalysis. 
 
 
Figure 1-3 Schematic of the active site of a typcial kinase 
The shown example is the active site of PKA, taken from Adams, et al. 2001. 
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1.1.4 Kinase substrate recognition 
Kinases vary greatly in the number of targets they are able to phosphorylate in the 
cell and this number can vary over orders of magnitude as demonstrated by 
phosphoproteomics analysis in yeast (Ptacek et al., 2005). The phosphorylation of 
a number of sites in a specific fashion requires kinases to not only be selective but 
to balance the need for a high level of substrate affinity with a requirement to 
maintain a fast turnover of phosphorylation reactions. Rapid mixing experiments 
have shown that the intrinsic affinity of kinases for their substrate is much lower 
than is suggested by affinities measured by steady state kinetic assays. The 
increased affinity between the substrate and kinase is due to a feature of the 
phosphoryl transfer reaction that draws the substrate towards the kinase. This 
method allows for substantial improvements in affinity while also favouring a fast 
turnover of sites after the reaction has occurred (Adams, 2001) 
 
Kinases show poor affinity for free amino acids and rely heavily on flanking 
residues for increased affinity. These local sequence elements are usually only a 
few (typically no more than 4) residues either side of the target site and often define 
a consensus sequence for the kinase for which specific residues determine its 
specificity. Such consensus sequences have been identified for a number of 
kinases and the length and specificity of such sequences varies between them. 
Such optimal sequences have been identified through both manual-screening 
methods in which phosphorylation sites for the kinase are identified and a 
corresponding library of peptides produced. Substitutions at various points in the 
sequence are made and the effect of such substitutions on steady state kinetic 
parameters can be measured. This labour intensive approach can then reveal the 
importance of each residue in the local sequence (Chan et al., 1982, Pearson and 
Kemp, 1991). Alternatively, random library approaches have been used in which all 
possible amino acids, excluding the phosphorylation site (the P site), are altered in 
the sequence and peptide sequencing and statistical methods can then be used to 
select optimal peptides (Luo et al., 1995, Songyang et al., 1995, Lam, 1998). The 
requirements for the consensus of kinases can also be specific to individual groups. 
An example of this is the CMGC group of kinases, many of which as described 
previously are proline-directed kinases that favour a proline residue directly 
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downstream from the target site (Clark-Lewis et al., 1991, Gonzalez et al., 1991, 
Songyang et al., 1996). In some cases an overlap is seen between kinases in in 
vitro assays highlighting the importance of distal recognition elements in dictating 
kinase specificity (Songyang et al., 1994, Nishikawa et al., 1997). 
 
Binding determinants away from the active site play an important role in dictating 
substrate specificity in vivo and many kinases also show an affinity orders of 
magnitude greater for more complete substrates than their corresponding peptides 
in vitro (Hawkins et al., 2000). One such example of a distal recognition element is 
the recruitment peptide of CDK2; this contains an RXL motif, which binds in a 
hydrophobic pocket of CDK2 40 Å away from the target peptide. This increases the 
affinity of the kinase for the peptide (Schulman et al., 1998, Brown et al., 1999b). In 
many cases substrate-docking sites exist as part of the kinase away from the active 
site. Such sites function to increase the local concentration of the substrate through 
an increase in affinity and may serve to activate the kinase allosterically or simply 
correctly orient the target peptide in the active site (Biondi and Nebreda, 2003). 
Docking sites have been identified in a diverse range of kinases including 3-
phosphoinositide dependent kinase 1 (PDK1), mitogen activated protein kinases 
(MAPK) and c-Jun N-terminal kinases (JNK) (Kallunki et al., 1994, Biondi et al., 
2000, Sharrocks et al., 2000). Beyond such docking sites, specificity of kinases can 
also be regulated by large-scale protein-protein interactions as well as through the 
localisation of the kinase in the cell. 
 
Currently very little is known about the substrate specificity of Cdc7. The 
consensus sequence appears to be any residue with a pre-phosphorylated Ser/Thr 
or and acidic residue directly downstream from the target site (in the P+1 position) 
(Montagnoli et al., 2006). As of now the structural basis of this consensus 
sequence is not known and any further requirements for substrate specificity have 
yet to be seen. Understanding how Cdc7 binds to its substrates will form a large 
part of the work in this study. 
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1.2 DNA replication 
An essential function required for the successful survival and growth of any species 
is the ability to faithfully duplicate its genome, allowing the correct genetic 
information to be transferred to the next generation of cells. As part of this process, 
it is important to ensure that the genome is not only correctly duplicated in its 
entirety with minimal mistakes, but is also only replicated once per cell cycle. 
Incorrect replication or over-replication can lead to a number of problems including 
chromosomal instability and rearrangements, which are the driving force for 
tumorigenesis (Arias and Walter, 2007, Blow and Gillespie, 2008). DNA replication 
is therefore regulated at a number of levels to ensure correct duplication in 
eukaryotes, whose genomes are larger and more complex than those of bacteria. 
  
1.2.1 Regulation of DNA replication 
In eukaryotes, replication of DNA is strictly coordinated with progression of the cell 
cycle (Figure 1-4). Genome duplication occurs in S-phase and is largely confined to 
this period in the cycle by the relative activities of a number of cell cycle kinases 
and the anaphase promoting complex/cyclosome (APC/C) E3 ubiquitin ligase. Due 
to the size of the genome, replication has to initiate at multiple origins to allow the 
full complement of chromosomes to be replicated in a timely fashion. This is in 
contrast to bacterial replication, which typically initiates from a single origin. DNA 
replication initiation at eukaryotic origins occurs in a two-step mechanism of origin 
licensing followed by origin firing (Blow, 1993, Diffley et al., 1994, Remus and 
Diffley, 2009). Rao and Johnson obtained the first evidence of this two-step 
mechanism in 1970, by performing experiments involving the fusion of mammalian 
cells at different points in the cell cycle. Fusion of a cell in G1 with a cell in S-phase 
led to the initiation of DNA replication in the G1 cell, while fusion of the S-phase cell 
with a cell in G2 had no such effect. This inferred the presence of a specific factor 
in S-phase cells that was required for the initiation of DNA replication (Rao and 
Johnson, 1970). Since this discovery a number of factors have been identified that 
ensure the sequential action of the origin licensing and origin firing steps. These 
factors and their roles in regulating DNA replication are discussed in detail in the 
following sections. 
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Figure 1-4 Phases of the cell cycle 
The cell cycle comprises four distinct phases. In G1, the cell duplicates the 
organelles and proteins required for the production of two daughter cells. If 
successful, the cells progress into S-phase, in which the genome is replicated, 
creating a pair of sister chromatids from each chromosome. In G2, the newly 
replicated chromatids are checked for errors, and the cell prepares to divide. Lastly, 
the cell enters mitosis, during which sister chromatids are separated into two 
nuclei, after which the cytoplasm is split in a process called cytokinesis. This 
process results in the production of two daughter cells. 
 
1.2.2 Origin licensing 
Origin licensing refers to the process that occurs in late mitosis/G1, in which the 
eukaryotic replicative helicase is loaded onto DNA, ready for subsequent 
replication. This heterohexameric helicase, known as the minichromosome 
maintenance 2-7 (Mcm 2-7) complex is responsible for the unwinding of duplex 
DNA to create the single stranded DNA (ssDNA) templates for loading of the 
replicative DNA polymerase and DNA synthesis. This process involves a number of 
factors, which work in sequence to load a pair of Mcm2-7 complexes around 
double stranded DNA (dsDNA) in an inactive form (Remus et al., 2009, Gambus et 
al., 2011).  
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Much of what is known today about origin licensing was determined through a 
reconstituted system for in vitro loading of Mcm2-7 (Evrin et al., 2009, Remus et al., 
2009). The first stage in licensing involves the binding of the origin recognition 
complex (ORC) to a replication origin. The origins are less defined in eukaryotes 
than in bacteria, where a sequence termed the oriC, which contains a specific 
sequence recognised by the DnaA initiator protein is required for the initiation of 
DNA replication (Yasuda and Hirota, 1977, Fuller and Kornberg, 1983). Amongst 
the majority of eukaryotes, replication origins are not defined by specific DNA 
sequences. In contrast, chromatin modifications, which affect the higher order 
structure of the genome, appear to be determinants of origin selection in eukaryotic 
systems. Chromatin can be modified in a number of ways, including the acetylation 
of histones (Eberharter and Becker, 2002). Acetylation of histone tails leads to a 
more relaxed and accessible chromatin structure. In Drosophila follicle cells 
hyperacetylation of specific regions of the genome co-localises with newly activated 
origins of replication, which are made more accessible to the replication machinery 
to enable developmental transitions (Aggarwal and Calvi, 2004). Chromatin 
remodelling due to such modifications can also lead to changes in DNA topology, 
such as the induction of supercoiling. Negative supercoiling has been shown to 
increase the affinity of the origin recognition complex (ORC) for origins in 
Drosophila (Remus et al., 2004). The budding yeast S. cerevisiae is somewhat 
unusual in that it contains relatively defined origin DNA sequences, termed 
autonomously replicating sequences (ARSs), which have been shown to act as 
replication initiation sites in vivo. (Brewer and Fangman, 1987). This is one of the 
many features that made this organism an excellent model for the study of 
eukaryotic DNA replication. However, histone modifications and nucleosome 
composition were also shown in S. cerevisiae to be important in origin selection. 
Thus, acetylation of histones H3 and H4 around the origin is required for its 
activation in S-phase, suggesting the ARS alone is not sufficient for correct origin 
selection in a physiological setting (Eaton et al., 2010, Unnikrishnan et al., 2010).
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Figure 1-5 A model for the mechanism of origin licensing in S. cerevisiae 
Proteins referred to in brackets are responsible for ATP hydrolysis at the given 
stage. For details of the mechanism of licensing see section 1.3.2. (Adapted from 
Coster et al. 2014). 
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ORC is composed of six structurally related subunits, Orc1-6, of which two (Orc1 
and 5) are able to bind ATP and one (Orc1) is capable of ATP hydrolysis in vitro. 
The ATP binding is essential for ORC binding to origins of replication (Bell and 
Stillman, 1992, Klemm et al., 1997). While the exact role of ATP hydrolysis by ORC 
is unknown, recent data indicated that it may not be essential for its Mcm loading 
activity (Samson et al., 2013, Coster et al., 2014). In licensing, ORC initially binds 
DNA in an ATP-dependent manner and subsequently recruits cell division cycle 6 
(Cdc6) protein, which is also bound to ATP. Engagement of Cdc6 induces a 
conformational change in ORC, stabilising the ORC-DNA interaction (Speck et al., 
2005). The Cdc6-ORC-DNA complex is then competent for the recruitment of MCM, 
which in most model systems (excluding archaea) is pre-bound to Cdc10-
dependent factor 1 (Cdt1) (Tanaka and Diffley, 2002, Ferenbach et al., 2005, You 
and Masai, 2008). At this point, Mcm2-7 subunits are also bound to ATP, although 
Mcm2-7 loading does not require ATP hydrolysis (Frigola et al., 2013). This 
interaction triggers ATP hydrolysis of ORC and Cdc6 and loading of the Mcm2-7 
hexamer can occur, forming the pre-replication complex (pre-RC). The process can 
only occur successfully in the presence of all the pre-RC components and in the 
absence of CDK. CDK activity, as well as down regulating Cdc6 and promoting 
exclusion of Mcm2-7 from the nucleus, prevents the loading of the helicase 
(Nguyen et al., 2001). If these criteria are not met, the ATPase activity of ORC-
Cdc6 leads to the release of failed loading intermediates preventing aberrant origin 
licensing (Frigola et al., 2013).  
 
After successful loading, Cdt1 is the first protein to be released as a result of ATP 
hydrolysis by the Mcm2-7 complex (Fernandez-Cid et al., 2013, Coster et al., 2014, 
Kang et al., 2014). Left behind, the complex of ORC, Cdc6 and Mcm2-7 (OCM) is 
then able to load a second Mcm2-7 complex in a head-to-head orientation. This is 
thought to occur through a concerted mechanism, as there are no single hexamers 
observed on DNA when the reaction is carried out in the presence of ATP in vitro 
(Evrin et al., 2009, Remus et al., 2009). However, the mechanism of loading of the 
second Mcm2-7 remains a mystery, and several models have been proposed 
(Yardimci and Walter, 2014). Recent single molecule studies suggested that 
recruitment of the second Mcm2-7 complex occurs through interactions between 
the two hexamers. Loading of the second hexamer requires distinct Cdc6 and Cdt1 
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molecules but is directed by the single ORC complex. Interactions between the two 
hexamers for loading also ensure that loading is bi-directional (head-to-head) 
(Ticau et al., 2015). After both Mcm2-7 hexamers are loaded, the ATPase activity 
of Cdc6 is then required for its disengagement, giving way to the further steps in 
DNA replication initiation (Chang et al., 2015). At the end of origin licensing, a 
double hexamer of Mcm2-7 is loaded onto dsDNA in a head-to-head conformation, 
such that the ring formed by N-terminal domains in one interacts with the ring of N-
terminal domains of the other, with C-terminal domains pointing outwards (Remus 
et al., 2009). A recent high-resolution cryo-EM structure of the yeast Mcm2-7 
double hexamer from a G1 chromatin-bound fraction revealed fine details of this 
assembly (Li et al., 2015a). The double hexamer formation was also observed in a 
metazoan system, suggesting the mechanism of pre-RC assembly is conserved 
across eukaryotes (Gambus et al., 2011). A model for origin licensing is shown in 
figure 1-5. 
 
1.2.3 Origin firing 
Activation of the loaded replicative helicase occurs at the G1/S-phase boundary 
and throughout S-phase and requires extensive re-modelling of the Mcm2-7 
complex through the recruitment of numerous firing factors. A number of these 
have been identified in budding yeast including Sld3 (synthetically lethal with 
dpbb11-1), Sld7, Dpb11 (DNA polymerase B possible subunit 11), Sld2 and 
Mcm10. Furthermore, Cdc45 and the hetero-tetrameric GINS (go-ichii-ni-san) 
complex, which is composed of Sld5, Psf1 (partner of Sld5), Psf2, and Psf3, are 
required to interact with the Mcm2-7 complex to form a functional replicative 
helicase, minimally containing Cdc45, Mcm2-7 and GINS (referred to as the CMG 
complex) (Gambus et al., 2006, Moyer et al., 2006, Ilves et al., 2010). The 
molecular transactions leading to origin firing are regulated by cyclin-dependent 
kinases (CDKs) and dumbbell forming factor 4 (Dbf4)-dependent kinase Cdc7 
(Cdc7-Dbf4, often also referred to as DDK) that facilitate or restrict this process 
(Boos et al., 2012, Tanaka and Araki, 2013). While little is known about the exact 
mechanisms of Mcm2-7 activation, a number of experiments have elucidated some 
essential steps required to convert the inactive Mcm2-7 helicase to an active CMG 
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complex. These steps were largely elucidated through in vitro experiments using a 
cell extract system (Kubota et al., 2003, Pacek and Walter, 2004, Moyer et al., 
2006, Heller et al., 2011). More recently, Diffley and colleagues have been able to 
reconstitute the entire process of origin firing and DNA synthesis in vitro using 
purified components, which required 16 individual replication factors comprised of 
42 polypeptides (Yeeles et al., 2015). A schematic of origin firing can be seen in 
Figure 1-6. 
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Figure 1-6 A model for the mechanism of origin firing in S. Cerevisiae 
Phosphorylation events by Cdc7-Dbf4 and CDK are indicated with blue and pink 
hexagons, respectively. For details of origin firing see section 1.1.4. 
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The first step in origin firing, the recruitment of Sld3-7 and Cdc45, is dependent on 
phosphorylation of Mcm2-7 by Cdc7, an S-phase specific Ser/Thr protein kinase. 
Cdc7 strictly requires an activating subunit and two paralogous Cdc7 activators 
have been described: Dbf4 and the Dbf4-related factor 1 (Drf1), of which the latter 
is restricted to metazoans and remains largely unstudied (Yabuuchi et al., 2006, 
Tanaka et al., 2011, Yeeles et al., 2015). The official name of Drf1 is Dbf4B, 
however, for clarity, Drf1 will be used throughout this thesis. CDK is not required at 
this early stage, and it was previously shown that Cdc7-Dbf4 acts upstream of CDK 
in origin firing (Jares and Blow, 2000, Walter, 2000). However, at least in vitro, CDK 
and Cdc7-Dbf4 are able to act in any order (Yeeles et al., 2015). At the G1/S-phase 
transition, an increase in CDK activity facilitates the recruitment of Sld3 and Sld2 to 
the adaptor protein Dpb11. The interaction occurs due to the CDK-dependent 
phosphorylation of Sld2 and 3 which leads to the recruitment of these proteins to 
the two BRCA1 C-terminus (BRCT) tandem repeats in Dpb11. Sld3 binds to BCRT 
I and II while Sld2 is recruited to BRCT III and IV. Simultaneous to this, the pre-
loading complex (pre-LC) is also formed, which consists of Dpb11, Sld2, GINS and 
the eukaryotic leading strand polymerase Polε (Muramatsu et al., 2010). This 
complex is thought to be relatively unstable. Due to Sld2 and Sld3 being bound to 
the pre-LC and pre-RC respectively, Dpb11 acts as an adaptor that allows for the 
CDK-dependent recruitment of GINS to the replisome. Upon full formation of the 
CMG at the origin, significant re-modelling of Mcm2-7 must occur to allow for DNA 
unwinding to occur. While recruitment of the various firing factors has been well 
studied, we still know very little about how the activation occurs. The Mcm2-7 
remodelling leads to the formation of two individual CMG complexes that can fire 
bi-directionally. There is a suggested role for Mcm10 downstream of this formation, 
which may promote the ATP hydrolysis activity of the helicase and origin unwinding 
(van Deursen et al., 2012). It is still unknown whether the Mcm2-7 complex 
encircles ds- or ss-DNA during unwinding, and what triggers the separation of the 
double hexamers and the initiation of DNA unwinding.  
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1.2.4 The role of kinases in the regulation of DNA replication 
Kinases play an integral role in the regulation of the cell cycle and their expression 
and activities are tightly coordinated with their functions (Figure 1-7). A number of 
kinases are involved in regulating the initiation of DNA replication through the 
phosphorylation of numerous replication factors including the Mcm2-7 subunits. 
 
 
Figure 1-7 Oscillations of kinase activities during the cell cycle 
 
1.2.4.1 Regulation of origin licensing by S-phase CDKs 
Restriction of DNA replication to S-phase in the cell cycle can be largely attributed 
to differences in kinase activity brought about by differential expression of 
activating subunits of CDKs and Cdc7-Dbf4. In budding yeast, CDK activity as a 
means of preventing pre-RC formation during S-phase is well studied. S-phase 
CDKs (Cdc28-Clb5 and Cdc28-Clb6 in yeast) phosphorylate a number of 
components of the pre-RC to prevent loading, and the cyclin Clb5 can directly 
interact with the Orc6 subunit (Weinreich et al., 2001, Wilmes et al., 2004). Both 
forms of yeast S-CDK phosphorylate Orc2 and 6. Phosphorylation of Orc6 
specifically leads to a loss of interaction between ORC and Cdt1, preventing pre-
RC formation (Nguyen et al., 2001, Chen and Bell, 2011). Phosphorylation of ORC 
can also lead to the release of helicases prior to successful loading upon ATP 
hydrolysis by ORC and Cdc6 as part of a proofreading mechanism to prevent 
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aberrant origin licensing. (Frigola et al., 2013). Moreover, CDKs can also prevent 
pre-RC formation through phosphorylation of Cdc6, targeting it for degradation by 
the 26S proteasome. During mitosis, binding of the mitotic cyclin Clb2 to Cdc6 
prevents its activation during this stage of the cell cycle (Drury et al., 2000, Mimura 
et al., 2004). Most of the Mcm2-7 subunits are spatially separated from the origins 
outside of G1, as CDK-dependent phosphorylation of Mcm3 promotes the nuclear 
export of the complex (Nguyen et al., 2000, Mimura et al., 2004). 
 
In metazoans, pre-RC formation is additionally regulated by phosphorylation of 
Cdt1 by CDK, directing this essential Mcm2-7 loading factor for ubiquitination and 
proteasomal degradation (Li et al., 2003, Nishitani et al., 2006). However, due to 
the importance of Cdt1, it is also regulated in other ways including the binding of 
the inhibitory protein geminin, which, in turn, is degraded in late mitosis and G1 
phase (McGarry and Kirschner, 1998, Wohlschlegel et al., 2000). In addition, the 
interaction with chromatin-bound proliferating cell nuclear antigen (PCNA) directs 
Cdt1 for ubiquitination and subsequent degradation during S phase (Arias and 
Walter, 2006).  
 
1.2.4.2  Regulation of origin firing by S-phase CDKs and Cdc7-Dbf4 
In budding yeast, the accumulation of G1 cyclins leads to a gradual increase in 
CDK activity. The CDKs are then able to phosphorylate Whi5, an inhibitor of the 
transcription factors SBF and MBF, which in turn leads to the increased expression 
of a number of replication factors including S-phase cyclins (Nasmyth and Dirick, 
1991, Spellman et al., 1998, Costanzo et al., 2004, Eser et al., 2011). CDKs also 
phosphorylate and promote the degradation of the CDK inhibitor Sic1, thus 
increasing the overall CDK activity in the cell, both through regulation of kinase 
expression and preventing the inhibition of CDKs (Feldman et al., 1997, Verma et 
al., 1997, Koivomagi et al., 2011). In S phase, the key role of the APC/C complex is 
also diminished. In G1, the APC/C complex binds to the adaptor protein Cdh1. In 
this active form, APC/C-Cdh1 is responsible for the degradation of Dbf4, the 
activation subunit of Cdc7 (Oshiro et al., 1999, Weinreich and Stillman, 1999, 
Ferreira et al., 2000). In S phase, the increase in CDK activity leads to 
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phosphorylation of Cdh1, which prevents binding to APC/C complex (Zachariae et 
al., 1998, Jaspersen et al., 1999). This allows for the accumulation of Dbf4 in the 
cell and formation of the catalytically competent Cdc7-Dbf4 heterodimer, which in 
concert with the CDKs promotes origin firing (alongside the role of the CDKs in 
preventing re-licensing of the duplicated genome). 
 
The predominant role of CDK in budding yeast appears to be the phosphorylation 
of Sld2 and 3, facilitating Dpb11 binding, which is the minimal requirement for S 
phase entry and progression (Tanaka et al., 2007, Zegerman and Diffley, 2007, 
Kumagai et al., 2010, Kumagai et al., 2011). This in turn facilitates the transition of 
the pre-RC to the pre-LC. The phosphorylation of Sld3 by CDK is conserved in 
metazoan systems and the human homologue of Sld3 (Treslin), binds to the human 
homologue of Dpb11 (TOPBP1) in a CDK-dependent manner (Kumagai et al., 
2010, Boos et al., 2011, Kumagai et al., 2011). However, the proposed human 
homolog of Sld2 (RecQL4) is able to bind to TopBP1 in the absence of CDK 
suggesting the minimal requirements of CDK activity vary across model systems. 
 
The predominant function of Cdc7-Dbf4 is the phosphorylation of the N-terminal 
tails of the Mcm2-7 subunits, in particular Mcm2, 4 and 6 (Masai et al., 2006, 
Montagnoli et al., 2006, Sheu and Stillman, 2006, Randell et al., 2010). 
Phosphorylation target sites of Cdc7-Dbf4 have a limited amino acid sequence 
consensus, with the P+1 position occupied by a negatively charged residue (Asp, 
Glu or a phospho-Ser/Thr) (Cho et al., 2006, Charych et al., 2008). Phosphorylation 
of the Mcm2-7 complex is thought to induce an important conformational change in 
the helicase, which is required for activation. This is supported by the observation 
that removing residues 74-174 of Mcm4 allows for DNA replication in vivo in the 
absence of Cdc7-Dbf4 (Sheu and Stillman, 2010). This is suggestive of Cdc7-Dbf4 
relieving an inhibitory action of the N-terminus of Mcm4 to promote origin firing. 
Another class of budding yeast mutants known to bypass the requirement for Cdc7-
Dbf4 occurs within Mcm5 (Hardy et al., 1997). This is an interesting mutant, as 
Mcm5 has not been implicated as a potential target for Cdc7 activity (Lei et al., 
1997). These data indicate that the structural changes triggered by Cdc7-Dbf4 may 
affect the global structure of Mcm2-7. However, structural studies of the 
phosphorylated Mcm2-7 showed little in the way of gross conformational 
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rearrangements within the hexamer (On et al., 2014). Activity of Cdc7-Dbf4 is also 
important for the recruitment of Sld3/7 and Cdc45 to origins of replication both in 
vitro and in vivo with multiple phosphorylation sites on the Mcm2-7 tails appearing 
to be integral to successful Sld3 loading (Yabuuchi et al., 2006, Heller et al., 2011, 
Tanaka et al., 2011, Deegan et al., 2016).  
 
1.2.5 Key differences between yeast and human systems in origin loading 
and firing 
The vast majority of studies on the mechanism and regulation of origin loading and 
firing for DNA replication have been performed in yeast model systems. This is due 
to the relative ease of performing such studies in yeast and the considerable 
functional conservation across eukaryotes. However, important differences exist 
between yeast and higher eukaryotes, which are important to consider when 
working in a human system. 
 
The final product of origin licensing in both yeast and human consists of a loaded 
double hexamer suggesting that the mechanism of licensing is highly conserved 
across eukaryotes. To prevent premature firing of origins, CDK activity levels are 
kept low. Regulation of this process are also highly conserved, particularly the 
phosphorylation of and cyclin binding of Cdc6 to prevent relicensing outside of S-
phase which both prevent origin binding and direct it for degradation by the the 26S 
proteasome (Drury et al., 2000, Mimura et al., 2004). In yeast, a further method to 
prevent relicensing is the exclusion of Mcms from the nucleus outside of G1 
triggered by the CDK dependent phosphorylation of Mcm3 (Nguyen et al., 2000, 
Mimura et al., 2004). Importantly in many higher eukaryotes, exclusion of Mcms 
does not occur and in human cells Cdc6 is exported from the nucleus outside of G1 
phase in a Crm1 dependent fashion upon phosphorylation by CDK2 (Jiang et al., 
1999b). However, in contrast to the typical role of CDKs in regulation of licensing, 
phosphorylation of Cdc6 in human cells by CDK2-CyclinE has been shown to 
stabilise Cdc6 and facilitate origin licensing in cells that are exiting quiescence and 
beginning to proliferate. This phosphorylation event prevents association of Cdc6 
with the APC/Cdh1 complex and allows accumulation of Cdc6 prior to the 
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accumulation of geminin and cyclin A as cells approach S-phase. This allows for 
efficient licensing prior to S-phase entry (Mailand and Diffley, 2005). This suggests 
an important interplay between the Cyclin A and Cyclin E bound forms of CDK2 in 
ensuring properly regulated DNA replication. 
 
Perhaps the most significant difference between the Yeast and Human systems is 
the protein Geminin. Geminin is a regulatory protein present only in higher 
eukaryotes, which plays an essential role in preventing re-licensing of origins and 
subsequent re-replication during S-phase (Wohlschlegel et al., 2000). Binding of 
geminin to Cdt1 prevents loading of Mcm2-7 complexes and licensing is facilitated 
in G1 through the APC dependent degradation of geminin in late mitosis and G1 
(McGarry and Kirschner, 1998). Cdt1 is a focal point for prevention of re-licensing 
in mammalian cells in which it is actively targeted for degradation outside of G1 
which occurs through multiple distinct degradation pathways including the SCF-
Skp2 E3 ubiquitin ligase complex in a CDK dependent fashion as well as well as 
the Cul4–Ddb1–Cdt2 E3 ubiquitin ligase complex which is directed by PCNA. This 
method of degradation also occurs in fission yeast (Gopalakrishnan et al., 2001, Hu 
and Xiong, 2006). However in budding yeast regulation of Cdt1 is achieved through 
its export from the nucleus along with the Mcm2-7 proteins during S-phase 
(Nguyen et al., 2000, Nguyen et al., 2001). The multiple redundant pathways 
centered upon regulating origin licensing through Cdt1 highlight its importance as a 
key regulator in DNA replication. This is further highlighted by the observation that 
over expression of Cdt1 or down regulation of geminin is sufficient to induce re-
replication and subsequent genome instability. (Mihaylov et al., 2002, Arias and 
Walter, 2007). 
 
Differences between yeast and higher eukaryotes in origin firing centre on the SDS 
complex (Sld2, Sld3 and Dpb11) for which functional homologues have been 
identified in higher eukaryotes including humans. As previously stated, Sld2 and 
Sld3 represent the minimal CDK targets for successful origin firing in yeast.  
Despite the conservation of Dpb11, Sld2 and Sld3 in humans (TopBP1, RecQL4 
and Treslin), sequence conservation for these proteins is much less than for other 
replication factors and there are functional differences in their roles in origin firing. 
Treslin and TopBP1 have retained their crucial role in origin firing, with Treslin 
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showing significant homology to Sld3 and interacting with TopBP1 in a CDK 
dependent manner analogous to that seen in yeast (Sanchez-Pulido et al., 2010, 
Boos et al., 2011, Kumagai et al., 2011).  
 
RecQL4, the functional homologue of Sld2, shares very limited sequence identity 
with its yeast counterpart and also appears to have diverged in terms of its binding 
to TopBP1. While the BCRT repeats required for RecQL4 binding (IV and V) are 
conserved in TopBP1, binding of RecQL4 has been shown to occur in a CDK 
independent manner (Makiniemi et al., 2001, Matsuno et al., 2006, Kumagai et al., 
2010) and the phosphorylation sites present in Sld2 required for binding to Dpb11 
are not conserved (Tanaka et al., 2007, Zegerman and Diffley, 2007). However 
much of this work has been conducted in Xenopus systems and needs to be 
confirmed in human cell lines. This is of particular importance, as C. elegans 
requires CDK activity for the recruitment of Sld2. This data suggests possible 
divergence in function even among higher eukaryotes (Gaggioli et al., 2014). In 
contrast to Sld2 comprising part of the pre-LC in yeast, RecQL4 has been shown to 
form a complex with the CMG, Ctf4 and Mcm10 (Xu et al., 2009, Im et al., 2015) 
suggesting that the role of RecQL4 has changed in evolution to fulfil a function in 
elongation. Studies in human cells have suggested that the N-terminal region of 
RecQL4 which shows homology with Sld2 is sufficient for the origin firing role of the 
protein (Kohzaki et al., 2012) suggesting the C-terminal helicase domain may play 
a role in elongation. This has yet to be confirmed but this region has at least been 
shown to be essential in Drosophila. The function of this region of RecQL4 requires 
significant further investigation in a number of metazoan systems. It is at least clear 
that RecQL4 is required for the formation of the CMG complex in human cells (Im 
et al., 2009) and that it may also play a role in the recruitment of polymerase α. The 
current data suggests that RecQL4 may bind to the replisome prior to S-phase to 
facilitate correct CMG formation before fulfilling its role in elongation after origin 
firing. This is in stark contrast to the yeast system in which Sld2 is released upon 
DNA unwinding. 
 
Further to these differences, two more proteins have been identified in higher 
eukaryotes, which bind to TopBP1. Geminin coiled coil domain containing 1 
(GEMC1) appears to have a role in facilitating Cdc45 recruitment. It is also heavily 
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phosphorylated by CDK2-Cyclin E and this activity contributes to its ability to 
stimulate DNA replication (Balestrini et al., 2010). DNA unwinding element binding 
protein B (DUE-B) has also been shown to associate with Cdc45 (Chowdhury et al., 
2010) and its ability to form complexes with the Mcm2-7 complex is regulated by 
phosphorylation of its C-terminus. This phosphorylation is regulated by the interplay 
between Cdc7 and PP2A activity, suggesting a novel regulatory mechanism for 
Cdc45 recruitment in higher eukaryotes (Gao et al., 2014).  
 
It is clear from this data that there is still much left to discover about the initiation of 
DNA replication in humans and other higher eukaryotes. While yeast has provided 
a powerful tool as a model system, when studying replication in human cells it is 
important to appreciate that many factors may exist that have not yet been 
identified. 
 
1.3 Cdc7-Dbf4 
Cdc7 and its activating subunit Dbf4 were first identified in budding yeast genetic 
screens. Cdc7 mutants lead to an S-phase arrest in non-permissive conditions 
(Hartwell, 1971, Hartwell, 1973).  The arrest of cells with 1C DNA content later 
confirmed the importance of Cdc7 activity in the initiation of DNA replication 
(Hereford and Hartwell, 1974). In the following years, the CDC7 gene was 
confirmed as a Ser/Thr kinase and its importance in both mitosis and meiosis was 
reported (Patterson et al., 1986, Bahman et al., 1988, Hollingsworth and Sclafani, 
1990, Buck et al., 1991b, Yoon and Campbell, 1991). Dbf4 mutants also lead to an 
S-phase arrest phenotype, leading to cells that formed a dumbbell-like shape which 
is often associated with a defect in the initiation of DNA replication (Johnston and 
Thomas, 1982b, Johnston and Thomas, 1982a). The similar phenotypes of Cdc7 
and Dbf4 suggested that they both played a role in the G1/S-phase transition. The 
interaction between the two was first suggested due to the synthetic lethality of 
their temperature sensitive mutants (Kitada et al., 1992). Overexpression of Dbf4 
was also able to rescue the temperature sensitive mutant of Cdc7 suggesting a 
direct interaction between Cdc7 and Dbf4, where the latter modulated the activity of 
the former (Kitada et al., 1992). 
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1.3.1 Regulation of Cdc7-Dbf4   
Cdc7-Dbf4 activity peaks at the G1/S-phase boundary and is maintained at high 
levels throughout S-phase (Jackson et al., 1993, Oshiro et al., 1999). Dbf4 protein 
levels are shown to oscillate throughout the cell cycle with the highest levels of 
expression coinciding with a peak in kinase activity, while Cdc7 levels remain 
relatively stable throughout the cell cycle (Oshiro et al., 1999, Weinreich and 
Stillman, 1999, Ferreira et al., 2000). Total levels of Dbf4 in the cell also correlated 
with the amount of Dbf4 immunoprecipitated with Cdc7 in the above studies.  
 
Dbf4 levels are regulated by the APC/C, which targets it for degradation except in S 
phase, when the activity of APC/C is inhibited (Oshiro et al., 1999, Weinreich and 
Stillman, 1999, Ferreira et al., 2000). In eukaryotes, replication origins can be 
classified by the time they fire as early, intermediate and late and these relative 
firing times appear to be decided in G1 (Dimitrova and Gilbert, 1999). Concordantly, 
Cdc7-Dbf4 is essential not only for G1/S transition, but also for the continued 
progression of S phase to its completion (Bousset and Diffley, 1998, Donaldson et 
al., 1998). Moreover, recent evidence indicates that Cdc7 play a role in the 
temporal regulation of S phase progression and efficiency of firing of individual 
origins. This activity is regulated by the telomere binding protein Rap-interacting 
factor 1 (Rif1). Depletion of Rif1 leads to a loss of mid-S replication foci profiles, 
reduced stimulation of initiation events in early S-phase and changes in long range 
replication timing domain structures (Yamazaki et al., 2012). This is due to Rif1 
targeting protein phosphatase 1 (PP1) to replication origins and counteracting 
Cdc7-Dbf4 activity. Rif1 is itself also regulated by Cdc7-Dbf4 phosphorylation, 
which creates a binding site for PP1. This system allows for timely replication 
across all of the replication origins and this timing is tightly linked to Cdc7-Dbf4 
activity (Dave et al., 2014, Hiraga et al., 2014, Mattarocci et al., 2014). The fission 
yeast ortholog of Cdc7-Dbf4, Hsk1-Dfp1, was also shown to regulate the timing of 
origin firing, with higher local levels of the kinase increasing the odds of firing for 
less efficient origins (Patel et al., 2008) 
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Cdc7 and its activation subunit are conserved from yeast through to humans, with 
orthologs identified in fission yeast and a number of metazoan species. The human 
version of Cdc7 was discovered by 1997, and its partner Dbf4, also known as the 
activator of the S-phase kinase (ASK), was identified in yeast two-hybrid screens 
two years later (Sato et al., 1997, Jiang et al., 1999a, Kumagai et al., 1999). Drf1, 
the alternative Cdc7 activator, was identified more recently in a search for proteins 
that shared sequence homology with Dbf4 (Montagnoli et al., 2002). It was then 
shown that Drf1 interacted with and activated Cdc7 in vitro. Drf1 has so far only 
been found in metazoans, and its functions have not been well studied. Some 
evidence suggests that it may play roles in early development in Xenopus 
(Takahashi and Walter, 2005a) as well as fulfilling the many roles of Dbf4 in 
Xenopus extracts including DNA replication, checkpoint responses and 
coordinating chromosome cohesion with replication (Takahashi and Walter, 2005a, 
Silva et al., 2006, Takahashi et al., 2008, Tsuji et al., 2008). When the cell acquires 
somatic characteristics, Drf1 is depleted and replaced by Dbf4 for the cellular 
functions of Cdc7 (Takahashi and Walter, 2005b). Human Cdc7 and Dbf4 exhibit 
similar patterns of activity and expression as their budding yeast counterparts. 
Transcription of the human DBF4 gene and levels of the protein oscillate with 
mRNA levels at their lowest at the G2/M phase of the cycle and steadily increasing 
towards entry into S phase. Dbf4 protein levels also peak during S phase with 
levels starting to increase from late in G1 (Kumagai et al., 1999). As expected the 
human Cdc7-Dbf4 kinase activity strongly correlated with expression of Dbf4 
(Kumagai et al., 1999). These results must be taken with the caveat that regulation 
of Drf1 remains largely unexplored. Conditional knockout of Cdc7 in mouse 
embryonic stem (ES) cells also lead to cells being blocked in S-phase with a 
reduction in DNA synthesis (Kim et al., 1998) and in a mouse model, deletion of 
Cdc7 was embryonically lethal (Kim et al., 2002).This collective data not only 
highlights the importance of Cdc7 activity in a number of systems, but also the 
functional conservation of the activation of Cdc7-Dbf4 across all eukaryotes. The 
conservation of Cdc7-Dbf4 activation and action is further demonstrated by the 
ability of synthetic human CDC7 and DBF4 genes to support DNA replication and 
cell division in a budding yeast system (Davey et al., 2011). 
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1.3.2 Key differences in Cdc7 regulation in yeast and human systems 
While this functional conservation highlights the importance of Cdc7 activity and its 
correct regulation it is important to appreciate there are differences in the regulation 
of Cdc7 activity between yeast and higher eukaryotes such as in human systems. 
As previously discussed, regulation of Cdc7 in both systems is largely based on 
binding of Dbf4, the levels of which peak at the G1/S phase transition and 
throughout S-phase. In both systems levels of Dbf4 are regulated through APC 
mediated degradation. A key difference between model systems is the chromatin 
binding of Cdc7 and Dbf4. In budding yeast, Cdc7 remains associated with 
chromatin throughout the cell cycle while Dbf4 binds at the G1/S-phase transition in 
an ORC dependent fashion and remains throughout S-phase (Weinreich and 
Stillman, 1999, Duncker et al., 2002). In the human system, ASK is accumulates in 
the nucleus at the post mitotic phase but does not associate to with chromatin until 
late G1. This is also the case when ASK is ectopically expressed. Cdc7 however 
binds to chromatin immediately after mitosis and remains bound through G1 and S-
phase (Sato et al., 2003). This spatial regulation of the kinase and its activating 
subunit will have implications for origin firing across different model systems. 
Further to the binding of Dbf4, recent data has revealed a role for phosphorylation 
of Cdc7 as a means of regulating its activity outside of S-phase. Phosphorylation of 
a number of sites on Cdc7 by CDK1 leads to the dissociation of Cdc7 from origins. 
This prevents inappropriate replication occurring in mitosis and possible genome 
instability. Protein phosphatase 1 α (PP1α) is then required to dephosphorylate 
Cdc7 to facilitate the next round of replication (Knockleby et al., 2016). A recent 
study in mammalian cells has also revealed a method of regulation in which p53 
influences Cdc7 levels in response to genotoxic stress to enforce a block in the G1 
phase. This occurs both post-transcriptionally to reduce Cdc7 expression but also 
through ubiquitination to promote its degradation. Such mechanisms of Cdc7 
regulation have yet to be described in yeast (Tudzarova et al., 2016).  
 
Phosphorylation of Cdc7-Dbf4 as a means of regulating its activity in response to 
genotoxic stress is discussed in more detail in section 1.4.1. Lastly, the most 
significant difference between yeast and human systems is the presence of an 
alternative activator of Cdc7 in higher eukaryotes called Drf1 (Montagnoli et al., 
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2002). Drf1 has been implicated in a number of cellular functions and is discussed 
in detail in section 1.4.5 as well as in the relevant sections about the various roles 
of Cdc7 in the cell. 
 
1.3.3 Structural organisation of Cdc7-Dbf4 
1.3.3.1  Structural and functional features of Cdc7 identified by early studies 
Cdc7 contains a number of conserved kinase motifs (I-XI), which are common to all 
Ser/Thr kinases. However, the canonical kinase organisation is interrupted by 
kinase insert (KI) sequences. In budding yeast, three such inserts (named KI1, KI2 
and KI3) can be identified, while only two (KI2 and KI3) are present in metazoan 
orthologs. The position of the insert sequences relative to the conserved kinase 
domains is the same across all eukaryotes with KI1 (when present) between I and 
II, KI2 between VII and VIII and KI3 between X and XI (Patterson et al., 1986, 
Hanks et al., 1988, Masai et al., 1995, Jiang and Hunter, 1997, Sato et al., 1997, 
Faul et al., 1999, Guo and Lee, 1999). However, the lengths of the kinase inserts 
and their amino acid sequence varies widely among Cdc7 orthologs, and they are 
predicted to be largely devoid of secondary structure. Differences between closely 
related orthologs of Cdc7 can also be seen as with budding and fission yeast 
(Figure 1-8). Despite the two proteins being identical in length budding yeast Cdc7 
has a significantly larger KI2 and KI3 than its fission yeast counterpart. However, 
the fission yeast ortholog appears to compensate for this with a larger KI1 and 
significantly longer N- and C-terminal non-conserved regions. This suggests that 
the structural feature required for activity of each kinase may vary significantly and 
these differences are likely to be even greater in metazoan species. Of note, the 
presence of kinase insert sequences as such, is not unique to Cdc7. For instance, 
protein kinase R (PKR), a kinase that phosphorylates eukaryotic initiation factor 
2alpha (eIF2α) to regulate the initiation of translation contains an insert sequence 
between catalytic sub domains IV and V. Deletion of this insert as well as point 
mutation of Ser355 abrogates kinase activity while having no effect on substrate 
binding in vivo (Craig et al., 1996). The mitogen activated protein kinases (MAPKs) 
also contain an insert sequence between the αG and αH helices of the C-lobe 
(Canagarajah et al., 1997). In the case of the MAPK Erk2 (extracellular signal-
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related kinase 2), this insert becomes disordered upon phosphorylation of the 
kinase to allow for kinase activation through decreased interaction with the 
phosphorylation lip of Erk2 as well as having a role in substrate binding 
(Canagarajah et al., 1997, Chou et al., 2003). An interesting example of a poorly 
conserved kinase insert sequence is that of Greatwall kinase (Gwl). Gwl is a kinase 
required for M phase entry and maintenance across a number of model systems 
(Yu et al., 2004, Burgess et al., 2010). Greatwall specifically deactivates protein 
phosphatase 2A (PP2A) bound to B55 type regulatory subunits to prevent the 
removal of M-phase specific phosphorylation events catalyzed by CDK1-CyclinB 
(Vigneron et al., 2009). Greatwall kinase contains a particularly large insert 
sequence of approximately 500 amino acids termed the non-conserved middle 
region (NCMR), which splits the conserved N and C-lobes of the kinase. Deletions 
in the NCMR have minimal affect on kinase activity in vitro and the ability of the 
kinase to maintain its mitotic functions in the Xenopus system (Blake-Hodek et al., 
2012). Much like Cdc7, structural information about Gwl is largely restricted to 
conserved kinase sequences. It has also recently attracted attention as a possible 
target for ant-cancer therapeutics and as such represents another important but 
challenging kinase for structural studies (Ocasio et al., 2016). 
 
Extensive mutagenesis of human Cdc7 undertaken showed that large portions of 
the insert sequences are not strictly essential for the specific enzymatic activity in 
vitro (Kitamura et al., 2011, Hughes et al., 2012). In particular, deletions in KI3 
required for the initial crystallization had no effect on the ability of the kinase to 
phosphorylate an Mcm2-derived substrate peptide in vitro. However, a deletion of 
132 residues (Δ228-359) in KI2 did have a deleterious effect on activity. However, it 
is important to note that KI2 is present between the conserved DFG and APE 
motifs of Cdc7 and thus extends the activation loop of Cdc7 by 172 amino acids 
(Hughes et al., 2012). Kinase inserts 2 and 3 were reported to play a role in the 
nuclear import and export of Cdc7 (Kim and Lee, 2006, Kim et al., 2007). Thus, a 
nuclear localisation signal (NLS), identified within KI2, mediates the interaction with 
importin-β and facilitates nuclear import of the kinase (Kim and Lee, 2006). 
Moreover, a nuclear retention (NRS) sequence present within the NLS is essential 
for chromatin binding upon entry into the nucleus. One of two nuclear export 
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sequences (NES) is present in KI3, highlighting the role of the insert sequences in 
the localisation and spatial regulation of Cdc7 (Kim et al., 2007). 
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Figure 1-8 Schematic of the S. cerevisiae and human Cdc7 and Dbf4 structures 
Conserved kinase motifs of Cdc7 are labelled with roman numerals (I-XI) and insert 
sequences labelled as KI1, KI2 and KI3. Non-labelled portions of Cdc7 are non-
conserved N-terminal regions. The conserved motifs-N, M and C of Dbf4 are also 
indicated.  
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1.3.3.2  Domain organisation of Dbf4 
Across orthologs of Dbf4, the amino acid sequence conservation and predicted 
secondary structures are confined to three short regions named by the their relative 
positions along the protein sequence: motif-N, -M and -C (Kumagai et al., 1999, 
Takeda et al., 1999, Masai and Arai, 2000).  The relative positions of these motifs 
along the protein vary amongst Dbf4 orthologues (Fig 1-8). The N-motif of Dbf4 in 
human is considerably closer to the N-terminus than is seen in budding and fission 
yeast, and the contains a significant C-terminal sequence of ~300 amino acids 
which appears to be entirely devoid of conserved features. In the case of the two 
yeast orthologues, the C-motif is present towards the extreme C-terminus of the 
protein with a an extended stretch between the M and C motifs relative to that seen 
in human. Interestingly between budding yeast Dbf4 and Fission yeast Dfp1 there 
is a significant difference in the protein size that appears to be attributed to a 
significant decrease in the number of residues between the M and C motifs. This 
suggests that in fission yeast at least, a large stretch of this region of the protein 
was not essential for cell survival, while in budding yeast it may play an important 
role in the cell. These domains appear to act as Cdc7 binding/activation and 
chromatin tethering modules. A small fragment spanning motifs -M and -C of Dbf4 
is sufficient for Cdc7 binding and activation in vitro (Ogino et al., 2001, Ogino et al., 
2006, Kitamura et al., 2011, Hughes et al., 2012). The segment connecting the two 
motifs is poorly conserved and variable in length, although a string of positively 
charged residues is important for the kinase activity in vitro (Hughes et al., 2012). 
The importance of motifs-M and -C was clearly demonstrated in the yeast systems.  
In one study, deletion mutants of Dfp1 were used to complement the growth defect 
of S. pombe dfp1-null strains. Deletions of the N-terminal 222 amino acids did not 
affect the ability of the construct to complement the growth defect of the Dfp1-null 
cells. However further deletion up to the position 335 lead to a loss of 
complementation due to the removal of motif-M. Removing as few as 35 residues 
at the C-terminal end of Dfp1 also prevented complementation due to the disruption 
of the C-motif. This confirmed the importance of motifs -M and -C for Hsk1-Dfp1 
activity, while suggesting that motif-N of Dfp1 is dispensable under some conditions 
in vivo. Furthermore, small segments of the protein spanning motifs-M and -C could 
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bind Hsk1 individually, with binding of both being required for the activation of the 
kinase (Ogino et al., 2001). Similar observations were also made in budding yeast, 
where a fragment of Dbf4 spanning motif-M and the 100 amino acids immediately 
downstream was able to bind Cdc7, as was motif-C (Harkins et al., 2009). In 
humans, a minimal fragment of Dbf4 spanning motifs-M and C (174-350) was also 
capable of supporting kinase activity in vitro; however, addition of more residues 
preceding the motif-M (134-350) was needed for hyper-phosphorylation of Mcm2 in 
vivo.  
 
Motif-N of Dbf4 is dispensable for the kinase activity in vitro as well as for its ability 
to support the cell cycle in a number of systems. However, it has been suggested 
to play a role in the interaction with the replication machinery. Dbf4 co-localises 
with Orc2 and co-fractionates with it in the chromatin insoluble fraction in a manner 
dependent on correct formation of the ORC complex in yeast (Pasero et al., 1999). 
A direct interaction between Dbf4 and the Orc2 and 3 subunits was corroborated by 
later studies, and was shown to be reliant on motif-N (Duncker et al., 2002, Varrin 
et al., 2005). An N-terminal fragment of Dbf4 (110-296) was also shown to be 
required for the interaction with the loaded helicase of the pre-RC (Francis et al., 
2009). In the Xenopus system, not only Dbf4 activates Cdc7, but it also recruits it to 
the pre-RC. Dbf4 binds chromatin early in the cell cycle independently of origin 
licensing. Cdc7 is then recruited to chromatin upon Mcm2-7 loading. 
Immunodepletion of Dbf4 prevents this recruitment, indicating that the activating 
subunit acts as the chromatin-tethering module (Jares and Blow, 2000, Jares et al., 
2004). It is remarkable that a protein that is so evolutionarily diverse can maintain 
such an essential function. The presence of discreet modules in Dbf4 is likely 
necessary to allow Dbf4 to interact with a range of different proteins and fulfil 
multiple roles without the need for the expression of a number of different genes. 
This idea is further supported by the interaction between Dbf4 and a number of 
kinases implicated in cell cycle regulation, such as Rad53 and Cdc5 (Chen and 
Weinreich, 2010, Matthews et al., 2012). Very little is known about the function of 
Dbf4 regions outside of the three motifs, which collectively comprise over 80% of 
the protein’s mass.  
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1.4 Other roles of Cdc7-Dbf4 
Aside from its function in the initiation of DNA replication, Cdc7 plays a number of 
additional critical roles in the cell. Notably, Cdc7 is involved in mitotic exit, 
chromosome cohesion, responses to replication stress, as well as participating in 
DNA recombination and chromosome segregation in meiosis. Further to this, Cdc7 
has an alternative binding partner called Drf1, which functions alongside Cdc7 
during development. 
 
 
1.4.1 The role of Cdc7 in replication stress 
In addition to its well-established role during the normal cell cycle, Cdc7 has been 
implicated in responses to replication stress and, in particular, in the intra S-phase 
checkpoint. Aberrant DNA replication during S phase triggers suppression of late 
origin firing and stabilisation of replication forks. This process decreases the 
amount of damage caused by collapsed forks, while helping to salvage replication 
after the block has been removed (Segurado and Tercero, 2009).  
 
The evidence of the involvement of Cdc7 in response to replication stress came 
from early studies in budding yeast. S. cerevisiae strains lacking Cdc7 and capable 
of growth in the presence of the suppressing mcm5-bob1 mutation are 
hypersensitive to the treatment with hydroxyurea (HU) (Weinreich and Stillman, 
1999). Exposure to HU leads to hyper-phosphorylation of Dbf4 by the checkpoint 
kinase Rad53 (Chk2 in humans). Interestingly, Cdc7 also phosphorylates Rad53 in 
a manner that is important for full Rad53 activity upon checkpoint activation 
(Dohrmann et al., 1999, Weinreich and Stillman, 1999, Kihara et al., 2000). 
Furthermore, Rad53 was shown to interact with motif-N of Dbf4 and a deletion of 
this motif leads to a defect in the checkpoint response upon HU treatment (Ogino et 
al., 2001, Duncker et al., 2002, Varrin et al., 2005). Importantly, Dbf4 motif-N was 
shown to mediate an interaction with ORC (Pasero et al., 1999). Therefore, 
phosphorylation by Rad53 represents a method of preventing Cdc7 association 
with ORC following DNA damage, displacing it from replication origins 
(Santocanale and Diffley, 1998, Weinreich and Stillman, 1999, Duncker et al., 2002, 
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Varrin et al., 2005). A similar relationship exists between Hsk1 and the checkpoint 
kinase Cds1 in fission yeast (the homologue of Rad53), where the deletion of Dfp1 
motif-N also leads to defects in S-phase checkpoint control (Takeda et al., 1999). 
Cds1 hyper-phosphorylates Dfp1 upon HU treatment and subsequent replication 
fork stalling. Cds1 also phosphorylates Hsk1, and Hsk1 activity is required for full 
activity of Cds1 during HU treatment. (Brown and Kelly, 1999, Snaith et al., 2000, 
Takeda et al., 2001). The restart of replication and subsequent completion of 
mitosis upon HU treatment also depends on Hsk1 (Snaith et al., 2000). 
 
The importance of Cdc7 in checkpoint responses is maintained in higher 
eukaryotes. A decrease in phosphorylation of the checkpoint kinase Chk1 is 
observed in Cdc7-depleted mammalian cells upon HU treatment, increasing the 
sensitivity of cells to such treatment. A decrease in Chk1 activation was also seen 
in CDC7-null mouse ES cells, when subject to HU or UV treatment (Kim et al., 
2008). Depletion of Cdc7 also leads to a decrease of claspin phosphorylation and 
its association with chromatin. Claspin is an essential mediator of replication stress 
checkpoint that plays a critical role in the regulation of Chk1 (Chini and Chen, 2003, 
Chini and Chen, 2004, Kim et al., 2008). Conditional knockout of claspin in MEFs 
leads to S-phase defects due to a role in facilitating normal DNA replication. Cdc7 
binds an acidic patch in claspin. This interaction triggers phosphorylation of claspin 
by Cdc7 and prevents an intramolecular interaction between the acidic patch of 
claspin and its DNA binding domain. This data suggests a role for claspin in 
initiation of DNA replication through recruitment of Cdc7, in addition to its role in the 
S-phase checkpoint (Yang et al., 2016). In human cells, Cdc7 is inhibited by ATR-
dependent prevention of Dbf4 binding (Costanzo et al., 2003, Dierov et al., 2004). 
However, other data suggests that Cdc7-Dbf4 activity is not decreased during 
genotoxic treatments (Dierov et al., 2004, Tenca et al., 2007, Tsuji et al., 2008). 
Phosphorylation of Dbf4 upon genotoxic stress by checkpoint kinases was thought 
to be an integral part of the S-phase checkpoint, which ultimately leads to a 
decrease in origin firing (Lee et al., 2012). However, the same study concluded that 
phosphorylation of Dbf4 had little effect on the activity of Cdc7 and was likely 
involved in mediating a protein-protein interaction (Lee et al., 2012). 
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Cdc7-Dbf4 was shown to accumulate on chromatin in response to genotoxic stress, 
which is facilitated by ATR-Chk1 dependent inhibition of the APC/CCdh1 complex 
that is responsible for Dbf4 degradation (Yamada et al., 2013). It is thought that 
activation of the ATR-Chk1 pathway leads to auto-degradation of Cdh1, which in 
turns stabilises Cdc7-Dbf4 to secure replication restart after the block has been 
removed (Yamada et al., 2013). It is thought that stabilisation of Cdc7-Dbf4 is 
required for deciding which DNA repair pathway to utilise prior to replication restart. 
Cdc7-Dbf4 was shown to have a role in translesion synthesis in yeast (Njagi and 
Kilbey, 1982, Pessoa-Brandao and Sclafani, 2004). Furthermore, recent data in 
human cells demonstrated Cdc7-Dbf4 - dependent phosphorylation of RAD18 that 
leads to its interaction with the translesion synthesis (TLS) DNA polymerase η (Pol 
η) (Day et al., 2010, Vaziri and Masai, 2010). RAD18 also interacts with the Zn-
binding motif of Dbf4, therefore the translesion DNA synthesis machinery is 
recruited through Dbf4 via RAD18 (Yamada et al., 2013). This is an appealing 
concept for decisions regarding DNA repair pathways, as RAD18 is also known to 
interact with Rad51C, an essential factor for homologous recombination (Huang et 
al., 2009).  
 
The maintenance of Cdc7-Dbf4 on chromatin and its continued activity seem at 
odds with the suppression of late origin firing. A study in Xenopus suggested a 
possible role for PP1, which can be activated by checkpoint kinases to reverse 
phosphorylation of the Mcm2-7 complex, without affecting the activity of Cdc7-Dbf4 
itself (Poh et al., 2014). However, there is no evidence as yet that the depletion of 
such phosphatases prevents the inhibition of late origin firing. It is clear that the role 
of Cdc7 under genotoxic stress is complex and multifaceted, and this is likely to 
represent a large portion of future research into the many functions of this kinase. 
 
1.4.2 The role of Cdc7 in Meiosis 
Meiosis is a specialised cell division programme used for the production of haploid 
gametes. In meiosis, two consecutive chromosome segregation events occur after 
a single round of DNA replication (Sakuno and Watanabe, 2009). As with mitotic 
cells, this DNA replication requires Cdc7, however the kinase also plays a further 
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role in the initial chromosome segregation event (meiosis I). During this stage, 
Cdc7 is required for the initiation of meiotic recombination and chromosome 
segregation (Buck et al., 1991a, Ogino et al., 2006, Sasanuma et al., 2008, Wan et 
al., 2008). Meiotic recombination involves the intentional formation of double-strand 
breaks (DSBs) in chromosomal DNA. Cdc7-Dbf4 was shown to promote the 
formations of DSBs in budding yeast through phosphorylation of Mer2, the 
accessory factor to the meiotic endonuclease Spo11 responsible for the DSB 
formation. Mer2 is phosphorylated by both Cdc7-Dbf4 and S-CDKs, and this 
phosphorylation is essential for the recruitment of Spo11 to DSB sites (Sasanuma 
et al., 2008, Wan et al., 2008). 
 
Due to the mcm5-bob1 mutation, which bypasses the need for Cdc7 in DNA 
replication initiation in yeast, it was possible to analyse the effect of Cdc7 depletion 
on meiosis. These studies revealed that Cdc7-Dbf4 is required for homologous 
chromosome segregation in meiosis I (Valentin et al., 2006, Lo et al., 2008, Matos 
et al., 2008). A failure to segregate in meiosis I leads to sister chromatid 
segregation in meiosis II resulting in a pair of diploid spores in a process similar to 
mitosis (Lo et al., 2008, Matos et al., 2008). Components of the replisome in yeast 
(Tof1 and Csm3) were also shown to recruit Cdc7-Dbf4 to the replisome, where it 
phosphorylates Mer2 in the wake of the replication fork. This coordinates DNA 
replication with the subsequent formation of DSBs for meiotic recombination 
(Murakami and Keeney, 2014). Cdc7-Dbf4 also plays a key role as a gene specific 
regulator of the global transcription factor NDT80, which plays an important role in 
the transition to meiotic division in fission yeast (Lo et al., 2012). Cdc7-Dbf4 
increased NDT80 transcription by relieving repression mediated by a complex of 
Sum1 (suppressor of mar1-1 protein), Rfm1 (repression factor of MSEs protein 1), 
and the histone deacetylase; Hst1. Cdc7-Dbf4 phosphorylates Sum1 at 11 meiosis-
specific sites. Sum1 is also phosphorylated by CDK1 and the meiosis-specific 
kinase Ime2, and this is a key regulatory step in the transition to the meiotic cell 
cycle.  
 
Cdc7-Dbf4 also plays a more direct role in facilitating the separation of chromatids 
during meiosis I. Phosphorylation is a key regulatory step in determining whether 
cohesin is cleaved by separase during cell division, and the phosphatase PP2A 
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inhibits this cleavage event. Conversely, in concert with casein kinase 1 (CK1), 
Cdc7-Dbf4 promotes the cleavage of the cohesin subunit Rec8 and allows for 
chromosome segregation to proceed (Katis et al., 2010). 
 
1.4.3 The role of Cdc7 in chromosome cohesion 
Cdc7 was shown in a number of model systems to play a role in the establishment 
and maintenance of chromosome cohesion. A key aspect of chromosome cohesion 
is the loading of the cohesin complex by the Scc2-Scc4 complex during the G1 
phase of the cell cycle (Uhlmann and Nasmyth, 1998, Lengronne et al., 2006). 
Cohesin loading is also dependent on the presence of the pre-RC in Xenopus egg 
extracts, and Cdc7 activity is required for the recruitment of Scc2-Scc4 to the pre-
RC. Conversely, Cdc7 depletion significantly reduces the association of Scc2-Scc4 
with chromatin (Gillespie and Hirano, 2004, Takahashi et al., 2004, Takahashi et al., 
2008).  
 
In budding yeast, the activity of Cdc7-Dbf4 was also shown to be important for the 
coordination of DNA replication and chromosome cohesion. Thus, Cdc7-Dbf4 
accumulates on kinetochores in telophase, through an interaction with the Ctf19 
kinetochore complex. This in turn allows for Sld3-Sld7 recruitment to 
pericentromeric replication origins, so that they initiate replication early in S phase. 
Cdc7-Dbf4 can then facilitate the recruitment of the Scc2-Scc4 cohesin loading 
complex, which facilitates robust sister chromatid cohesion at microtubule 
attachment sites (Natsume et al., 2013).  
 
Similarly, in fission yeast, Hsk1-Dfp1 directly interacts with Swi6, the S. pombe 
ortholog of heterochromatin protein 1 (HP1). Swi6 is required for cohesin 
recruitment to heterochromatin and for establishing cohesion at centromeres. 
Hsk1-Dfp1 is able to phosphorylate Swi6 both in vitro and in vivo (Bernard et al., 
2001, Nonaka et al., 2002, Bailis et al., 2003b). Truncation mutant of Dfp1 
containing only the first 376 residues of the protein showed a drastic reduction in 
Rad21, an essential component of the cohesin complex, at centromeric 
heterochromatin but not along the arms of the chromosome. This phenotype is 
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typical of swi6-null cells, highlighting the importance of the interaction between the 
Hsk1-Dfp1 and Swi6 for proper maintenance of chromosome cohesion (Bailis et al., 
2003a).  
 
1.4.4 The role of Cdc7 in mitotic exit 
Cdc7 was also shown to interact with Cdc5, the single Polo kinase in budding yeast. 
Cdc5 plays an important role in regulating mitotic progression and cytokinesis, 
including its recently elucidated role in facilitating the removal of centromeric 
cohesin during mitosis (Mishra et al., 2016). An interaction between the N-terminus 
of Dbf4 and a polo box domain (PBD) of Cdc5 alters the substrate targeting of 
Cdc5, preventing it from activating the mitotic exit network (MEN), without affecting 
the kinase activity of Cdc5 (Miller et al., 2009). Dbf4 mutants that are unable to 
interact with Cdc5 can support the progress through S-phase, but this is followed 
by aberrant chromosome segregation in mitosis. Dbf4 therefore acts as an inhibitor 
of Cdc5 to ensure cells exit mitosis correctly (Miller et al., 2009). The interaction 
between Dbf4 and the PBD of Cdc5 is unusual in that it does not require Dbf4 to be 
phosphorylated. Dbf4 contains an atypical PBD-interaction domain that binds the 
PBD via a region distinct from that used by phosphoproteins (Chen and Weinreich, 
2010). Thus, Cdc7-Dbf4 is an important regulator in mitosis that prevents mis-
segregation of chromosomes and subsequent genome instability. 
 
1.4.5 The role of Cdc7-Drf1 
Drf1 was initially identified through sequence similarity with both the yeast and 
human homologues of Dbf4 and was shown to co-purify with and to activate Cdc7 
allowing for phosphorylation of an Mcm2-derived substrate (Montagnoli et al., 
2002). Drf1 and Dbf4 do not bind Cdc7 simultaneously, suggesting these paralogs 
evolved to regulate Cdc7 for different functions in the cell (Montagnoli et al., 2002). 
However, expression levels of Drf1 are similar to that of Dbf4 in primary human 
fibroblasts throughout the cell cycle, peaking in S-phase and decreasing after 
mitosis suggesting some redundancy in function (Montagnoli et al., 2002). 
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In the Xenopus system, Drf1 was reported to play a role in the initiation of DNA 
replication during oogenesis and the early embryogenesis, before being replaced 
by Dbf4 after maturation. Thus, at least in frogs, Drf1 appears to be a 
developmentally regulated functional equivalent of Dbf4 (Takahashi and Walter, 
2005a, Silva et al., 2006). Immunodepletion of both Drf1 and Dbf4 showed that 
they are found individually bound to Cdc7, and there is a 5-fold molar excess of 
Drf1 relative to Dbf4. Depletion of Dbf4 also had minimal effect on DNA replication, 
while depletion of Drf1 lead to significant inhibition of Mcm4 phosphorylation and 
subsequent DNA replication (Takahashi and Walter, 2005a, Silva et al., 2006). 
Cdc7-Drf1 is also the active form of the kinase required for regulation of 
chromosome cohesion in the Xenopus system (Takahashi et al., 2008).  
 
1.5 Cdc7-Dbf4 and cancer 
Due to its numerous roles in cell cycle progression and responses to replicative 
stress, Cdc7-Dbf4 has attracted a lot of attention as an attractive target for the 
development of cancer therapeutics (Sawa and Masai, 2009, Swords et al., 2010). 
Cdc7 is overexpressed in a number of cancers and this expression often correlates 
with patient prognosis (Nambiar et al., 2007, Bonte et al., 2008, Kaufmann et al., 
2008, Clarke et al., 2009, Kulkarni et al., 2009, Hou et al., 2012, Cheng et al., 2013, 
Melling et al., 2015, Ghatalia et al., 2016). Knockdown of Cdc7 using siRNAs in 
cancer cell lines also leads to cell death through the accumulation of nuclear 
damage in S-phase, which is followed by apoptosis or mitotic crisis (Montagnoli et 
al., 2004, Im and Lee, 2008). Normal fibroblasts were able to survive such 
treatments, in large part due to checkpoint mechanisms regulated by p53, which is 
often mutated in cancers. Use of the cell cycle dye Fucci in cancer cell lines 
revealed that cell cycle defects caused by Cdc7 depletion vary greatly between 
p53-positive and negative cells. Cells negative for p53 arrest predominantly in G2 
and accumulate proteins involved in mitotic regulation, such as cyclin B1. This 
leads to aberrant entry into mitosis and subsequent cell death. Cells positive for 
p53 do not accumulate in G2 and appear to die due to an aberrant S-phase. This 
knowledge of distinct mechanisms of cell death in different cellular contexts may 
allow for the development of treatments that could be used in conjunction with 
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Cdc7 inhibitors to achieve synergistic effects (Ito et al., 2012). Tumours expressing 
mutants of checkpoint-related genes are also likely to be hyper-sensitive to Cdc7 
inhibitors, possibly allowing killing of cancerous cells, while sparing normal tissue. 
 
Considerable efforts have already been expended to create Cdc7 inhibitors, with 
the first small molecules, heteroaryl-pyrrolopridinones, reported 8 years ago by 
Nerviano Medical Sciences (Vanotti et al., 2008). Optimisation of these compounds 
led to the development of PHA-767491, which inhibited Cdc7-Dbf4 - specific 
phosphorylation of Mcm2 and prevented origin firing without impeding replication 
fork progression (Montagnoli et al., 2008). Further to this, treatment of cancer cell 
lines with PHA-7674891 lead to apoptotic cell death, and tumour growth was 
inhibited in pre-clinical models. PHA-7674891 has shown some promise as a 
possible inhibitor for the treatment of pancreatic adenocarcinoma (Huggett et al., 
2016), and was shown to have a synergistic effect in inhibiting both Cdc7 and 
CDK9 in hepatocarcinoma and to enhance the efficacy of 5-fluorouracil (Li et al., 
2015b). In the following years, a more potent and specific Cdc7-Dbf4 inhibitor, 
XL413, was reported by Exelxis (Koltun et al., 2012), which advanced into clinical 
trials. However, the ability of XL413 to inhibit Cdc7 in various cancer cell lines was 
hampered by poor cell permeability, and work is now underway to identify new 
Cdc7 inhibitors that are more readily taken up by the cell (Sasi et al., 2014). Cdc7 
inhibitors clearly represent a promising class of anti-cancer therapeutics and 
detailed structural and functional information about Cdc7-Dbf4 could inform the 
design of the next generation of inhibitors. 
 
1.6 Crystal structure of a minimally active Cdc7-Dbf4 construct 
Due to the inherent flexibility of Dbf4 and the insert sequences in Cdc7, structural 
characterisation of the heterodimeric kinase was a daunting challenge. Cdc7 
displays no detectable kinase activity on its own (Ogino et al., 2001, Kitamura et al., 
2011) and is prone to aggregation, necessitating its co-expression and co-
purification in the form of the heterodimer with Dbf4. Having screened through a 
large number of deletion constructs Hughes et al. were able to obtain diffracting 
crystals of Cdc7 lacking 132 and 46 residues from KI2 and KI3, respectively, bound 
Chapter 1 Introduction 
62 
 
to a 141-residue fragment of Dbf4 spanning conserved motifs-M and -C. The 
crystallized construct also lacked the 36 N-terminal Cdc7 residues, which are highly 
susceptible to proteolysis in vitro and predicted to be disordered. The construct 
retained only partial activity, and the observed defect was mapped to the deletion in 
KI2 (Hughes et al., 2012).  
 
Cdc7 has the classic bi-lobal architecture characteristic of protein kinases, 
comprising N- and C- lobes, with the active site buried in a deep cleft between 
them (Taylor and Kornev, 2011). The N-lobe (Cdc7 residues 41-135) consists of a 
an antiparallel β-sheet of 5 strands (β1-5), the αC helix, important for kinase 
activation, and two non-canonical helices at its N-terminus (N1 and 2) (Hughes et 
al., 2012) (Figure 1.9). The C-lobe of the kinase is made up largely of α helices and 
contains a number of features conserved across protein kinases including the 
catalytic loop containing the RD signature (Arg176, Asp177) and the conserved 
DFG and APE motifs, which flank the activation loop of the kinase (196-198 and 
381-383 respectively). Despite extensive deletions in Cdc7 KI2 and KI3, these 
motifs were well ordered, and the deletions appeared to have little effect on the 
overall structure of the kinase. The small portion of KI2 that was visible in the 
crystals contained an α helix, which packs against the αC helix and provides 
contacts between the N- and C- lobes of Cdc7. The ordered portion of KI3 
contributes a β-strand and two α helices to the canonical C-lobe structure (Hughes 
et al., 2012). 
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Figure 1-9 Crystal structure of Cdc7-Dbf4 previously determined in the lab  
The structure is shown in two orthogonal orientations, with protein chains shown as 
cartoons. Conserved regions of Cdc7 are shown in green and the non-canonical N-
terminus, KI2 and KI3 in pink, and Dbf4 in cyan. Nucleotide (ADP) bound to the 
active is shown as sticks with carbon atoms in orange with the remaining atoms in 
standard coloration (blue for nitrogen, red for oxygen and orange for phosphorus 
atoms); grey spheres are Mg and Zn atoms (Hughes et al. 2012). 
 
The structure revealed that Dbf4 makes a bipartite interaction with Cdc7 with motif-
M and motif-C latching onto the C-lobe and N-lobe, respectively. Each interface 
buried approximately 3,000 Å2 of predominantly hydrophobic molecular surface. 
Motif-M contains a pair of β strands, of which one forms anti-parallel β-sheet with a 
β strand from KI3. Motif-M also contains an ordered coiled region that makes 
extensive hydrophobic interactions with C-lobe. The interactions between KI3 and 
motif-M were characterised earlier using mutagenesis and site-specific crosslinking 
(Kitamura et al., 2011).  
 
Motif-C contains a conserved Zn-binding domain, comprised of a single Zn atom 
coordinated by the side chains of Cys296, Cys299, His309 and His315, which are 
invariant amongst Dbf4 orthologs. Further to this, motif-C contains three α-helices 
and two β strands, of which the β strands and the first 2 α-helices are involved in 
formation of the metal binding site. The Zn-binding domain makes numerous 
interactions with the N-lobe of Cdc7, of which interactions with αC are particularly 
important for kinase activation (Figure 1-10) (Hughes et al., 2012). The linker 
between the two motifs is poorly conserved as with other species. The only 
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conserved feature is an array of charged residues (288-293) immediately preceding 
the motif-C. Mutations of these residues were shown to be detrimental to kinase 
activity, despite them not being ordered in the crystal structure.  
 
 
 
              
Figure 1-10 Structure of the Dbf4 motif-C Zn-binding site and its interaction with 
αC 
A) Close up view of the Zn-binding domain of Dbf4. The residues responsible for 
coordination of a Zn atom are indicated. B) Close up view of the interaction 
between Dbf4 motif-C and the αC helix of Cdc7. Residues involved in the 
interactions are shown as sticks and labelled. 
  
 
Chapter 1 Introduction 
65 
 
The activation of Cdc7 was proposed to be analogous to that of the CDKs, where 
cyclin binding leads to repositioning of the αC helix. This in turn allows for the 
formation of an essential salt bridge involving a highly conserved Glu residue 
located within αC and a Lys residue from the kinase AxK motif (Jeffrey et al., 1995). 
In the case of Cdc7, the salt bridge is formed between Glu104 and Lys90 and this 
interaction is integral to the structure of the active site. Through producing a range 
of deletion constructs of the Dbf4 fragment it was shown that motif-C and the 
preceding charged residues were essential and minimally sufficient for Cdc7 
activation. The interaction between the Dbf4 Zn-binding domain and Cdc7 αC were 
shown to be particularly vital, and point mutations in residues involved in this 
interaction (V327E and C298E) substantially reduced kinase activity without 
preventing complex formation. Similar results were also achieved through 
disruption of the Zn-binding domain itself. The relative protection of a buried 
cysteine residue in Cdc7 in the presence and absence of motif-C also confirmed 
that the binding of motif-C stabilises αC of Cdc7 in the active conformation, much 
like the conformational changes brought about by Cyclin A binding to CDK2 
(Jeffrey et al., 1995). Regulation via αC is so common among protein kinases that 
the helix is sometimes referred to as the Signal Integration Motif (Jeffrey et al., 
1995, Yang et al., 2002, Bayliss et al., 2003, Sessa et al., 2005, Taylor and Kornev, 
2011). The structure is consistent with a mechanism whereby motif-M tethers Dbf4 
to Cdc7 and plays a role in stabilising the C-lobe, and allowing motif-C 
binding/dissociation to act as an on/off switch of Cdc7 activity. Another interesting 
observation in the structure was the lack of an activation threonine in Cdc7. In 
many kinases, including CDK2, there is a threonine residue present in the 
activation loop, which upon phosphorylation by another kinase, forms part of a 
hydrogen bond network that is essential for forming the active kinase conformation 
(Madhusudan et al., 1994, Russo et al., 1996, Canagarajah et al., 1997). In the 
structure of Cdc7, this threonine appears to be replaced by Glu217 and the 
previously suggested candidate of Thr376 (Masai et al., 2000) does not overlay 
with the activation threonine of other kinases. 
 
The structure of Cdc7 also revealed some previously unexpected shared features 
with other kinases including the MAP kinases, which contain an insert sequence 
similar to KI3 that was shown to be important for interaction with other proteins 
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(Chou et al., 2003). MAP kinases also contain a C-terminal extension harbouring a 
small helix (αL16), which packs against the N-lobe in a similar way to motif-C of 
Dbf4. Similarly, hydrophobic motifs found within the C-terminal extensions of 
protein kinases A, B, C, G are involved in the alignment of the αC (Yang et al., 
2002, Kannan et al., 2008).  
 
Crystallisation of Cdc7-Dbf4 with two inhibitors revealed the determinants for their 
binding and explained the increased affinity and selectivity of XL413 over 
PHA767491 (Figure 1-11). Both inhibitors interacted with the side chains of the 
conserved Lys90 and Asp196 residues of Cdc7, PHA767491 also interacted with 
the main chain amide of Leu137, while XL413 engaged the side chain amide of 
Asn182. All further interactions were accounted for by van der Waals interactions 
with the nucleotide-binding pocket. XL413 made more extensive contacts with the 
P-loop of Cdc7, which lead to an inward motion of the loop and closing of the 
pocket. Both inhibitors also made contacts with residues in the active site that are 
not conserved among kinases (Met118 and His139) and XL413 made one further 
contact with Ser70. These increased interactions relative to PHA767491 likely 
explain the higher potency and selectivity of XL413 (Hughes et al., 2012). 
 
While the crystal structures determined by Hughes et al revealed a great deal of 
previously unknown information about the mechanism of Cdc7 activation by Dbf4, 
many questions remained about the roles of KI2 and KI3 in the kinase, and how the 
kinase facilitates interactions with a number of possible substrates. These 
questions form a large part of the work in this study. 
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Figure 1-11 Binding of inhibitors to Cdc7-Dbf4 
A) Chemical structure of PHA767491 and its binding to the active site of Cdc7. B) 
XL413. Protein chains are shown as cartoons, with the N-lobe of Cdc7 in green and 
the C-lobe in purple. Interacting residues are shown as sticks. Inhibitors are shown 
as sticks in orange with all non-carbon atoms shown with standard colouration. 
Interactions between amino acid side chains and the inhibitors are shown as 
dashes (adapted from Hughes et al. 2012). 
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1.7 Project aims 
Although much is already known about Cdc7-Dbf4 and its structure and function, a 
number of important features for its activity and physiological functions still remain 
a mystery. With Cdc7 inhibition appearing to be a promising target for drug 
development, it is important to elucidate the structural and functional features 
unique to this kinase. The aim of this project was to use X-ray crystallography in 
tandem with biochemistry and cell biology to structurally and functionally 
characterise a Cdc7-Dbf4 construct with kinase activity equivalent to that of the wild 
type (WT) heterodimer. In chapter 3, the design and purification of Cdc7-Dbf4 
constructs for use in crystallography is described. In chapters 4 and 5, three 
structures of an active Cdc7-Dbf4 construct are presented bound to XL413, an ATP 
mimic and an Mcm2-derived substrate peptide. In chapter 6, the functional 
relevance of the structural features of Cdc7 revealed in the previous chapters is 
investigated in cellula using an inducible knockout cell line created as part of this 
study. 
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Chapter 2. Materials & Methods 
2.1 General methods for DNA plasmid construction 
2.1.1 Polymerase chain reaction (PCR) for amplification of DNA 
PfuUltra II fusion hot start DNA polymerase (Agilent) was used for PCR 
amplification of DNA templates unless otherwise stated. A typical reaction mixture 
of 100 µl contained 50-250 ng of template DNA, 250 µM of each deoxynucleotide 
triphosphate (dNTP) [deoxyribo-adenosine triphosphate (dATP), deoxyribo-
thymidine triphosphate (dTTP), deoxyribo-cytidine triphosphate (dCTP) and 
deoxyribo-guanosine triphosphate (dGTP) with 100 pmol of each oligonucleotide 
primer and 1µl of enzyme in PfuUltra II reaction buffer supplied with the enzyme. All 
PCR reactions were carried out using a Thermocycler C1000 instrument (BioRad). 
A typical PCR programme consisted of one cycle of denaturation at 95°C for 5 min 
followed by 30 cycles of amplification consisting of a further 30 s of denaturation at 
95°C, 30 s primer annealing at 54°C and 2 min/kb template extension at 72°C, 
ending with a 7-min incubation at 72°C to complete replication of the DNA template. 
 
PCR products were separated by gel electrophoresis in 1-1.5% (w/v) agarose gels 
made up in TAE buffer (40 mM Tris Base, 20 mM acetic acid, 50 mM 
ethylenediaminetetraacetic acid (EDTA)) and containing a 1 in 10,000 dilution of 
GelRed (Biotium) for visualisation. Higher percentage agarose gels (2%) were used 
for separation of smaller PCR fragments.  
 
2.1.2 Overlap-extension (splice) PCR 
This method was used to splice DNA fragments for production of deletion mutants 
of Cdc7 as well as for the N-terminal fusion of mCherry to Cdc7 for cell line 
production. Typically, splicing PCR reactions of 100 µl contained 10 µl of each 
fragment to be fused together, 250 µM of each deoxynucleotide triphosphate 
(dNTP) and100 pmol of each end primer for the final construct. Reactions were 
performed in 1xPfuUltra II reaction buffer supplied with the enzyme. 1 µl of the 
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polymerase was added last before initiating the PCR.  The PCR reaction was then 
carried out as previously described before excision and purification. 
 
2.1.3 DNA purification from agarose gels 
Fragments were isolated and purified using a QIAquick gel extraction kit (Qiagen) 
as per the manufacturers instructions. The excised gel slice containing the desired 
DNA fragment is dissolved in 3 volumes of QG buffer (supplied) by incubation at 
50°C. The high salt conditions force the DNA to bind to the silica-gel membrane 
filter of the QIAquick spin column, while impurities such as dNTPs, PCR buffer 
components and protein, pass through and are discarded. The spin column is then 
washed and the DNA is eluted in distilled water or the low-salt EB buffer (supplied). 
 
2.1.4 DNA digestion for plasmid construction 
Five to ten µg of plasmid of PCR product was mixed with 40-80 U (2-4 µl) of the 
relevant restriction enzyme (New England BioLabs) in the presence of the reaction 
buffer supplied with the enzyme. Double digests using two enzymes were 
performed when the reaction buffers were compatible. Reactions were made up to 
a final volume of 100 µl with distilled water and incubated at 37°C for 2-4 hours. 
When different reaction buffers were required for the two restriction enzymes, the 
single digested DNA was purified using a QIAquick PCR purification kit (Qiagen) as 
per the instructions and used to set up a digestion reaction with the second enzyme. 
Prior to use, DNA fragments were separated in 1-2% (w/v) agarose and isolated 
using the QIAquick gel extraction kit (Qiagen) as described previously (2.1.3). 
 
2.1.5 DNA ligation 
A 1:1 molar ratio of fragments were mixed and ligated using 1U (1 µl) T4 DNA 
ligase (Invitrogen) in the reaction buffer supplied with the enzyme (50 mM Tris-HCl 
pH 7.6, 10 mM MgCl2, 1 mM adenosine triphosphate (ATP) and 1 mM dithiothreitol 
(DTT) in a final reaction volume of 10 µl. Reactions were incubated for at least 2 h, 
but typically overnight, at 15°C. 
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2.1.6 Transformation of chemically competent E.coli cells 
One to five µl of the DNA ligation reaction or 1-100 ng of plasmid DNA was added 
to 25-50 µl chemically competent E. coli cells and incubated on ice for 15 min. The 
bacteria were then heat shocked at 42°C for 50 sec before cooling on ice for 1 min; 
250 µl of SOC medium (casein enzymatic hydrolysate 20 g/L, yeast extract 5 g/L, 
NaCl 0.5 g/L, MgSO4 2.4 g/L, KCl 0.186 g/L and 0.4% glucose) was added and 
bacteria were allowed to recover at 37°C for 30 min with gentle shaking. The 
culture was then seeded on selective LB agar plates containing the relevant 
antibiotic. The plates were incubated overnight at 28°C or 37°C and single colonies 
were used to inoculate liquid LB or TB broth cultures containing antibiotic(s) 
required for selection.  
 
2.1.7 Colony-PCR 
Bacterial colonies were screened directly from selection plates by colony-PCR to 
identify plasmids with the correctly ligated insert. A pair of primers was selected 
such that PCR product would span a ligation point. A fraction of each colony was 
added to a 20 µl PCR mixture containing 125 µM of each dNTP, 10 pmol of each 
primer, 0.5 units of Taq DNA polymerase (Invitrogen) and 2 mM MgCl2 made up in 
the reaction buffer provided with the enzyme. As a positive control, 0.5 µl of ligation 
reaction was used. PCR cycling conditions consisted of 8 min at 95°C to lyse the 
cells and denature the DNA, 25 cycles consisting of 30 sec of denaturation at 95°C, 
primer annealing for 30 sec at 54°C followed by 0.5-1 min template extension at 
72°C. Reaction products, separated by electrophoresis in 1.5-2% (w/v) agarose, 
were detected by staining with Ethidium bromide or GelRed. Bacterial colonies 
containing the plasmid construct of the expected structure produced a DNA band 
migrating at the expected position, as in the positive control. This method allowed 
screening large numbers of bacterial colonies in a short time.  
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2.1.8 Small-scale preparation of plasmid DNA (miniprep) 
Plasmid DNA was purified from 3-ml cultures described previously (8.1.5) using 
commercial QIAprep Spin Miniprep protocol (Qiagen). Bacteria were lysed in buffer 
P2 (supplied) and the lysate neutralised by addition of buffer N3 (supplied). Buffer 
N3 also provides the high salt conditions required to precipitate contaminants (such 
as cellular debris and chromosomal DNA) while maintaining circular plasmid DNA 
in solution. The lysate, pre-cleared by centrifugation at 10,000 g for 20 min, was 
applied onto a silica membrane with the QIAprep spin column, which binds DNA 
under high salt conditions. After washing with ethanol-containing PE buffer 
(supplied), pure plasmid DNA was eluted in 30-50 µl of distilled water or low-salt 
EB buffer (supplied). 
 
2.1.9 Large-scale preparation of plasmid DNA (maxiprep) 
To prepare highly concentrated and pure plasmid DNA for use in transfections, a 
Plasmid Maxi kit (Qiagen) was used as per the manufacturers instructions. A single 
bacterial colony was used to inoculate 200-300 ml of LB culture supplemented with 
the relevant antibiotic(s), which was grown overnight at 37°C with vigorous shaking 
(250-300 rpm). Bacteria, pelleted by centrifugation and re-suspended in buffer P1 
buffer containing RNAse (supplied), were lysed by addition of 10 ml P2 buffer 
(supplied). The lysate was then neutralised with 10 ml of chilled N3 buffer and 
precipitated contaminants were removed by centrifugation at 20,000 g for 30 min. 
The clear supernatant, containing plasmid DNA, was loaded onto Plasmid Maxi 
column pre-equilibrated with QBT buffer (supplied). Plasmid DNA binds to the 
anion exchange resin under low ionic strength and low pH conditions while 
impurities are able to flow through. The column was washed twice with 30ml QC 
buffer (supplied) before elution with 15ml of high salt QF buffer (supplied) and 
precipitation with 11.5 ml isopropanol. Purified plasmid DNA was then collected by 
centrifugation and washed with 70% ethanol before dissolving in an appropriate 
volume of distilled water (0.25-0.5 ml). 
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2.2 DNA constructs 
Plasmids used in this study are listed in Table 8-1 and 8-2. Primers used in PCR 
and plasmid construction are listed in Table 8-4 (Appendix).  Plasmids used in this 
work but not described in this chapter have been created by others and are 
referenced in tables 8-1 and 8-2. New England Biolabs supplied all restriction 
enzymes, and all generated plasmids were verified by sequencing to check for 
unwanted mutations (LRI sequencing Department). All constructs used for 
expression in mammalian cells were purified by maxiprep as described previously 
(2.1.9). 
 
2.2.1 Constructs for bacterial expression of Cdc7-Dbf4 and Cdc7-Drf1 
heterodimers 
A number of deletion constructs were created of Cdc7 for co-expression with Dbf4 
and Drf1 in E. coli. The deletions in Cdc7 KI2 and KI3 were created by overlap-
extension PCR using constructs previously made by Hughes et al. (2012) as a 
starting material. The constructs and PCR primers were designed using Vector NTI 
software (Invitrogen). Reverse and forward deletion primers incorporated 20-30 nt 
of complementary sequences in their 5' regions to allow PCR splicing. Primer SH78 
and the reverse primer for the deletion were used for PCR as previously described. 
SH78 was used to maintain the ΔN (1-36) deletion, which was maintained in all 
bacterial expression constructs. The forward deletion primer was then used with 
primer SH81 for PCR. SH81 is the reverse primer annealing at the very end of the 
Cdc7 coding region. The fragments produced were separated by agarose gel 
electrophoresis and gel extracted as previously described. These DNA fragments 
were then used for overlap-extension PCR and the production of a single DNA 
fragment with a desired deletion. The spliced fragment, digested with XhoI and 
NcoI and purified by gel extraction, was ligated between the NcoI and XhoI sites of 
the pRSFDuet1 bacterial expression vector (Novagen) (Figure 2-1). The NcoI site 
is located upstream of the hexahistidine tag (His6) coding sequence, allowing for 
expression of untagged proteins. 
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The Dbf4 MC2 fragment was cloned into a modified version of the pCDFDuet1 
bacterial expression vector encoding a recognition sequence for the human 
rhinovirus 14 (HRV14) 3C protease downstream of the His6 tag (Hughes et al., 
2012) (Figure 2-1). Primers SD25 and SD20 were used as forward and reverse 
primers, respectively. The resulting fragment was digested with XmaI and XhoI, 
purified using agarose gel electrophoresis and ligated between XmaI and XhoI 
sites of the modified pCDFDuet1-3C vector. The use of the XmaI site allows in-
frame fusion of the vector-derived sequence encoding the His6 tag and the HRV14 
3C site with the ligated fragment. Constructs for expression of Drf1 fragments were 
constructed in a similar way utilising the relevant primers incorporating XmaI and 
XhoI sites. For a list of primers used in plasmid production see Table 8-4. Accuracy 
of all constructs was confirmed by sequencing of small scale DNA preparations 
(2.1.8) after transformation in E. coli. 
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Figure 2-1 Plasmids used for expression of Cdc7 and Dbf4/Drf1 constructs for 
expression in bacteria 
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2.2.1.1  Site directed mutagenesis 
Site directed mutagenesis was used to create point mutations in Cdc7 for use in in 
vitro kinase assays and in cell line production. Mutations were made in the pRSF-
Cdc7 (ΔN) and pBABE-FLAG-Cdc7 vectors. Vectors were mutagenized using the 
QuikChange procedure (Braman et al., 1996). Primer pairs relevant to each 
mutation can be found in Table 8-4. For site directed mutagenesis, 100 ng template 
DNA was denatured at 95°C for 3 min and was amplified for 18 cycles. Each cycle 
consisted of a 30 s denaturation step at 95°C, primer annealing for 1 min at 54°C 
and template extension for 12 min at 72°C followed by incubation at 72°C for 15 
min. The products, treated with DpnI for 3 h at 37°C to digest the template, were 
used for transformation of E. coli. Mutations were confirmed by sequencing of 
small-scale plasmid preparations (2.1.8). 
 
2.2.2 Lentiviral and retroviral constructs for expression of Cdc7 in human 
cells 
A number of constructs and mutants of Cdc7 were produced for expression in 
mammalian cells via retroviral and lentiviral transduction. Plasmids used for 
mammalian expression can be found in Table 8-2.  
 
A construct for expression of mCherry-Cdc7 fusion was created on the basis of the 
lentiviral pWPT-GFP vector, a gift from Didier Trono (Addgene plasmid # 12255) 
(Figure 2-2), which incorporates LoxP sites allowing for excision of the expression 
cassette by the action of Cre recombinase. Overlap-extension PCR was used to 
splice a DNA fragment encoding mCherry (produced by PCR with primers SD28 
and SD16) and a synthetic codon-shuffled DNA fragment encoding full-length WT 
Cdc7 (synthetized by GeneArt and PCR amplified using primers SD17 and SD31). 
Codon-shuffled Cdc7 coding sequence was used to make the transgene resistant 
to disruption by CRISPR/Cas9 constructs designed to target endogenous CDC7 
alleles. The spliced DNA fragment, digested with MluI and SalI and purified by 
agarose gel electrophoresis, was ligated between MluI and SalI sites of pWPT, 
replacing the originally present sequence encoding GFP.  
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A range of DNA constructs for expression of FLAG-Cdc7 variants in human cells 
were made inserted and into pBABE (puro) (Figure 2-2) (Morgenstern and Land, 
1990) and pWZL (hygro) retroviral vectors . PWZL (hygro) was a gift from Scott 
Lowe (Addgene plasmid # 18750). A DNA fragment encoding FLAG-tagged Cdc7 
was PCR-amplified using pQFLAG-Cdc7 (Hughes et al., 2010) as templates and 
primers SD145 and SD149. The product, digested with SnaBI and ApaI and 
purified by agarose gel electrophoresis, was ligated between SnaBI and ApaI sites 
of the pBABE (puro) vector. This resulted in the pBABE-FLAG-Cdc7 (WT) construct, 
which was then used to produce mutants of Cdc7 by site directed mutagenesis 
and/or overlap-extension PCR (2.2.1.1 and 2.1.2). DNA fragments encoding Cdc7 
with Δ2aq mutations were also cloned into the pWZL (hygro) vector by amplification 
by PCR with SD150 and SD96 and subsequent ligation using the SnaBI and SalI 
sites. For a list of all primers used see Table 8-2.  
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Figure 2-2 Plasmids used for lentivirus and retrovirus production for expression 
of Cdc7 constructs in mammalian cells 
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2.3 Cell lines 
Cell lines created and used as part of this study can be found in Table 8-3. All cell 
lines were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen) 
supplemented with 10% foetal bovine serum (FBS, Invitrogen) and 100 U/ml 
penicillin and streptomycin (Invitrogen). Some cell lines were further supplemented 
with puromycin or hygromycin as described. Cells were cultured in a humidified, 
5% CO2 atmosphere. HEK-293T cells and HT1080 cells were provided by the LRI 
Cell Culture Facility (Clare Hall).  
 
2.3.1 Transduction of human cells with lenti- and retroviral vector particles 
All cell lines were generated by transduction of cells with lentiviral or retroviral 
vectors, which were produced by transfection of HEK-293T cells with the designed 
transfer vector and the relevant packaging (HIV-derived lentiviral p8.2 or MLV-
derived retroviral pCG-GAGPOL) and envelope (pMDG, encoding vesicular 
stomatitis virus glycoprotein G) constructs.  
 
Transfection of HEK-293T cells was performed using X-tremeGENE 9 lipid DNA 
transfection reagent (Roche) as per the manufacturer’s instructions. Cells were 
seeded in 10-cm culture dishes (2.8x106 cells per dish) 16 h prior to transfection. 
Fifteen µl of lipid reagent, diluted in 500 µl Opti-MEM (Invitrogen), was mixed with 5 
µg DNA mixture containing transfer, packaging and envelope constructs at a weight 
ratio of 10:8:2, and lipid-DNA complexes were allowed to form at room temperature 
for 15 min. During this time, culture media was removed from the HEK-293T cells 
and replaced with pre-warmed DMEM supplemented with 10% FBS but lacking 
antibiotics. After 15-min incubation, the 500-µl DNA:lipid mixture was added to the 
cells in a drop-wise fashion, and the dish was returned to a tissue culture incubator. 
After 24 h, the culture medium was replaced with fresh medium containing penicillin 
and streptomycin as previously described. Conditioned medium containing viral 
vector particles was harvested 48 and 72 h post-transfection and filtered through 
45-µm filters to produce a cell-free supernatant containing the desired virus without 
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any cell debris. The supernatant was then diluted 1:2 with fresh medium and used 
for infection of HT1080 cells.  
 
Lentiviral vector particles used to make the HT1080 mCherry-Cdc7(LoxP) cell line 
were produced using the pWPT-mCherry-Cdc7 lentiviral transfer plasmid in 
conjunction with the lentiviral packaging vector p8.2 and the viral envelope 
expressing construct pMDG. Two rounds of infection of HT1080 cells were 
performed 24 h apart to ensure a high efficiency of infection. Cells were then 
cloned by limited dilution to produce single colonies in 96-well plates, which were 
expanded for detection of Cdc7 expression by Western blotting (2.4.3). The result 
cell line was named HT1080 mCherry-Cdc7(LoxP). 
 
Retroviral particles used for expression of FLAG-Cdc7 and its mutant forms in the 
conditional knockout cell line CDC7(-/-) mCherry-Cdc7(LoxP) were produced by co-
transfection of HEK-293T cells with WT or mutant pBabe-FLAG-Cdc7 
supplemented with the retroviral packaging vector pCG-GAGPOL (Ulm et al., 2007) 
and the envelope construct pMDG. Conditional knockout cells were subjected to a 
single round of infection to reduce the chances of overexpression. Cells were 
treated with puromycin (1 µg/ml). To avoid clonal effects, selected cells were used 
as mixed populations.  
 
2.3.2  Disruption of endogenous CDC7 alleles using the CRISPR/Cas9 
system 
Four gRNAs targeting exons one or two of the CDC7 gene were cloned into the 
pX459 vector (Ran et al., 2013). To increase the odds of obtaining a frame shift 
with a complete knock out of the kinase expression, the gRNA target sites were 
selected immediately downstream of the Cdc7 start codon. HT1080 mCherry-
Cdc7(LoxP) cells were transfected with the CRISPR/Cas9 constructs as previously 
described  (2.3.1) and grown for 48 h before addition of 1 µg/ml puromycin. The 
antibiotic selected for successfully transfected cells, increasing the frequency of 
gene modification in the surviving cell population. After 24 h in the presence of 
puromycin, cells were diluted for single colonies and after expansion were tested 
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for Cdc7 expression by Western blotting. Any apparent knockouts were verified by 
amplification of the part of the gene targeted by the guide RNA by PCR, which was 
subsequently cloned into a Topo-TA sequencing vector (Life technologies). This 
was then used to transform NEB-5α competent E.coli. Bacteria were the plated out 
for single colonies on selective agar plates and small-scale plasmid preparations 
were made for a number of colonies for each clone. These were sequenced at the 
in house sequencing facility (London Research Institute) to verify disruption of the 
CDC7 gene. The resultant cell line after CDC7 knockout was named HT1080 
(CDC7-/-)mCherry-Cdc7(LoxP). 
 
2.3.3 Transgene excision from the conditional knockout cell line for cell 
cycle assays 
As part of the assays used to test Cdc7 mutants in cellula, the mCherry-Cdc7 
cassette, flanked in the pWPT backbone by a pair of LoxP sites, can be removed 
by expression of Cre recombinase. To achieve this, cells were harvested and 
counted before seeding in 12-well dishes (70,000 cells/well). Adenoviral vector for 
expression of Cre recombinase and GFP (Ad-Cre-GFP) or a control vector 
expressing GFP alone (Ad-GFP) was applied to the cells at a concentration of 5 
x106 PFU/ml in 0.5 ml of cell growth medium. The cell-virus mixture was transferred 
to the tissue culture incubator and agitated every 20 min for the initial 2 h of 
incubation. Twenty-four h post infection the media containing the adenovirus was 
removed and replaced with fresh media; the cells were then expanded for 
downstream analyses as needed.  
 
2.4 Protein analyses 
2.4.1 Sodium dodecyl sulphate – polyacrylamide gel electrophoresis (SDS-
PAGE) 
SDS-PAGE gels used for separation of protein samples were composed of a 4% 
stacking gel layered on top of a 11% running gel. Resolving gels were prepared by 
supplementing the monomer mix of 11% acrylamide, 0.29% bisacrylamide (w/v), 
0.1% sodium dodecyl sulphate (SDS) and 0.38 M Tris-HCl pH 8.8) with 0.042% 
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(w/v) ammonium persulphate (APS) and 0.84% (v/v) N,N,N’,N’-
Tetramethylethylenediamine (TEMED).  The stacking gel mix was prepared by 
supplementing a monomer mix of 4% acrylamide, 0.1% bisacrylamide, 0.1% (w/v) 
of SDS and 0.12 M Tris-HCl pH 6.8 with 0.046% (w/v) APS and 0.123% (v/v) 
TEMED.  Commercial gradient 4-20% Tris-glycine gels (BioRad) were used in 
some instances.  
 
Protein solubilised in Lamelli buffer (2% (w/v) SDS, 10% (v/v) glycerol, 0.0025% 
bromophenol blue, 62.5 mM Tris-HCl pH 6.8) supplemented with 25 mM β-
mercaptoethanol (BME) were separated by SDS-PAGE in 11% or 4-20% Tris-
Glycine gels run at 200 V in Tris-Glycine-SDS (TGS) buffer (25 mM Tris base, 250 
mM glycine, 0.1% (w/v) SDS). 
 
2.4.2 Coomassie staining 
Proteins separated by SDS-Page were visualised by staining with Coomassie. Gels 
were rocked in Coomassie staining solution (40% (v/v) methanol, 10% (v/v) acetic 
acid, 0.1% (w/v) Coomassie Blue R250) until protein bands were visible. Staining 
solution was then replaced with de-staining solution (40% (v/v) methanol, 5% (v/v) 
acetic acid) to achieve a clear background. 
 
2.4.3 Western blotting 
2.4.3.1  Preparation of whole cell extracts 
Cells harvested by trypsinisation were washed with phosphate buffered saline 
(PBS) supplemented with 0.1 mM phenylmethylsulphonyl fluoride (PMSF) and 
lysed in modified RIPA buffer containing 0.1% SDS, 0.5% sodium deoxycholate, 
1% nonidet P40 (NP40), 150 mM NaCl, 50 mM Tris-HCl pH 8.0, 0.1 mM PMSF and 
EDTA-free protease inhibitor cocktail (Roche). When blotting with phospho-specific 
antibodies the RIPA solution was supplemented with phosphatase inhibitors (1 mM 
β-glycerophosphate and 1 mM NaF). Insoluble debris were removed by 
centrifugation at 13,000 g for 5 min and analysed by SDS-PAGE and Western 
blotting. Protein concentration of lysates was measured by bicinchoninic acid 
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(BCA) protein assay (Pierce) with a BSA standard as per the manufacturers 
instructions. 
 
2.4.3.2  Electrotransfer and detection 
Proteins separated by SDS-PAGE were electroblotted onto Trans-Blot Turbo Mini 
PVDF membranes (BioRad) using a Transblot Turbo semi-dry transfer unit 
(BioRad) for 30 min at 25 V. Membranes were blocked at room temperature in 
blocking solution containing 5% (w/v) skimmed milk power in PBS supplemented 
with 0.1% Tween-20 for at least 2 h to reduce non-specific antibody binding. The 
membranes were then incubated with appropriate primary antibodies diluted in 
blocking solution for 2 h at room temperature with gentle rocking. The membranes 
were then washed in three changes of PBS supplemented with 0.1% Tween-20 for 
a total of 45-60 min to remove any excess antibody before incubation with the 
appropriate horseradish peroxidase (HRP) conjugated secondary reagent. Milk 
powder and phosphate buffers were avoided when using phosphospecific 
antibodies. The membranes were blocked and incubated with antibodies diluted in 
3% (w/v) BSA (Melford) in TBS/Tween (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 
0.1% Tween-20). Membranes extensively washed to remove unbound secondary 
reagent were soaked in ECL-prime or ECL-Select chemiluminescent detection 
reagents (GE Healthcare) prepared as per the manufacturer’s instructions. 
Amersham Hyperfilm ECL films exposed to membranes were developed using 
automatic film processing system (JP-33, JPI). 
 
2.4.3.3  Stripping of PVDF membranes 
Membranes were rinsed in PBS/Tween to remove the detection reagent before 
incubating in stripping buffer (71 mM β-Mercaptoethanol, 2% (w/v) SDS, 62.5 mM 
Tris-HCl pH 6.8) for 30 min at 50°C. After several rinses with PBS/Tween the 
membrane was blocked and re-probed as previously described (2.4.3.2). 
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2.4.3.4  Antibodies used for Western blotting 
The following primary antibody dilutions were used for Western blotting: Mouse 
anti-Cdc7 (Neomarkers) 1:10,000, rabbit anti Mcm2-phospho-S40 (Abcam) 1:1,000, 
goat anti-Mcm2 (N19) (SantaCruz) 1:500 and mouse anti-β-tubulin (Abcam) 
1:5,000.   
 
Horseradish peroxidase-conjugated anti-rabbit, anti-mouse and anti-goat 
secondary antibodies (Abcam) were all used at a dilution of 1:10,000. 
 
2.4.4 Production and purification of Cdc7-Dbf4 and Cdc7-Drf1 constructs 
All Cdc7 mutants were expressed using the pRSF Duet1 bacterial expression 
vector (Novagen) without a tag. All Dbf4 and Drf1 constructs were produced in a 
His6-tagged form of pCDF-His6-3C (Hughes et al., 2012), which is a modified 
version of the pCDF Duet1 vector (Novagen). Crucially, the pCDF and pRSF 
vectors contain compatible origins of replications, allowing for the plasmids 
encoding Cdc7 and Dbf4 or Drf1 to stably co-exist and doubly transformed bacteria 
can be selected in the presence of spectinomycin and kanamycin.  
 
E. coli Rosetta-2 (DE3) cells (Novagen) co-transformed with the respective 
versions of pRSF-Cdc7 and pCDF-His6-3C-Dbf4 or pCDF-His6-3C-Drf1 and were 
used for expression of the recombinant heterodimers. Bacteria were grown in LB 
supplemented with 50 µg/ml kanamycin and 100 µg/ml spectinomycin in shake 
flasks at 30°C. Cells were then cooled to 18°C upon reaching an A600 of 0.8, 
supplemented with 50 µM ZnCl2, and protein expression was induced by addition of 
0.01% w/v isopropyl-β-D-thiogalactopyranoside (IPTG). Following incubation 
overnight (~16 h) at 18°C with vigorous shaking, the cells were harvested by 
centrifugation and stored at -80°C. 
 
For purification, cells were thawed and re-suspended in kinase core buffer (50 mM 
NaH2PO4, 300 mM NaCl, 10% glycerol, pH 7.5) supplemented with 0.1 mM PMSF, 
complete EDTA free protease inhibitor mix, 1 mg/ml lysozyme and 0.5% NP40. The 
cells were disrupted by sonication on ice and the lysate was clarified by 
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centrifugation at 17,000 g at 4°C for 30 min using a Sorvall SS-34 rotor. The 
clarified extracts, supplemented with 20 mM imidazole were incubated with 3 ml of 
Ni-NTA agarose (Qiagen) for 30 min at 4°C with gentle rocking. The resin, collected 
by filtration through an empty gravity column (BioRad), was washed with 4 changes 
of 30 ml kinase core buffer supplemented with 20 mM imidazole to remove 
unbound and weakly bound proteins. His6-tagged proteins were eluted with 10 ml 
of kinase core buffer supplemented with 200 mM imidazole in 1-ml fractions. 
Protein containing fractions were pooled, diluted with salt-free buffer to adjust NaCl 
concentration to 200 mM NaCl, supplemented with His6-tagged λ-protein 
phosphatase (1 mg per 15 mg of protein), His6-tagged HRV14 3C protease (1 mg 
per 50 mg of protein), 1 mM MgCl2, 2 mM MnCl2 and 1 mM DTT and incubated 
overnight at 4°C to allow for His6-tag cleavage from the Dbf4 or Drf1 mutant and 
de-phosphorylation of the proteins. The next day, precipitated material was 
removed by centrifugation and the soluble protein was dialysed against a large 
excess of low salt/imidazole buffer (50 mM Tris-HCl pH 7.5, 100 mM NaCl, 20 mM 
imidazole, 2 mM DTT) for 2 h at 4°C using a Slide-A-Lyzer cassette (Pierce). 
Dialysed protein was passed through a 1-ml HisTrap FF column to remove His6-
tagged phosphatase and protease. The recombinant Cdc7-Dbf4/Drf1, collected in 
the flow through, was diluted 1:5 in salt-free buffer to adjust NaCl concentration to 
~80 mM and filtered through a 1-ml HiTrap Q HP column to remove further 
contaminants. The heterodimers, collected in the flow through, were supplemented 
with 2 mM DTT and concentrated to ~5 ml using a VivaSpin 20 centrifugal 
concentrator with a 10,000 MWCO and PES membrane (Viva products). 
Complexes were then further purified by size exclusion chromatography on a 
Superdex 200 16/600 column operated in 150 mM NaCl, 25 mM Tris-HCl, pH 7.5. 
Fractions were analysed by SDS-PAGE and those containing Cdc7-Dbf4/Drf1 
heterodimers were pooled and dialyzed against excess of a ZnCl2 containing buffer 
(25 mM Tris-HCl pH 7.5, 150 mM NaCl, 2 mM DTT, 75 µM ZnCl2) overnight at 4°C. 
The protein was then concentrated to ~10 mg/ml and either used in crystal trials or 
supplemented with 10% glycerol and flash-frozen in liquid nitrogen for later use in 
kinase assays. 
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2.4.5 Crystal screens 
Crystal screening was performed using a range of commercially available screens 
of sparse matrix conditions. Such screens typically contain 96 conditions that have 
been identified as being previously successful in the crystallisation of other proteins 
through data mining. Many screens are designed for the crystallisation of specific 
protein families. Screens were prioritised for screening, which were specifically 
designed for crystallisation of kinases (JB Kinase) as well as prioritising those, 
which had contained promising conditions in previous experiments. Screens were 
utilized in the order presented in the table until the entire prepared protein sample 
had been utilised. 
 
Table 2-1 Table of commercially available screens used in this study 
Screen Name Manufacturer Product No. 
JB Kinase Jena Bioscience CS-204L 
JB cryo Jena Bioscience Discontinued 
JCSG+ Molecular Dimensions MD1-37 
PACT Premier Molecular Dimensions MD1-36 
Wizard Cryo 1+2 Molecular Dimensions 1008649 
Wizard 1+2 Molecular Dimensions 1008647 
Wizard 3+4 Molecular Dimensions 1008648 
Morpheus Molecular Dimensions MD1-47 
Peg Ion Hampton Research HR2-139 
Crystal Screen Hampton Research HR2-130 
Midas Molecular Dimensions MD1-59 
Natrix Hampton Research HR2-131 
MPD Suite Qiagen 130706 
 
 
2.4.6 Synthesis of ATPγS conjugated peptides 
All ATPγS-conjugated peptides used in this study were synthesised in the in-house 
peptide synthesis facility based at the London research institute (LRI), London. All 
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Fmoc-protected amino acids, N-α-Fmoc-N-β-4-methyltrityl-L-diaminopropionic acid 
and the Rink Amide resin were purchased from Merck. Adenosine 5ʹ-O-(3-
Thiotriphosphate) tetralithium salt and Adenosine 5ʹ-O-(2-Thiodiphosphate) 
trilithium salt were purchased from Calbiochem. Dichloromethane (DCM) and 
Dimethylformamide (DMF) were purchased from VWR. Acetonitrile (ACN) and 
Diethyl ether were purchased from Fisher. Bromoacetic acid, Triethylammonium 
bicarbonate buffer, Trifluoroacetic acid (TFA), Triisopropylsilane (TIS), and 
Diisopropylcarbodiimide (DIC) were purchased from Sigma. 
 
Peptides backbone were synthesised on a 433A peptide synthesiser by solid phase 
peptide synthesis following standard Fmoc chemistry. Peptides were assembled on 
a Rink Amide resin (LL 0.30 – 0.40 mmol/g) in order to have a C-terminal amide. 
ATP-peptide conjugates are usually used as bisubstrate analogue inhibitor of the 
serine/threonine kinase proteins. In this work serine was replaced with 
aminoalanine using the derivative N-α-Fmoc-N-β-4-methyltrityl-L-diaminopropionic 
acid (Fmoc-Dap(Mtt)-OH). After synthesis, the side-chain Mtt group was selectively 
removed by treatment of the peptidyl resin with 1% TFA, 4% TIS in DCM. 
Afterwords a bromoacetyl moiety was linked to the aminoalanine by reacting the 
peptidyl-resin with 8.3 eq of bromoacetic acid, 8.3 eq of DIC in a minimum amount 
of DMF under stirring condition for 2 hours at RT. Peptides were then cleaved from 
the resin by treatment with 10 ml (v/v) of 95% TFA, 2.5% TIS, 2.5% water for 2 hr. 
Peptides were precipitated with diethyl ether, dissolved in water after centrifugation 
and lyophilized. Purification was performed by reversed-phase HPLC using 1% 
ACN, 0.08% TFA in H2O (buffer A) and 90% ACN, 0.08% TFA in H2O (buffer B). 
The desired mass of the peptides was confirmed by LC-MS. The ATPγS/ADPγS-
peptide conjugates were obtained through a thioether bond formation by reacting 
the sulfhydryl group of ATPγS  and the bromoacetyl moiety linked to the 
aminoalanine.  
 
In previous methods (Parang et al., 2001) the purified bromoacetylated peptide was 
dissolved in a solution MeOH:H2O 4:1 and treated with ATPγS (adenosine 5’-O-
3-thiotriphosphate) for 24h at room temperature. The resulting peptide was purified 
by reversed phase HPLC using a gradient of H2O:ACN under neutral conditions 
without using TFA. For peptides used in this study, Triethylammonium bicarbonate 
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buffer (1M, pH 8.4-8.6) was used to perform this reaction since the 
bromoacetylated peptides were not soluble in the MeOH:H2O 4:1 solution. Peptide 
and ATPγS were dissolved separately in the buffer in a ratio 1:2 respectively. The 
two solutions were then mixed and the reaction was carried out for 24 h at room 
temperature. The compound was lyophilised 2 or 3 times until complete removal of 
the salt by addition of water. Peptides with pI > 3 were purified by reversed phase 
HPLC under neutral condition. Peptides with pI < 3 when dissolved in water were 
showing auto-hydrolysis of the ATPγS group, as this is very acid sensitive. 
Therefore these peptides were purified using an Extend-C18 column, which can 
withstand high pH (up to 11.5) compared to standard C18 column. These peptides 
were purified under a gradient of 10mmol NH4 (buffer A) and 90% ACN-10 mmol 
NH4 (buffer B). The purity of the final product was verified using LC-MS in negative 
ion mode. Overall, for most of the peptides, the use of Triethylammonium 
bicarbonate buffer resulted more convenient and efficient than the MeOH:H2O 
solution. 
 
 
2.4.7 In vitro kinase assays 
Cdc7 kinase assays were carried out using Mcm2-derived peptide substrates 
synthesized in the in-house peptide synthesis facility (Lincolns Inn Fields, London). 
The substrate peptides spanned residues 35-47 of human Mcm2 
(TDALTS[pS]PGRDLP-biotin) and were biotinylated at the N-termini. Unless stated 
the peptide contained a phosphate group attached to Ser41 [pS] residue, which is 
phosphorylated by CDK2 in vivo (Montagnoli et al., 2006). Where required by the 
experiment, substrate peptides were synthetized with mutations as indicated (Table 
8-5).  This assay was developed by Hughes et al. (2012). 
 
Each 25-µl kinase reaction mixture contained 5 µg biotinylated substrate peptide 
and 2.8 nM Cdc7-Df4 or Cdc7-Drf1 or corresponding molar equivalents of a mutant 
form with 3 µCi of [γ-32P]ATP (3,000 Ci/mmol) in 10 mM MgSO4, 2 mM DTT, 1 mM 
β-glycerophosphate, 1 mM NaF, 80 µg/ml BSA, 0.1% NP-40, 0.1 mM ATP, 40 mM 
Hepes-NaOH, pH 7.4. Kinase reactions, were incubated for 30 min at 30°C before 
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stopping with the addition of guanidine hydrochloride to a final concentration of 2.5 
M. The reactions were then spotted onto SAM2 biotin-capture membranes 
(Promega) before sequential washes with 2 M NaCl solution (three times), 2 M 
NaCl in PBS (four times) and distilled water (twice). Each washing step was 
performed with rocking for a minimum of 2 min. The membranes were then washed 
with 95% ethanol and air-dired. Incorporated radioactivity was detected and 
quantified by exposing the membranes to a phosphor storage screen which was 
then scanned using a Storm-860 phosphorimager (GE Healthcare). 
2.4.7.1  In vitro kinase assays with immobilized peptide arrays 
The membranes containing immobilized peptides derived from human Mcm2, 
Mcm4 and Mcm6 were briefly soaked in kinase assay buffer (50 mM Tris pH7.5, 10 
mM MgCl2, 2 mM DTT, 1 mM β-glycerophosphate, 1 mM NaF and 0.1% NP40) 
then washed with sequential changes of 50%, 25%, 12.5% and 5% methanol in 
distilled water followed by a 20 min incubation in distilled water. Following this 
procedure, all visible peptide spots on the membranes appeared hydrated. The 
membranes were washed twice with an excess of kinase buffer and processed for 
the in vitro phosphorylation assay. 
 
Each membrane was soaked in 6 ml kinase buffer supplemented with 80 µg/ml 
BSA, 700 µCi of [γ-32P]ATP. Recombinant Cdc7(ΔN)-Dbf4(MC) (1.4 µg) was then 
added to the reaction and the membrane was rocked at 30°C for 30 min. The assay 
was stopped by careful aspiration of the reaction mixture and soaking the 
membrane with 6 ml of 0.5 M EDTA for 10 minutes. The membrane was the 
washed sequentially with rocking in 1 M NaCl (20 min), 1% SDS (20 min), 2 M 
NaCl (twice for 10 min) and distilled water (twice for 10 min). The membrane was 
then washed 15 times (5 minutes per wash) in 0.5% phosphoric acid before leaving 
rocking in 20 ml 0.5% phosphoric acid over night at room temperature. The next 
day the membrane was rinsed with distilled water followed by submersion in 95% 
ethanol for 15 s and air-dried. Dry membranes were analysed by phosphorimaging 
using a Storm-860 instrument (GE Healthcare).  
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2.5 Cell cycle analysis using flow cytometry 
Cells were stained for actively replicating DNA using a Click-iT Plus EdU Alexa 
Fluor 647 Flow Cytometry Assay kit (Invitrogen) and for total DNA content using 
propidium iodide. Sample preparation was carried out according to the 
manufacturer’s instructions. Cells in culture in 10-cm dishes were incubated with 10 
µM EdU (supplied) by addition of a concentrated stock solution to the culture media 
for 2 h prior. Cells harvested by trypsinization and washed with PBS supplemented 
with 1% BSA were (PBS/BSA) fixed by re-suspension in 100 µl of Click-iT® fixative 
solution containing 4% paraformaldehyde in PBS for 15 min before washing again 
in PBS/BSA. Cells were then permeabilised by re-suspension in 100 µl 1X Click-iT 
saponin-based reagent (supplied, diluted 1:10 in PBS/BSA). The remaining steps 
were carried out away from direct light. After 30-min incubation, the cells were 
supplemented with 500 µl of the Click-iT Plus reaction cocktail (438 µl PBS, 10 µl 
copper protectant, 2.5 µl picolyl azide fluorescent dye and 50 µl of a 1:10 dilution of 
reaction buffer additive) to each sample and left for 30 min. In this step the 
fluorescent dye is covalently attached to the EdU nucleotides incorporated into the 
newly synthetized DNA. Cells were then washed with 3 ml of Click-iT saponin-
based reagent, pelleted and re-suspended in 100 µl of the permeabilisation reagent. 
Cells were then stained with propidium iodide by addition of 500 µl of 
permeabilisation solution supplemented with 0.25 µg/ml propidium iodide and 0.1 
mg/ml RNAse A (Sigma-Aldrich). Cells were incubated at 37°C for 30 min before 
analysis by flow cytometry using a FACSCalibur system (BD Biosciences). Alexa 
Fluor 647 was excited at 635 nm and detected with a 661 nm band pass filter. 
Propidium Iodide was excited at 488 nm and detected using a 585 nm band pass 
filter. The data were acquired using CellQuest software (BD Biosciences) and 
analysed in FlowJo v9.9. Cell populations were gated using the plot of forward 
scatter versus side scatter. Single cells were then discriminated from doublets by 
gating on the PI area vs PI height plots. These gated cells were then used for 
analysis of cell cycle profiles. 
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2.6 X-ray crystallography methods and theory 
X-ray crystallography is a well-established method for studying structures of 
macromolecules. Consequently numerous comprehensive texts have been 
published on X-ray crystallographic theory and practice (Rupp and Kantardjieff, 
2010). This section contains a brief overview of X-ray crystallographic theory and 
the techniques and computational processes used in this study. 
 
2.6.1 Production of protein crystals 
2.6.1.1 Crystal growth and optimisation 
Formation of crystals is achieved through inducing a highly purified protein 
preparation to enter a state of limited supersaturation that is prone to crystal 
nucleation and subsequent growth (Figure 2-3). There are 3 possible phases of 
supersaturation: 
 
1. Nucleation zone – excess protein can spontaneously form into new 
crystalline structures. 
2. Metastable zone – nucleation cannot occur to form new crystals, but 
currently existing crystals are able to grow. 
3. Precipitation zone – excess protein forms amorphous aggregates. These 
aggregates are of no use in crystallography. 
 
Crystal trials are used to sample supersaturation space and identify conditions, in 
which a given protein will enter the nucleation zone and subsequently move into 
the metastable zone, forming crystals without aggregating. The conditions needed 
to achieve this are specific to each protein and, therefore, thousands of conditions 
are often tried before gaining a single crystal. 
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Figure 2-3 Crystallisation by vapour diffusion 
 
X=optimal protein/precipitant concentration for crystal growth. 
 
 
A common method of sampling supersaturation space is vapour diffusion, whereby 
a small volume (0.05 -1 µl) of concentrated (5-20 mg/ml) protein solution is added 
to an equal volume of reservoir solution containing a precipitant. This drop is then 
sealed in a container with a large excess of reservoir solution and maintained at a 
constant temperature with minimal vibration. The protein-containing drop will 
equilibrate with the more concentrated reservoir solution through a vapour phase, 
which will usually slowly reduce the volume of the drop, causing the protein to 
sample super saturation space until the solutions have equilibrated. Typically, a 
wide range of reservoir solutions must be tested to identify optimal crystallisation 
conditions. A number of variables can be optimised, including pH and type of buffer, 
precipitant type and concentration, protein concentration and drop volume, 
temperature and nature of chemical additives. Upon identifying a suitable 
crystallisation condition, crystals are optimised by creating fine grids of conditions, 
in which each component of the reservoir solution is varied against the precipitant 
concentration to produce better diffracting crystals. At this point, it is also common 
to try adding a number of different chemical additives, which may improve crystal 
quality. Additive screening was integral to the optimisation of crystals obtained in 
this study, as was optimisation of the pH of the reservoir solution. 
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An important crystallography technique often used for production of crystals is 
microseeding, whereby small crystal fragments are used to nucleate crystal growth 
in conditions that would normally not allow spontaneous nucleation. In this study, 
crystals of Cdc7-Dbf4 bound to XL413, which could be obtained by spontaneous 
nucleation, were transferred to new protein-reservoir drops supplemented with 
alternative ligands. This process allowed the second series of drops to have a 
sufficiently low precipitant concentration to equilibrate directly into the metastable 
zone and produce crystals that were otherwise impossible to obtain.  
 
2.6.1.2  Cryo-protection of crystals 
Due to X-rays being an ionising form of radiation, crystals are subject to a large 
amount of radiation damage during data collection. Radiation damage in 
crystallography is present in two forms. Dose-dependent radiation damage is 
postulated to result from the ejection of electrons from the electron spheres of a 
molecule due to its interaction with X-ray photons (Henderson, 1990). Radiation 
damage can also be time dependent and this is thought to arise from the 
accumulation of free radicals within the protein crystals. Free radicals can damage 
the crystallised molecule and the large solvent content of protein crystals acts as a 
medium for their dissemination (Matthews, 1968). For this reason, experiments with 
crystals of macromolecules are almost always carried out at low temperatures 
(~100 K) to reduce radiation damage by minimising the movement of free radicals 
through the solvent (Haas and Rossmann, 1970). This drastically reduces the time 
dependent radiation damage in a given experiment, and even though dose 
dependent damage remains the same, the reduction in X-ray damage is usually 
sufficient to allow for a full data set to be collected from a single crystal. 
 
To prepare crystals for data collection, crystals are cryo-cooled by plunging into 
liquid nitrogen. However, it is crucial to avoid formation of crystalline ice during this 
process. Crystalline ice not only damages the crystal, but degrades diffraction data 
due to its ability to diffract X-rays. Therefore, cryoprotectants are used to create 
conditions that promote formation of amorphous ice. In macromolecular 
crystallography experiments, cryoprotectant solutions are typically comprised of a 
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solution similar to the crystallisation condition that has been supplemented with a 
cryoprotecting agent such as glycerol, polyethelene glycol (PEG) 400, ethylene 
glycol or 2-methyl-2,4-pentanediol (MPD). The optimal concentrations of a 
cryoprotectant and soaking time are determined experimentally and vary from 
crystal to crystal. It is also often necessary to adjust concentration of the 
cryoprotectant by gradually increasing its concentration to avoid crystal shrinking or 
cracking, both of which can have a detrimental effect on X-ray data quality 
Cryocooling also allows samples to be stored for extensive periods of time before 
data collection. 
 
2.6.2 Data collection and processing 
Prior to freezing, crystals are mounted on nylon loops, which create little in the way 
of background signal from X-ray diffraction. When collecting data, the loops are 
mounted either manually or by a robot onto a rotating goniometer head and aligned 
in the path of an X-ray beam, while a stream of liquid nitrogen vapour maintains the 
temperature of the crystal. The X-ray beam is directed at the rotating crystal and 
the X-rays are scattered by the electron shells of the macromolecules forming the 
crystal lattice. The diffraction data recorded on a detector can be subsequently 
used to calculate an electron density map of the crystallised material. 
 
2.6.2.1  Basic principles of X-ray diffraction  
X-rays are primarily scattered through interaction with the electron shells of the 
atoms of the crystallised molecule. The angles of these diffracted beams can be 
calculated if diffraction is treated as reflections from equivalent parallel planes 
designated by three numbers h, k, l, where evenly spaced parallel planes in relation 
to the unit cell are defined by the miller indices hkl. Braggs law gives the angles for 
coherent and incoherent scattering from a crystal lattice, in which X-rays of 
wavelength λ are reflected by a set of parallel planes (hkl) with a spacing of dhkl  
between planes at a given angle of incidence (θ). 
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2dhklsinθ = nλ 
 
                                  Equation 2-1 – Bragg’s Law 
 
Reflected waves can be in phase and constructively interfere, creating a diffracted 
beam, which is recorded by a detector. Constructive diffraction occurs when n is an 
integer at angle θ. The minimum inter-planar distance that creates constructive 
diffraction defines the maximum resolution of the collected data. When waves are 
not in phase they cancel each other in a process called destructive interference, 
which does not create a diffracted beam. The size of the unit cell of the crystal 
defines how many diffracting planes are present, with unit cells containing more 
planes producing more reflections. 
 
2.6.2.2  X-ray data collection 
In this thesis, all diffraction data was collected at synchrotron sources. A 
synchrotron uses a particle storage ring as a source of X-rays. Within this ring, 
powerful magnets accelerate electrons until they approach the speed of light. When 
accelerated electrons are forced into a curved path, they emit energy in the form of 
electromagnetic radiation at a number of different wavelengths. Monochromators 
and a series of mirrors are used to isolate and focus beams of X-rays at a required 
wavelength. This allows X-rays to be tuned for specific uses in diffraction 
experiments. Most protein crystal diffraction experiments use X-rays with 
wavelengths of 0.9-1 Å. Synchrotron sources allow for much faster data collection 
and detection of weaker reflections than would be possible using laboratory-based 
instrumentation due to the significantly greater intensity of the X-ray beam and the 
availability of cutting-edge detectors at the national shared facilities.  
 
A number of methods are available for detection of X-ray diffraction data. In this 
thesis, data collected at the ESRF beamline BM14 were acquired on a charge 
coupled device (CCD). A CCD detects visible light, which is created by a phosphor 
screen placed in front of the detector. This screen creates visible light proportional 
to the intensity of diffracted X-rays, which can then be read by the CCD. Data 
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collected at the Diamond Light Source beamline I03 used a new-generation Pilatus 
6M detector. This is a pixel device, in which X-rays are converted directly to electric 
signal by the photoelectric effect in silicon subject to a bias voltage. The electrical 
signal can then be rapidly detected by an application-specific integrated circuit. 
This drastically reduces the time required to collect a dataset by reducing the 
changeover times between images as well as allowing for shorter exposure times 
due to the increased sensitivity of the system. This, in turn, decreases the amount 
of radiation damage the crystal is subjected to, allowing for fast collection of high-
redundancy data. 
 
2.6.2.3  Mosaicity and oscillation 
Crystals are made up of an ordered lattice of molecules. In a perfect crystal, every 
unit cell would be identical and aligned at the same angle. However, in a typical 
crystal unit cells can vary slightly in size leading to imperfections in the alignment of 
the crystal lattice. Such heterogeneity is referred to as mosaicity, which is a 
prominent problem in macromolecular crystallography, as the crystallised 
molecules are relatively flexible and held together by weak interactions. Mosaicity 
leads to reflections that are spread as the crystal is rotated and can lead to partial 
reflections, in which the reflection is split over a number of frames. The oscillation 
angle between individual frames is an important factor to consider during data 
collection, as it is important to minimise the number of overlapping reflections. If the 
unit cell of a crystal is very large, reducing the oscillation to a very small angle can 
be helpful in reducing the number of overlaps. The choice of oscillation angle is 
also influenced by the X-ray source and detector used for the experiment.  A small 
oscillation angle requires more images for a complete data set, which can be 
prohibitive with weaker sources, and slower detectors. A larger oscillation angle 
may help to increase the signal-to-noise ratio. Consequently, oscillation angles are 
determined for each individual experiment to acquire an optimal data set.  
 
Chapter 2 Materials and Methods 
 
97 
 
2.6.2.4  Selecting oscillation range for data collection 
The number of individual frames that need to be collected is crystal-dependent, 
with those containing a higher order symmetry requiring less rotation/frames to 
achieve completeness (i.e. acquisition of ~100% possible diffraction spots for a 
given resolution range). The required oscillation range required can be predicted 
from a small number of test exposures (2-3 diffraction images separated by 90o), 
which can be processed using Mosflm (Leslie and Powell, 2007) or other indexing 
software. Mosflm determines the unit cell dimensions and predicts symmetry 
directly from the diffraction pattern. This process was straightforward for all the 
crystals obtained in this study, which had tetragonal symmetry (P41212) and similar 
unit cell dimensions. Due to the current speed of data collection it is common to 
collect more data than absolutely needed. This not only increases the signal to 
noise ratio of the data collected, but supplies more data for processing should the 
space group have been incorrectly calculated at a higher order of symmetry. 
 
2.6.2.5  Data processing 
Data processing for all structures was completed using the Xia2 automated pipeline 
(Winter, 2010a). Xia2 utilises the programmes XDS (Kabsch, 2010a) for indexing 
and integration, Pointless and Scala (Evans, 2006a) for determination of symmetry 
and scaling. XDS refines the size and orientation of the unit cell and determines 
possible space groups for the crystal. Pointless uses intensities of integrated 
reflections to determine point group and make a reasonable guess of a space 
group, based on systematic absences. Modern software is usually very good at 
determining the space group, however, errors in this process can sometimes be 
revealed at subsequent steps that can require the data to be re-processed. In less 
trivial cases, the initial space group assignment may need to be re-evaluated at a 
later stage, even during model refinement.  
 
Following indexing, peak intensities are integrated by XDS and the reflections can 
then be corrected for a number of experimental errors. Factors that can affect 
integration include crystal decay from radiation damage, incident beam polarisation 
and relative differences in sensitivity on different parts of the detector. Scala also 
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calculates standard deviations for equivalent reflections. The data quality in this 
respect is described by the Rmerge value, which describes the agreement of 
symmetry-related reflections with respect to the resolution of the data. Rmerge is 
used in conjunction with the <I/σ(I)> parameter (average signal-to-noise ratio) to 
decide the maximum resolution of data, which is of sufficient quality for subsequent 
processing. Rmerge is inversely related to the redundancy of the data, meaning that 
data quality appears to decrease as each reflection is measured multiple times. 
However, the accuracy of the mean intensity value is increasing, meaning 
improved data quality (Diedrichs and Karplus, 1997, Weiss and Hilgenfeld, 1997). 
Therefore, Rp.i.m. (precision indicating merging R factor) could be a better quality 
indicator, especially for the higher redundancy data. Scala was used (Evans, 
2006a) to merge all diffraction data and place them on a common scale before 
converting the newly merged intensities to structure factors.  
 
2.6.3 Structure refinement and model building 
2.6.3.1  Phase determination by molecular replacement and calculation of 
electron density maps 
The electron density map is calculated as a Fourier transform of the total structure 
factors. A structure factor is a vector with an amplitude ΙFhklI proportional to the 
square root of the corresponding reflection intensity (Ihkl) and a phase angle (αhkl). 
In an X-ray diffraction experiment, the structure factor amplitudes can be derived 
directly from the measured intensities. However, their phases are lost due to the 
lack of a reference waive. A number of methods exist for the solution of the “phase 
problem”. In the case of all structures in this study, the approximate initial phases 
were determined using molecular replacement. This method uses a model 
structure with sufficient amino acid sequence identity to the molecule in the crystal. 
In this case, the near-identical structure of Cdc7-Dbf4 obtained by Hughes et al. 
(2012) was used as a model.  Prior to molecular replacement, the number of 
molecules in the unit cell was calculated using the Matthews coefficient (Vm) 
(Matthews, 1968). The Matthews coefficient uses the unit cell size and 
crystallographic symmetry to estimate the solvent content and number of molecules 
in the assymetric unit. It is a simple equation that divides the total volume of the 
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unit cell by the product of the molecular weight of the molecule and the number of 
molecules in the assymetric unit. The likely value of Vm for crystals of 
macromolecules covers a small range as high numbers of molecules in the unit cell 
will be too tightly packed, and low numbers will contain too much solvent to 
successfully form a crystal lattice.  
 
Molecular replacement was performed using the programme Phaser (McCoy, 
2007), which uses a maximum likelihood method to test a series of hypotheses of 
possible orientations of the molecule in the unit cell. Each possibility is then used to 
calculate a solution and the programme calculates a probability that the given data 
could have been observed from each solution. Phaser orients each molecule in the 
assymetric unit individually and in sequence. It achieves this first by sampling 
different rotations of the model before determining solutions for a translation 
function. When more than one molecule is present in the asymmetric unit, the 
solutions for the first molecule are tested alongside subsequently added units. The 
likelihood scores for given solutions diverge drastically as more molecules are 
added, meaning the correct solution is often quite obvious. Once this solution is 
determined, Phaser uses the supplied model to perform a rigid body refinement of 
the molecules in the asymmetric unit to improve the fit to the calculated electron 
density maps.  
 
All structures solved in this study contained only one molecule in the asymmetric 
unit. This, in combination with the near 100% sequence identity of the model, made 
molecular replacement very straightforward. The XL413-bound structure obtained 
by Hughes et al. was used as a model for the new XL413 bound structure (PDB: 
4F9C). All subsequent structures used the newly solved structure as a model. 
 
2.6.3.2  Refinement, model building and structure validation 
Refinement and model building in crystallography involves an iterative process of 
manual model building and automated refinement. This process improves the 
accuracy of the electron density maps through improvement of the calculated 
phases. Automated refinement interprets the electron density maps based on 
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knowledge of protein chemistry and the sequence of the supplied model. Observed 
structure factors (Fobs) are compared with calculated structure factors (Fcalc), and, 
as the correlation of these values improves, the Rwork value decreases. Rwork is used 
as an indicator of how well the model fits the obtained data and, therefore, the 
likelihood that the given solution is correct. The calculated Rwork does not factor in 
the inherent bias introduced by the initial model and the subsequent rounds of 
refinement. For this reason, the Rfree value is calculated comparing the calculated 
structure factors with the observed structure factors using a small subset of data 
(2,000 reflections or more, typically comprising 5% of the dataset), which has not 
been used in refinement. When the modelling is in agreement with the data, each 
round of refinement will decrease both the Rwork and Rfree parameters. Significant 
divergence between Rwork and Rfree (> 6%) may indicate over-refinement, which can 
often be resolved by using tighter geometric or non-crystallographic symmetry 
restraints during refinement. An important consideration when using 
crystallographic data is the data-to-parameter ratio. Refinement of a small crystal 
structure (50-kDa protein) involves Cartesian coordinates and B-factors of 
thousands of atoms. Therefore, in macromolecular structure refinement, the data-
to-parameter ratio is often very low. However, the knowledge of the physical 
properties of the atoms making up the unit cell helps to refine a macromolecular 
structure. While there is infinite number of ways atoms could be positioned in a 
given lattice to reproduce a given diffraction pattern, there is only one that is 
physically possible. Atoms do not penetrate each other and form bonds with well-
known parameters, which are used as restraints when refining a macromolecular 
structure. At higher resolutions, the data-to-parameter ratio is improved, and 
restraints can be relaxed or even avoided during refinement.  
 
For all structures refined in this study, automated refinement was performed using 
phenix.refine (Adams et al., 2010b). Each round of refinement produced two 
weighted Fourier maps with the refined phase information: 2Fo-Fc map which 
should cover built parts of the model and the difference Fo-Fc map, which is very 
convenient to reveal missing or incorrectly built portions of the model. Model 
building was done using Coot (Emsley and Cowtan, 2004b) between rounds of 
automated refinement. Due to the high resolution of the collected data it was very 
straightforward to build newly added parts of the structure into the calculated 
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density. The number of residues that could be fitted correctly also increased with 
each round of refinement as the calculated phases improved. 
 
Validation of the structures was performed using a range of tools in Coot, which 
identifies large areas of positive or negative density as well as identifying outliers in 
torsion angles of amino acids. Molprobity reporting, incorporated into the 
phenix.refine programme, also provided validation information with regard to 
possible clashes in the structure and geometric distortions, which allowed for fine-
tuning of the structure (Chen et al., 2010). Building and validation were performed 
side-by-side in each round of manual model building. After each round of 
refinement, the backbone dihedral angles of each residue were also reviewed by 
plotting them on a Ramachandran plot that can be viewed in Coot. The plot shows 
allowed regions for the Ψ and Φ angles of each residue and identifies any residues 
in the structure that fall outside of the favoured regions of the plot. This is an 
indicator they may have been incorrectly modelled. Final structures had good 
geometry with over 97% of residues in the most favourite regions of 
Ramachandran plot.
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Chapter 3. Results 1 – Design, production and 
activity of Cdc7-Dbf4 and Cdc7-Drf1 constructs 
 
3.1 Aims 
A crystal structure of a hetero-dimeric Cdc7 (ΔN/2q/3b)-Dbf4(MC) was previously 
solved in the lab (Hughes et al., 2012). Due to inherent flexibility, significant 
portions of the kinase were removed to assist crystallization. The deletions were 
made at the N-terminus of Cdc7 (residues 1-36), in KI2 (residues 228-359) and in 
KI3 (residues 484-529). Deletions in KI2 of Cdc7 lead to significant decreases in in 
vitro kinase activity, and it proved impossible to gain a substrate-bound structure of 
this construct (Hughes et al., 2012).  
 
The aim for this part of the project was to express and purify an improved Cdc7-
Dbf4 construct with activity comparable to that of the full-length kinase in quantities 
sufficient for crystallisation trials. In this chapter, the rationale for construct design 
is presented along with the production of a number of novel Cdc7-Dbf4 
heterodimers with different combinations of KI2 and KI3 deletions. Numerous 
soluble and well-expressed constructs were obtained; revealing that only a small 
portion of KI2 needed to be added back to the crystallised construct to restore WT 
levels of activity. The construct was also further optimised to allow for crystallisation 
of an active heterodimer through engineering of KI3 and optimisation of different 
ATP analogues for the use in crystallisation trials. 
 
 
3.2 Rationale for design of Cdc7 constructs with improved 
levels of activity 
In the previously crystallised Cdc7-Dbf4 construct, deletions at the N-terminus of 
Cdc7 and within KI3 had no effect on the in vitro kinase activity. In contrast, the 
deletion in KI2 led to a ~2-fold reduction in activity (Hughes et al., 2012). The 
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truncations were designed based on sequence alignments (see appendix) and 
secondary structure predictions, as well as results of limited proteolysis that 
suggested that such regions may be disordered in the context of the dimer. The 
construct that yielded diffracting crystals only contained a small portion of Dbf4 
(residues 210-350) corresponding to the conserved motifs-M and C with the natural 
linker between them. This was previously shown to be the minimal module required 
for Cdc7 activation, while much of the rest of Dbf4 is predicted to be disordered 
(Ogino et al., 2001, Kitamura et al., 2011).  
 
Therefore, in order to obtain an active Cdc7-Dbf4 complex, residues were added 
back into the previously crystallised construct while maintaining the N-terminal and 
KI3 deletions. Residues were initially added to the Arg373 at the C-terminal end of 
KI2, due to its close proximity to the active site in the structure (Figure 3-1). A panel 
of KI2 deletions were created for expression, purification and subsequent testing in 
in vitro kinase assays. After achieving WT levels of activity, further engineering of 
KI3 was conducted to create mutants that would be more amenable to 
crystallisation (Table 3-1). 
 
The nomenclature of deletion constructs was based on the order in which specific 
deletions in Cdc7 were made. The first attempted KI2 deletion was termed Δ2a and 
each subsequent construct was assigned the next letter of the alphabet. Upon 
reaching z, constructs were then named Δ2aa, 2ab and so on. The same system 
was utilised for KI3 deletions and the Drf1 constructs while the two MC fragments 
were simply named MC and MC2. This was a system developed by Siobhan 
Hughes that allowed simple identification of the features of each given construct. 
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Figure 3-1 View of the Cdc7 active  site in the  crystal structure solved by 
Hughes et al. (2012) 
Protein chains are shown as cartoons with conserved regions and KI2 of Cdc7 
shown in green and pink respectively. Dbf4 is shown in cyan. The nucleotide (ADP, 
with carbon atoms in magenta) and selected Cdc7 active site residues are shown 
as sticks (PDB: 4F99). 
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Table 3-1 Cdc7, Dbf4 and Drf1 constructs produced for crystallography trials 
 
 
Red letters represent inserted amino acids to link ends of the truncated protein 
chain (*constructs made by S. Hughes). The previously crystallised Cdc7 construct 
and the construct crystallised in this study (ΔN/2aq/3e) are shown in bold.  
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3.3 Expression and purification of Cdc7-Dbf4 and Cdc7-Drf1 
complexes 
Recombinant heterodimers were expressed and purified as described previously 
(Hughes et al 2012), with some modifications. One crucial modification of the 
protocol was the inclusion of the phosphatase treatment, which, as explained below, 
resulted in considerable recovery of the activity in Cdc7-Db4 constructs harbouring 
complete KI2. Cdc7 constructs were expressed using the pRSFDuet-1 vector 
without a tag. Dbf4 and Drf1 constructs were expressed using a modified 
pCDFDuet-1 vector encoding an HRV14 3C protease site following the N-terminal 
hexahistidine tag. The vectors contain compatible origins of replications, meaning 
that the two plasmids are able to stably coexist in a bacterial cell. The plasmids 
expressing Cdc7, Dbf4 or Drf1 were introduced into E. coli Rosetta 2(DE3) cells 
and expression was induced at 16°C overnight. The proteins initially purified by 
batch absorption to immobilized metal affinity resin (NiNTA) were incubated with 
HRV14 3C protease and λ phage phosphatase to release the affinity tag and 
reverse autophosphorylation of the recombinant kinase. The proteins were further 
purified by ion exchange and size exclusion chromatography (Figure 3-2). For 
further details see 2.4.4. 
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Figure 3-2 Example purification of a Cdc7-Dbf4 deletion construct 
(A) Size exclusion chromatography of Cdc7(ΔN/2aq/3e)-Dbf4(MC) construct. The 
major peak eluting at 80 ml contained Cdc7-Dbf4. The peak was collected in 1.5-ml 
fractions (fractions 1-7). (B) SDS-PAGE of the various stages of the purification (Ni-
NTA eluted = protein eluted from Ni-NTA beads after incubation wiith bacterial 
lysate, 3C+λPP=protein after cutting and dephosphorylation, NiNTA-FT and NiNTA 
bound are the protein fractions that passed through (low imidazole) and were then 
eluted (high imidazole) from the HisTrap FF column respectively, Q FT and Q 
bound = protein that flowed through (low salt) and was eluted (high salt) from the 
HiTrapQ HP column respectively. The full purification is described in section 2.4.4. 
Chapter 3 Results 
 
108 
 
3.3.1 Dephosphorylation of recombinant Cdc7-Dbf4 leads to a substantial 
increase in activity 
When produced in E. coli, active Cdc7-Dbf4 constructs undergo extensive auto-
phosphorylation (Hughes et al., 2010) resulting in substantial heterogeneity of 
protein preparations. Furthermore, it was known that brief incubation of the kinase 
in the presence of ATP leads to a rapid inactivation of the enzyme (S. Hughes, 
unpublished observations), suggesting that autophosphorylation is likely 
detrimental to the activity. We reasoned that enzymatic dephosphorylation of the 
recombinant Cdc7-Dbf4 preparations may help improve the chances to crystallize 
an enzymatically active construct and allow the study of its interaction with 
substrates. To dephosphorylate the Cdc7-Dbf4 heterodimers, the proteins were 
incubated with λ-phage phosphatase in the presence of Mn2+, its natural co-factor 
(Barik, 1993). Comparison of untreated and treated Cdc7-Dbf4 in in vitro kinase 
assays revealed a considerable difference in activities between deleted constructs 
and those with a full KI2. In particular, the relative activity of the previously 
crystallized construct Cdc7(ΔN/2q/3b)-Dbf4(MC), reduced from the ~50% reported 
by Hughes et al. to ~4% (Figure 3-3) upon phosphatase treatment. The kinase 
mutants that are inherently more active, such as those with complete KI2, are more 
prone to autophosphorylation during expression in bacteria, leading to gross 
underestimation of their activity. Therefore, the effect of the 2q deletion in the 
crystallized construct appears to be much greater than previously appreciated. 
 
3.4 Optimisation of Cdc7-Dbf4 constructs for crystallography 
3.4.1 Achieving wild type activity by adding residues into KI2 
A number of constructs of Cdc7 were designed maintaining the deletions at the N 
terminus and in KI3 but increasing the number amino acids in KI2. Remarkably, 
addition of as few as 10 amino acid residues at the C terminus of KI2 restored or 
even superseded the WT levels of activity in in vitro kinase assays (Figure 3-3). 
Sequence alignments of divergent Cdc7 orthologs revealed the presence of a 
highly conserved Cys residue alongside four Cys residues that are invariant in 
metazoans (Figure 3-4).  
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Figure 3-3 Comparison of recombinant kinase activity with different KI2 deletions 
The graph shows in vitro kinase activities of Cdc7(ΔN/3b)-Dbf4(MC) constructs 
additionally harbouring the indicated deletions in the KI2. The activities are plotted 
relative to a matched construct with full KI2; error bars represent standard 
deviations determined from three replicates of a single experiment. ΔN/2q/3b-MC is 
the construct previously crystallised by Hughes et al (2012). 
 
 
3.4.2 Invariant cysteine residues in KI2 are essential for kinase activity in 
vitro 
In the published crystal structure of Cdc7(ΔN/2q/3b)-Dbf4(MC), two of the four 
invariant cysteine residues were removed as part of the 2q deletion in KI2. Results 
gained in this study strongly suggested that these residues could be required for 
the kinase activity. This was confirmed through expression and purification of 
recombinant Cdc7(ΔN)-Dbf4(MC) mutants. Mutations of any of the 4 invariant Cys 
residues lead to a drastic reduction in in vitro activity (Figure 3-5).  
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Figure 3-4 Sequence alignment of metazoan orthologues of Cdc7  
Conserved and invariant residues are highlighted in red boxes. 
 
 
Figure 3-5 Kinase activity of mutants of invariant cysteine residues 
Ala substitutions of the invariant cysteine residues Cys351, Cys353, Cys360 and 
Cys363 were made in the context of the Cdc7(ΔN)-Dbf4(MC) construct and tested 
in the in vitro kinase assay. The results were normalized to the activity of 
Cdc7(ΔN)-Dbf4(MC). Error bars represent standard deviations determined from 
three replicates of a single experiment. 
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3.4.3 Zn2+ increases the activity of recombinant Cdc7 
The presence of clusters of invariant Cys residues is often indicative of Zn binding 
sites (Pace and Weerapana, 2014). Dialysis of recombinant Cdc7-Dbf4 against 
Kinase GF buffer (25 mM Tris pH 7.5, 150 mM NaCl) supplemented with 75 µM 
ZnCl2 lead to a 110 ± 10% increase in activity. In contrast, the activity of a construct 
harbouring a disrupted tetra-cysteine motif remained almost unchanged, increasing 
only by ~10% (data not shown). 
 
 
3.4.4 Optimisation of KI3 
Deletions in KI3 of the previously crystallised construct had no effect on kinase 
activity (Hughes et al., 2012). However, in the structure of Cdc7(ΔN/2q/3b)-
Dbf4(MC), 24 residues that are present in the construct were disordered and not 
visualised in the structure. In order to minimise this flexibility and to increase the 
chance of crystallization, these residues were removed from the construct and 
replaced with bridges of alternating Ala and Gly residues of different lengths. 
Optimisation of the length of the bridge allowed a complex of Cdc7-Dbf4 with a less 
flexible KI3 to be produced for crystallisation trials. Bridges that were too long or 
too short led to substantially reduced or total loss of expression of Cdc7. A number 
of these deletions had no detrimental effect on kinase activity in vitro (Figure 3-6). 
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Figure 3-6 Comparison of recombinant kinase activity with different KI3 deletions 
Comparison of in vitro kinase activities of Cdc7(ΔN/2o)-Dbf4(MC) constructs with 
additional deletions in KI3. Activities were normalised to ΔN-MC. Error bars 
represent standard deviations determined from three replicates of a single 
experiment.  
 
 
3.4.5 Reducing the MC fragment of Dbf4 drastically reduces Dbf4 
expression 
As with KI3, a number of residues from the MC fragment in the structure of 
Cdc7(ΔN/2q/3b)-Dbf4(MC) were not visualised in the published structure, 
suggesting flexibility. However, reducing the size of the Dbf4 fragment by as few as 
12 amino acids, as in Dbf4(MC2), lead to poor expression of the construct and a 
total loss of the heterodimer in purification (data not shown). For all future crystal 
trials, the MC fragment used by Hughes et al. was maintained. 
 
3.4.6 Co-expression of Cdc7 with Drf1 
Drf1 has also been shown to be an activating subunit when bound to Cdc7 
(Morgenstern and Land, 1990, Montagnoli et al., 2002). It has been shown to play a 
role in early development, linking chromosome cohesion to the initiation of DNA 
replication in Xenopus egg extracts (Montagnoli et al., 2002, Takahashi and Walter, 
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2005a, Takahashi et al., 2008). Drf1 shares many common features with Dbf4 in 
that it is largely disordered with conserved motifs-N, M and C. The motifs-M and C 
of Drf1 share significant sequence identity with Dbf4 (45% and 53% respectively) 
(Figure 8.3) and therefore likely form a similar Cdc7 binding and activation module. 
Based on this similarity, a number of Drf1 constructs were produced guided by 
secondary structure predictions and sequence conservation, which covered the 
predicted motifs-M and C of the protein .The constructs were cloned for expression 
in bacteria using the modified pCDFDuet-3C vector.  This allowed for successful 
co-expression and co-purification of the Drf1 fragments with deletion constructs of 
Cdc7, some of which displayed robust activity in the in vitro kinase assay (Figure 3-
7 and 3-8).  
 
However, despite obtaining good quantities of pure Cdc7-Drf1 heterodimers, 
crystallisation trials failed with all constructs using a number of different nucleotide 
analogues. This suggests that Drf1 may have a different effect on the orientation of 
the N and C lobe of Cdc7 to Dbf4, preventing the protein from forming suitable 
crystal contacts. Interestingly, adding residues beyond the conserved M and C 
motifs of Drf1 lead to significant decreases in activity. It is not possible to say 
whether this is due to the stability of the purified complex or whether there is an 
inhibitory role for the regions of Drf1 outside of the conserved activation motifs. 
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Figure 3-7 Example purification of  the Cdc7(ΔN/2aq/3e)-Drf1 (211-345) construct 
(A) Size exclusion chromatography; the major peak eluting at ~85 ml contained the 
recombinant heterodimer. The peak was collected in 1.5-ml fractions (fractions 1-
7). (B) SDS-PAGE of the various stages of the purification. Ni-NTA eluted = protein 
eluted from Ni-NTA beads after incubation with bacterial lysate, 3C+λPP=protein 
after cleavage of the His6 tag and dephosphorylation, NiNTA-FT and NiNTA bound 
are the protein fractions that passed through (low imidazole) and were then eluted 
(high imidazole) from the HisTrap FF column respectively, Q FT and Q bound = 
protein that flowed through (low salt) and was eluted (high salt) from the HiTrapQ 
HP column respectively. The full purification is described in section 2.4.4. 
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Figure 3-8 Activities of Cdc7(ΔN/2aq/3e) bound fragments of Drf1 compared to 
Cdc7(ΔN)-Dbf4(MC) and Cdc7(ΔN/2aq/3e)-Dbf4(MC) 
Activity normalised to Cdc7(ΔN)-Dbf4(MC). Error bars represent standard deviations 
determined from three replicates of a single experiment. 
 
 
3.4.7 Optimisation of bound nucleotide 
Binding of ligands to the active site is expected to induce subtle changes to the 
relative orientations between the N- and C-lobes of the kinase, which may help in 
crystallization. For this reason, a number of different nucleotide analogues and 
Cdc7 inhibitors were tested in crystallisation trials with a number of promising 
constructs (Table 3-2). Nucleotide analogues were used in the range of 1-5 mM 
either alone or in the presence of MgCl2 (2.5-10 mM).  
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Table 3-2 Table of nucleotide analogues and Cdc7 inhibitors used in 
crystallography trials 
Ligand Type Supplier 
AMP-PNP Nucleotide Analogue Jena Bioscience 
ATPγS Nucleotide Analogue Sigma-Aldrich 
AMP-PCP Nucleotide Analogue Jena Bioscience 
ADP-AlF4- Nucleotide Analogue Sigma-Aldrich 
ADP-BeF3- Nucleotide Analogue Sigma-Aldrich 
XL413 Cdc7 Inhibitor Sigma-AldrichXlysis 
PHA767491 Cdc7/Cdk9 Inhibitor Sigma-Aldrich 
CRT Cdc7 Inhibitor Cancer Research 
Technologies 
 
3.5 Conclusions 
A total of 26 deletion constructs of Cdc7 were expressed and purified in various 
combinations with two Dbf4 and seven Drf1 fragments. A number of constructs 
were produced in sufficient quantities for crystallography with activity equivalent to 
that of a WT kinase in in vitro kinase assays. Addition of as few as 10 amino acids 
restored full kinase activity and examination of this region of the protein revealed a 
potential metal binding site composed of 4 invariant Cys residues, which was 
disrupted in the previously crystallised construct. A significant increase in in vitro 
activity in the presence of Zn salts further supported the idea that metal binding 
may be important in correct folding of the more complete construct. Despite 
achieving full activity with small changes to KI2, significant engineering of KI3 was 
required to reduce the flexibility of the kinase for crystallisation. Further deletions in 
this insert were not detrimental to kinase activity and the heterodimeric complexes 
were sufficiently stable to allow co-purification from bacteria. Attempts to reduce 
the flexibility of the complex further by deletion of disordered residues in the MC 
fragment of Dbf4 were unsuccessful leading to a significant reduction in kinase 
yields during purification. 
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Increasing the size of the Drf1 fragment beyond the conserved motifs-M and C also 
lead to a significant decrease in activity (Figure 3-8). It is impossible to say without 
structural data whether this is due to the complex being unstable or whether the 
less ordered regions of Drf1 have auto inhibitory effects. A lack of progress in 
attempting to crystallise Cdc7-Drf1 suggests that the binding mode of Drf1 is 
sufficiently different to prevent crystallisation. This may be due to properties of Drf1 
itself or the orientation of the N and C lobes of Cdc7 when Drf1 is bound. Further 
structural work on this complex may reveal important features for Cdc7 activation 
and could explain the different roles of Cdc7 bound to each activating partner.  
 
It is interesting that high levels of activity can be achieved in vitro with deletions of 
residues 228-345 and 467-533 in KI2 and KI3, respectively. Therefore, these 
portions of the inserts play no role in the minimal peptide substrate binding and 
catalysis. Conceivably, they could be involved in protein-protein interactions 
required for Cdc7 to fulfil its many roles in the cell cycle. Further functional work in 
cellula will be carried out to ascertain the importance of these inserts in a more 
physiological setting (Chapter 6). Further to this, the clear role that phosphorylation 
plays in the activity of Cdc7 in vitro is indicative of another layer of Cdc7 regulation 
beyond Dbf4 and Drf1 binding. 
 
The following chapters build on the production and characterisation of the various 
Cdc7-Dbf4 complexes presented here, providing structural data on an active Cdc7-
Dbf4 construct bound to an ATP analogue and a potent Cdc7 Inhibitor in chapter 4. 
In chapter 5 the requirements of substrate binding are revealed by the structure of 
a Cdc7-Dbf4 construct bound to an Mcm2-derived substrate peptide. 
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Chapter 4. Results 2 – Crystallisation of a minimal 
Cdc7-Dbf4 construct bound to XL413 and ADP-BeF3- 
 
4.1 Aims 
The main aim of this project was to determine a crystal structure of a deletion 
construct of Cdc7-Dbf4 with improved activity compared to the strongly attenuated 
previously crystallised construct. The expectation was that the structure would 
reveal novel features that are critical for the kinase activity. As described in the 
previous chapter, a number of different Cdc7 constructs were expressed and 
purified with different mutants of the activating subunits Dbf4 and Drf1. This 
construct screening approach resulted in successful crystallization and structure 
determination of one highly active heterodimeric construct. 
 
In this chapter, the structures of Cdc7(ΔN/2aq/3e)-Dbf4(MC) bound to a potent 
Cdc7 inhibitor XL413 and a non-hydrolysable ATP mimic ADP-BeF3- are presented. 
The inhibitor bound structure was refined to a resolution of 1.44 Å. As previously 
observed by Hughes et al., the small molecule is bound in the active site of the 
kinase. The structure reveals a previously unseen Zn binding domain in KI2 of 
Cdc7. This domain pins back the activation loop of Cdc7 against motif-M of Dbf4, 
sandwiching it against the C-lobe of the kinase. This appears to be vital for proper 
engagement of the kinase with Dbf4, resulting in an open platform for substrate 
binding. By superimposing previously obtained kinase structures with the new 
structure of Cdc7 it is possible to hypothesise residues that may be involved in 
substrate binding, explaining the minimal consensus sequence of Cdc7. 
 
The structure of Cdc7(ΔN/2aq/3e)-Dbf4(MC) bound to ADP-BeF3-  was obtained 
and has the same overall architecture as the XL413 bound kinase. However, the 
structure also reveals the position of ATP γ-phosphate, mimicked by the BeF3 
moiety, as well as the pair of Mg2+ cation cofactors, which are essential for the 
catalysis of the phosphoryl transfer. 
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4.2 Crystal screens, optimisation and freezing of 
Cdc7(ΔN/2aq/3e)-Dbf4(MC)XL413    
 
4.2.1 Initial screening of kinase complexes   
Crystal screens were performed with each expressed and purified kinase complex 
in the presence of various ATP analogues or small molecule inhibitors (Table 3-2), 
in the presence or absence of MgCl2 chloride (2.5-20 mM). Kinase complexes, 
concentrated to approximately 10 mg/ml were incubated with the ligands for 10 min 
on ice prior to crystallization screening. High-throughput screens were setup with 
each purified protein at 18°C in the order presented (Table 2.1) using 200-nl drops 
aliquoted by a Mosquito robot (TTP LabTech). For each construct, as many sparse 
matrix conditions were trialled as possible with the amount of protein obtained. A 
typical experiment used ten to twelve 96-well crystallization trays (960 to 1152 
sparse matrix conditions). Initial crystals were obtained with Cdc7(ΔN/2o/3e)-
Dbf4(MC)AMP-PNP. However, these diffracted poorly even after painstaking 
optimisation. Eventually diffracting crystals were obtained with the development of 
the Cdc7(ΔN/2aq/3e)-Dbf4(MC) construct.  
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4.2.2 Crystallisation of Cdc7(ΔN/2o/3e)-Dbf4(MC)AMP-PNP    
A minimal construct Cdc7(ΔN/2o/3e)-Dbf4 (MC), was successfully crystallised in 
the presence of AMP-PNP in a number of conditions containing PEG 8000.  These 
conditions produced rod-like crystals (Figure 4.1). Despite extensive optimisation of 
the precipitant concentration, buffer pH, MgCl2 and NaCl concentration, these 
crystals only diffracted to ~13 Å on a synchrotron X-ray source, and could not be 
optimised further.  
 
 
                         
Figure 4-1 Crystals of Cdc7(ΔN/2o/3e)-Dbf4 (MC) grown in the presence of AMP-
PNP 
Crystals were grown at 18°C by vapour diffusion in hanging drops.   
 
 
4.2.3 Optimisation of Cdc7(ΔN/2aq/3e)-Dbf4(MC)XL413 crystallisation 
Addition of four more amino acids back into KI2 gave the Cdc7(ΔN/2aq/3e)-Dbf4 
(MC) construct, which in the presence of XL413 readily yielded polycrystalline 
precipitates in a number of conditions with acidic pH. Numerous batches of the 
heterodimeric construct were used to optimise buffer pH, precipitant, NaCl and 
ZnCl2 concentration at 18°C and 4°C. Further to this, additive and ionic liquid 
screens were utilised to gain crystals of sufficient size and quality for X-ray 
diffraction (Figure 4.2). The best crystals grew in 0.1 M MIB (sodium malonate, 
imidazole, boric acid) buffer pH 5.5, 21% poly ethylene glycol (PEG) 1500 and 
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5mM MgCl2. Crystals were grown in manually created 2 µl hanging drops at 18°C 
and generally grew to full size within 16 h. 
 
 
Figure 4-2 Crystals of Cdc7(ΔN/2aq/3e)-Dbf4 (MC) grown in the presence of 
XL413 
Crystals were grown by vapour diffusion in hanging drops in 0.1 M MIB buffer pH 
5.5, 21% PEG 1500 and 5 mM MgCl2. Crystals were grown at 18°C and harvested 
after 48 hours.  
 
 
4.2.4 Optimisation of cryo conditions   
Crystals grown in optimised conditions diffracted to approximately 1.8 Å resolution 
on a Rigaku MicroMax-007 generator, equipped with an image plate detector. Prior 
to data collection at a synchrotron, snap freezing conditions were optimised to 
avoid degradation of X-ray diffraction due to crystal cracking or shrinkage caused 
by cryo-protectants. Crystals, harvested from mother liquor were incubated in 5-ml 
drops containing 2.5 mM XL413, 100 mM NaCl, 2.5 mM MgCl2, 10 mM Tris-HCl 
and 80 mM MIB, pH5.5, with stepwise increases in PEG 1500 (21-25% in 1% 
steps) and the cryo-protectant PEG 400 (5-25% in 5% steps). An optimal freezing 
condition was achieved at 24% PEG1500 and 20% PEG 400.    
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4.3 Data collection and structure refinement of 
Cdc7(ΔN/2aq/3e)-Dbf4(MC)XL413    
 
4.3.1 Data collection 
Crystals of Cdc7(ΔN/2aq/3e)-Dbf4(MC)XL413 complex grown and cryopreserved 
under optimized conditions were used for X-ray data collection on the BM14 
beamline of the European Synchrotron Radiation Facility (ESRF, Grenoble, 
France). BM14 is a macrocmolecular crystallography beamline with a tuneable 
energy range of 7-17 keV. The beamline is also equipped with a MarCCD detector 
with an active area of 225x225 mm. The majority of the crystals diffracted to 1.3-2.5 
Å resolution, and the best dataset with measurable signal extending to 1.44 Å was 
used to determine and refine the structure (Figure 4-3, Table 4-2). 
 
 
 
Figure 4-3 A sample X-ray diffraction pattern from a crystal of Cdc7(ΔN/2aq/3e)-
Dbf4 (MC)XL413 
 
 
   
 
1.3Å 
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4.3.2 Data processing and structure refinement 
The collected X-ray diffraction data were processed using XDS (Kabsch, 2010b) 
and Scala (Evans, 2006b) via the Xia2 automatic data reduction pipeline (Winter, 
2010b). The best dataset contained measurable signal (<I/sigI> over 1.5) to the 
highest resolution shell of 1.491-1.440 Å. The structure was determined by 
molecular replacement using Phaser (McCoy et al., 2007), and built using Phenix 
Autobuild (Adams et al., 2010a). The previous crystal structure of Cdc7-Dbf4 was 
used as a search model (PDB: 4F9C). The structure was refined using 
phenix.refine (Adams et al., 2010a) and Refmac (Murshudov et al., 1997)  with 
manual model building in Coot (Emsley and Cowtan, 2004a). X-ray data collection 
and refinement statistics are given in Table 4-1. 
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Table 4-1 Data collection and refinement statistics for Cdc7(ΔN/2aq/3e)-Dbf4(MC) 
bound to XL413 and ADP-BeF3 
  XL-413 ADP-BeF3- 
Data collection *    
Beamline ESRF BM14 DLS I03 
Space group P 41 21 2 P 41 21 2 
Unit cell parameters   
a, b, c (Å) 61.64, 61.64, 233.91 61.15, 61.15, 235.44 
α, β, γ (o) 90, 90, 90 90 90 90 
Wavelength (Å) 0.9796 0.9796 
Resolution range (Å) 42.85 -1.44 (1.491 -1.44) 48.24  - 1.79 (1.854  - 1.79) 
Average multiplicity 9.1 (6.7) 11.5 (7.4) 
Completeness (%) 99.52 (95.76) 98.98 (91.15) 
CC1/2 1 (0.789) 0.999 (0.827) 
CC* 1 (0.939) 1 (0.951) 
Rmerge 
 
 
0.05269 (0.6114) 0.0698 (0.6182) 
Rmeas 
 
0.05585 (0.6621) 0.07311 (0,6639 
<I>/<sig(I)> 26.48 (2.96) 23.66 (3.02) 
Wilson <B> (Å2) 13.55 21.62 
Solvent content (%) 47 47 
Refinement    
Resolution 42.85 -1.44 48.24  - 1.79 
Reflections (total/free) 750697/52186 492798/42930 
Rwork/Rfree 0.1649/0.1969 0.1877/0.2192 
CC (work) 0.969 (0.852) 0.966 (0.880) 
CC (free) 0.951 (0.840) 0.956 (0.881) 
No. Atoms  4022 3718 
Protein 3534 3535 
Ligand/ion 38 35 
Water 450 148 
Average B-factors (Å2) 20.70  24.50 
Protein 19.30 24.50 
Ligand/ion 28-20 17.60 
Water 31.00 26.00 
R.m.s. deviations from ideal    
Bond lengths (Å) 0.013 0.007 
Bond angles (°) 1.35 1.15 
Ramachandran (%)    
Favoured 97 97 
Outliers 0.27 0.27 
Number of TLS groups 6 6 
   
*Data for the highest resolution shell are shone in parentheses. 
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4.4 The structure of Cdc7(ΔN/2aq/3e)-Dbf4(MC)XL413   
 
4.4.1 A novel zinc binding domain is present in KI2 
Cdc7(ΔN/2aq/3e)-Dbf4(MC)XL413 crystallised in the space group P41212 with one 
molecule of the kinase present in the asymmetric unit. The newly added residues of 
Cdc7, shown in orange in Figure 4-4, comprise a previously unseen portion of the 
activation loop in KI2. The crystal structure reveals the presence of a novel Zn 
binding domain within KI2 (Figure 4-4). Within this domain, Cys351, Cys353, 
Cys360 and Cys363 coordinate a single metal atom, in excellent agreement with 
the results of the mutagenesis analyses (Figure 3-5). The presence of the Zinc 
atom in the structure was confirmed by anomalous X-ray scattering using X-ray 
diffraction data collected at a wavelength of 1.2837 Å, corresponding to the 
absorption K-edge of Zn (Figure 4-5).  
 
 Zinc binding domains are found across a range of proteins and are particularly 
common in proteins involved in DNA binding proteins such as those required for 
transcription. Zinc binding folds can be classified into a number of groups based on 
the sequence homology and structural features involved in the coordination of the 
Zinc ion (Krishna et al., 2003). Zinc binding domains have been identified in a 
number of kinases. Zinc ribbon folds, one group of zinc binding domains have been 
identified in kinases, including adenylate kinase from Bacillus stearothermophilus 
(PDB:1ZIN) in which the zinc binding domain is found in the lid region of the active 
site and plays an integral role in stabilizing the structure of the kinase (Berry and 
Phillips, 1998). The zinc ribbon fold is also seen in the Tec family of Tyrsoine 
kinases in which the zinc is found in a Btk motif which is present downstream of the 
pleckstrin homology domain of the protein (PDB :1B55) (Baraldi et al., 1999). Zinc 
binding has also been shown to play a regulatory function in kinases, Protein 
kinase C (PKC) contains zinc a zinc binding domain which is able to bind to lipid 
second messengers, binding of which leads to activation of the kinase. PKC can 
also be activated by changes in redox state and work by Zhao et al. showed that 
this activation is due to a common mechanism in which lipid messenger binding 
leads to Zinc release and significant structural changes. This change in structure is 
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integral to kinase activation under such conditions (Hubbard et al., 1991, Zhao et 
al., 2011). The Zinc binding domain identified in Cdc7 appears to most closely 
resemble the short zinc binding loop class of folds. Such folds are generally small 
but separate domains which are stabilized by the binding of Zinc. They are not 
typically part of larger secondary structural elements, though in some cases one 
coordinating residue may be part of a secondary structural feature. Such a fold is 
present in the atypical kinase structure of a transient receptor potential (TRP) 
channel which has retained its phosphotransferase activity (Yamaguchi et al., 
2001). Another interesting example of a Zinc binding domain in a kinase structure 
is that of casein kinase 2 (CK2), the most closely related kinase to Cdc7. The 
domain present in CK2 is similar to that of Cdc7 in that it involves four invariant 
cysteine residues, which coordinate the zinc in a tetrahedral conformation. 
However, in CK2 the Zinc binding domains of two individual monomers form 
extensive interactions with each other, which facilitates dimerization (Chantalat et 
al., 1999). This represents an intriguing possibility that the Zinc binding domain of 
Cdc7 may be involved in such a protein-protein interaction that is important for its 
function in the cell. However it is not possible to ascertain this from the obtained 
structure due to the significant portion of KI2 that has been removed which may 
occlude such an interaction in the context of the full protein. Despite the presence 
of Zinc binding domains in kinase structures, the domain observed in Cdc7 appears 
to be the first example, which is present in the activation loop of the protein. This 
may be due to the significant length of the activation loop of Cdc7 relative to other 
kinases, requiring structural features such as a Zinc binding domain to maintain a 
structure suitable for activity. 
 
4.4.2 The Cdc7 KI2 Zn binding domain interacts with motif-M of Dbf4 
resulting in full ordering of the activation segment 
In the published structure the activation segment was not fully ordered (Figure 3-1), 
and the active site seemed to be partially occluded by a slight movement of Cdc7 
Arg373. In the new structure, the KI2 Zn binding domain tightly interacts with Dbf4 
motif-M, thereby pinning the activation segment of Cdc7 to the C-lobe. 
Unexpectedly, in the new structure Dbf4 motif-M is sandwiched between the Zn- 
binding domain of KI2 and the C lobe of the kinase. This arrangement may help to 
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ensure that full activation of the kinase takes place only upon proper engagement 
of Dbf4 motifs-M and -C. 
 
 
 
Figure 4-4 Overall structure of the ΔN/2aq/3e-MC construct of Cdc7-Dbf4 bound 
to XL413 
Protein chains are shown as cartoons with Dbf4 shown in cyan. Cdc7 residues 
present in the structure by Hughes et al are shown in green and the newly added 
residues are shown in orange. XL413 is shown in pink as sticks with non-carbon 
atoms following standard colouration. Zinc atoms are shown as grey spheres. 
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Figure 4-5 Zinc binding domains in Cdc7 KI2 (A) and Dbf4-C (B) 
Metal binding His and Cys residues are shown as sticks. Phased anomalous 
electron density maps are shown as pink chicken wire, contoured at 5.0σ. 
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4.4.3 Comparison of ΔN/2aq/3e-MC to the previous structure 
Superposing the bound crystal structure of Hughes et al (4F9C, bound to XL413) 
with the newly obtained structure shows results in r.m.s. displacements for the 
common Cα atoms of only 0.615 Å (Figure 4-6). The largest change is brought 
about by the presence of the KI2 Zn-binding domain. Close inspection of the 
structures confirms the suspected reason for the reduced activity of the previously 
crystallised construct. The partially disordered activation loop projects into the cleft 
of the kinase, likely partially obstructing access to the active site (Figure 4-7). The 
Zn-binding domain pins the activation loop, removing this portion of the activation 
loop from the active site allowing for substrates to enter the active site. 
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Figure 4-6 Overall structure of the ΔN/2aq/3e-MC construct of Cdc7-Dbf4 
superimposed on the previously crystallised structure 
Cdc7 and Dbf4 of the structure solved by Hughes et al. (2012)  (PDB 4F9C) is 
shown in purple and pink for Cdc7 and Dbf4 respectively.  
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Figure 4-7 Close up of the active site of Cdc7(ΔN/2aq/3e)-Dbf4(MC) superposed 
on the published structure. 
Residues discussed in the text are shown as sticks with non-carbon atoms 
following standard colouration. 
 
 
4.4.4 Comparison with a peptide bound PKA structure highlights Cdc7 
residues potentially involved in substrate binding 
Superposition of a substrate peptide-loaded structure of PKA (PDB: 3X2W) with 
Cdc7(ΔN/2aq/3e)-Dbf4(MC) suggested that Arg373 and Arg380 may be poised to 
make interactions with the P+1 position of the Cdc7 substrate peptide, normally 
occupied by an acidic residue of a pre-phosphorylated Ser (Cho et al., 2006) 
(Figure 4-8). Intriguingly, both Arg373 and Arg380 are invariant among Cdc7 
orthologues. To confirm their importance for Cdc7 function, the recombinant Cdc7-
Dbf4 heterodimers harbouring substitutions at these positions were produced. In 
vitro kinase assays revealed a significant decrease of activity associated with the 
mutations (Figure 4-9). This decrease in activity was observed with peptides 
containing sites containing a pre-phosphorylated serine at the N+1 position and a 
sit containing an SE site. However, no further requirements for substrate binding 
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can be inferred from the current structure, highlighting the need for crystallization of 
a substrate-bound form of the kinase. 
 
      
Figure 4-8 A model for Cdc7-substrate interaction 
The model was constructed by superposition of a substrate peptide-bound PKA 
structure (PDB: 3X2W) with the (ΔN/2aq/3e)-Dbf4 (MC) structure. Cdc7-Dbf4 is 
shown as cartoons, and the backbone of the substrate peptide from 3X2W is 
represented as sticks. For clarity, the chain of PKA is hidden.  
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Figure 4-9 Arg373 and Arg380 are essential for Cdc7 activity in vitro 
Alanine substitutions of the invariant cysteine residues Arg373 and Arg380 were 
made in the context of the Cdc7(ΔN)-Dbf4(MC) construct and tested in the using an 
in vitro kinase assay. Activity is normalized to the activity of Cdc7(ΔN)-Dbf4(MC). 
Error bars represent standard deviations determined from three replicates of a 
single experiment. A) Kinase assay using a peptide containing the primed Mcm2-
S40 site with pre-phosphorylated S41. B) Kinase assay using a peptide containing 
the SE site Mcm2-S53. 
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4.5 Crystallisation and crystal screen optimisation of the 
ADP-BeF3- bound Cdc7-Dbf4 complex 
 
4.5.1 Crystallisation of Cdc7(ΔN/2aq/3e)-Dbf4(MC)ADP-BeF3 
Crystal screening for Cdc7(ΔN/2aq/3e)-Dbf4(MC)ADP-BeF3 was performed using a 
microseed matrix approach. The method involves adding a small amount of a seed 
stock to each condition of a sparse matrix screen. The seed stock is made by 
crushing crystals of the identical or a similar protein construct. Seeding often leads 
to rapid nucleation of protein crystals, allowing the second series of drops to have a 
sufficiently low precipitant concentration to equilibrate directly into the metastable 
zone enabling formation of crystals that may otherwise be impossible to obtain (see 
section 2.6.1). Microseed matrix screening has been used successfully in the 
crystallisation of a diverse range of proteins (Ireton and Stoddard, 2004, Obmolova 
et al., 2010, Till et al., 2013, D'Arcy et al., 2014, Kolek et al., 2016). The use of 
microseed matrix screening was particularly promising in this case as the seed 
stock could be made from crystals of an identical Cdc7-Dbf4 construct to that which 
was undergoing crystallisation screening. As the ligand was the only difference 
between the two complexes, the probability of the XL413-bound crystals nucleating 
the growth of the ADP-BeF3- bound kinase was deemed high.  
 
Crystals of Cdc7(ΔN/2aq/3e)-Dbf4(MC)XL413 harvested from mother liquor were 
crashed by vortexing with a seed bead (Hampton Research) to create a seed stock. 
A mosquito robot was programmed to supplement each 400-nl sitting drop with 10 
nl of seed stock. Cdc7(ΔN/2aq/3e)-Dbf4(MC)ADP-BeF3 was also supplemented with 
various substrate peptides (2.5mM) in an attempt to make transition complexes 
with the kinase (Chapter 5). The obtained crystals were grown in the presence of 
the S53L peptide (Table 5-2), derived from the N-terminal region of Mcm2.  
The crystals of Cdc7(ΔN/2aq/3e)-Dbf4(MC)ADP-BeF3- were obtained in a number of 
crystallisation conditions with acidic pH. Numerous purifications of the complex 
were used to optimise buffer pH, precipitant concentration, salt concentration, 
MgCl2 and ZnCl2 concentrations at 18°C. Further to this, additive and ionic liquid 
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screens were utilised and the concentrations of beneficial additives were also 
optimised against the precipitant concentration. The most readily optimised crystals 
grew in 21% PEG 1500, 20 mM MgCl2,15% v/v acetonitrile, and 0.1 M DL-malic 
acid/MES/Tris (MMT) buffer pH 6.57. Crystals were grown in manual 2-µl hanging 
drops at 18°C and generally grew to a full size within 16 h. Microseeding was still 
required in manual optimisation plates, and was done using a microseeding fibre 
(Hampton Research). 
 
4.5.2 Optimisation of cryo conditions for Cdc7(ΔN/2aq/3e)-Dbf4(MC)ADP-BeF3 
Crystals were harvested from wells and moved through a number of drops 
containing 75 mM NaCl, 20 mM MgCl2, 1 mM ADP, 70 mM MMT buffer pH 6.57, 5 
mM Tris-HCl, 15% acetonitrile, 1 mM BeF3  and 0.5 mM S53L peptide with 
stepwise increases in PEG1500 (19-24% in 1% steps) and the cryo-protectant 
MPD (5-25% in 5% steps). An optimal freezing condition was achieved at 22% 
PEG1500 and 20% MPD. 
 
                             
Figure 4-10 Crystals of Cdc7(ΔN/2aq/3e)-Dbf4(MC)ADP-BeF3grown in the presence 
of ADP-BeF3- 
Crystals were grown by vapour diffusion in 2ul hanging drops in 0.1 M MMT buffer 
pH 6.57, 21% PEG 1500, 15% v/v acetonitrile and 20 mM MgCl2. Crystals were 
grown at 18°C and harvested after 48 h. 
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4.6 X-ray data collection and refinement of the 
Cdc7(ΔN/2aq/3e)-Dbf4(MC)ADP-BeF3  structure 
 
4.6.1 Data Collection 
Data was collected at the macromolecular crystallography beamline I03 of the 
Diamond Light Source (Didcot, UK). I03 has a tuneable working wavelength range 
of 0.6-2.48 Å and is equipped with a Pilatus3-6M direct detector. All data was 
collected at the standard working wavelength of 0.976 Å (12.7 keV) 
The optimised crystallisation and cryo-cooling conditions allowed for data to be 
obtained at a resolution of 1.79 Å (Figure 4-11). 
 
 
 
Figure 4-11 A sample X-ray diffraction image from a crystal of Cdc7(ΔN/2aq/3e)-
Dbf4 (MC)ADP-BeF3  
A sample diffraction pattern is shown for crystals of Cdc7(ΔN/2aq/3e)-Dbf4 (MC) in 
complex with ADP-BeF3-, a full data set was collected at beamline I03 at the 
Diamond Light Source (DLS) to 1.7Å. 
 
 
   
 
1.7Å 
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4.6.2 Data processing and structural refinement 
Cdc7(ΔN/2aq/3e)-Dbf4(MC)ADP-BeF3 also crystallised in the space group P41212 with 
one molecule of the kinase present in the asymmetric unit. The collected X-ray 
diffraction data was processed using XDS (Kabsch, 2010b) and Scala (Evans, 
2006b) via the Xia2 automatic data reduction pipeline (Winter, 2010b). The 
structures were solved by molecular replacement in Phaser (McCoy et al., 2007), 
and built using Phenix Autobuild (Adams et al., 2010a). The previous crystal 
structure of Cdc7(ΔN/2aq/3e)-Dbf4(MC)XL413 was used as a model. The structure 
was refined using phenix.refine (Adams et al., 2010a) and Refmac (Murshudov et 
al., 1997)  with manual model building in Coot (Emsley and Cowtan, 2004a). The 
structure was refined to 1.79Å. X-ray data collection and refinement statistics are 
given in table 4-2. 
 
 
4.7 Structure of (ΔN/2aq/3e)-Dbf4 (MC)ADP-BeF3   
 
4.7.1 Overall architecture of (ΔN/2aq/3e)-Dbf4 (MC)ADP-BeF3 
The overall architecture of (ΔN/2aq/3e)-Dbf4 (MC)ADP-BeF3 is similar to that of 
(ΔN/2aq/3e)-Dbf4 (MC)XL413 aside from a small difference in orientation between the 
N and C lobes of the kinase. ADP-BeF3- is bound in the ATP binding pocket as 
expected alongside the two Mg atoms required for phosphoryl transfer. Although 
the crystals were obtained and optimized in the presence of an Mcm2-derived 
peptide, no density attributable to the peptide was not observed. This is not 
unexpected as kinase-substrate interactions are meant to be rapid and therefore 
the affinity of a kinase for a substrate peptide is often low, with interactions away 
from the active site likely contributing more to the affinity of a kinase for its 
substrate than those in the immediate vicinity of the active site.  
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4.7.2 Active site of Cdc7 (ΔN/2aq/3e)-Dbf4 (MC)ADP-BeF3 
The previous structure of Cdc7-Dbf4, solved with AMP-PNP, contained no density 
for the γ-phosphate, either due to flexibility of the moiety or due to the ability of 
Cdc7 to hydrolyse AMP-PNP. The structure consequently contained only one of the 
two Mg2+ ions required for the phosphor-transfer reaction (Hughes et al., 2012). In 
the current structure the BeF3- moiety occupies the position of the ATP γ-phosphate, 
flanked by the two necessary Mg atoms (Figure 4-12). 
 
        
 
Figure 4-12 Active site of Cdc7-Dbf4 in complex with ADP-BeF3- 
ADP-BeF3- bound in the active site and selected Cdc7 residues are and shown as 
sticks. Mg atoms are shown as yellow spheres. 
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4.8 Conclusions 
In this chapter a method for obtaining diffraction quality crystals of a minimal Cdc7-
Dbf4 construct with apparent WT levels of kinase activity has been described. The 
construct allowed determination of two near-atomic structures of the kinase in 
complex with XL413 and the ATP mimic ADP-BeF3-. Structural information gained 
in this chapter has shed new light on the features of Cdc7 critical for full activation 
of the kinase upon Dbf4 binding. A previously unseen Zn-binding domain in KI2 
sandwiches Motif-M of Dbf4 between the C-lobe of Cdc7 and the new domain. This 
leads to full engagement of the kinase with its activating subunit. Importantly, this 
new interaction pins back and orders the activation loop of Cdc7. This newly 
ordered portion of KI2 appears to form a peptide-binding platform, onto which 
peptides from other kinase structures can be successfully docked. The structural 
importance of the KI2 Zn-binding domain correlated well with mutagenesis analysis 
in chapter 3, which showed the Cys residues coordinating the Zn atom are 
essential for in vitro kinase activity. 
 
The structures also suggested a possible role for two Cdc7 residues Arg373 and 
Arg380 in substrate recognition. These residues, conserved across all known Cdc7 
orthologs, seem to be ideally positioned to make favourable interactions with the 
P+1 residue of the substrate, which in the case of Cdc7 is occupied by an Asp, Glu, 
or a pre-phosphorylated Ser residue. However, without a substrate-bound structure 
of Cdc7-Dbf4 it is impossible to infer any further important features required for 
substrate binding. This poses further questions, which will be addressed in Chapter 
5. 
 
The first structure of Cdc7-Dbf4 bound to an ATP analogue is also presented. 
Previous structures of Cdc7-Dbf4 lacked the γ-phosphate of the analogue possibly 
due to hydrolysis during crystallization. In the newly obtained structure, BeF3- 
mimics the ATP γ-phosphate and is present along with a pair of Mg atoms. These 
Mg atoms overlay perfectly with those in the transition state crystal structure of 
CDK2-CyclinA obtained by Bao et al. (2011). As the most abundant divalent metal 
ion in the cell, Mg2+ presents the most obvious choice for a metal co-factor for 
kinase activity. However, kinases are able to utilise a number of divalent metal ions 
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for activity, which can be used as a method of fine-tuning kinase activity. Structures 
of the cyclic AMP (cAMP) dependent PKA have been refined with product 
complexes utilising a number of cofactors including Mg2+, Ca2+, Sr2+ and Ba2+ 
(Gerlits et al., 2013). The ability of PKA to utilise Ca2+ for phosphoryl transfer may 
have physiological relevance. This kinase is localised near calcium channels in the 
cell, suggesting PKA as a possible link between cAMP and calcium signalling. 
Calcium has been shown to decrease the affinity of PKA for pseudosubstrate 
inhibitors and, while it is able perform its catalytic function, it inhibits the release of 
the phosphorylated substrate, leading to reduced turnover rates (Knape et al., 
2015). In this respect, choice of metal ion could be used for kinase regulation in 
response to different cellular signals.  
 
The two metal mechanism of catalysis is also utilised by CDK2, which requires two 
Mg2+ ions to function. Binding of a second Mg2+ is proposed to create a more rigid 
and enclosed active site to better shield the γ-phosphate from solvent while 
stabilising the build-up of negative charge. This allows for faster catalysis to occur 
(Bao et al., 2011) However, the presence of two such ions actually limits the rate of 
turnover as the second Mg2+ ion stabilises the produced ADP in the binding pocket 
and reduces its dissociation rate. This product release is thought to be the rate-
limiting step for CDK2 (Jacobsen et al., 2012), revealing a fine balance between 
the kinetics of both substrate binding and phosphoryl transfer to maintain sufficient 
levels of kinase activity. 
.  
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Chapter 5. Results 3 – Crystallisation of a Cdc7-Dbf4 
heterodimer in complex with an ATPγS-conjugated 
peptide 
 
5.1 Aims 
Structures determined in Chapter 4 revealed the active site of Cdc7 in a fully open 
state and a potential substrate-binding platform. The next aim of the project was to 
elucidate the structural features of the kinase required for substrate recognition and 
binding. The optimised construct Cdc7(ΔN/2aq/3e)-Dbf4(MC) was maintained and 
efforts were made to identify suitable peptide substrates for co-crystallisation. 
Various methods of forming transition complexes between the kinase and peptide 
substrates were attempted to increase the affinity of the interaction to aid in co-
crystallisation. A range of different target sites were used to try and ascertain the 
possible variations in binding requirements between phosphorylation-primed sites 
and SD/E target sites. 
 
In this chapter a crystal structure of Cdc7(ΔN/2aq/3e)-Dbf4(MC) bound to an 
Mcm2-derived peptide is presented. The structure confirms the hypothesised 
importance of Arg373 and Arg380 in substrate recognition and reveals a further 
binding pocket in Cdc7 that accommodates the P+4 residue. 
 
5.2 Identification and optimisation of Cdc7 substrate peptides 
 
The Mcm2-7 complex, the heterohexameric helicase responsible for DNA 
unwinding during replication, is believed to be the main target of Cdc7-Dbf4. The 
phosphorylation of MCM2-7 is thought to trigger conformational changes in the 
helicase en route to origin firing in S-phase (Lei et al., 1997, Cho et al., 2006, 
Masai et al., 2006, Francis et al., 2009, Sheu and Stillman, 2010). The majority of 
phosphorylation sites map to the N-terminal tails of the Mcm2-7 subunits (Randell 
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et al., 2010). In yeast, the predominant target of Cdc7-Dbf4 appears to be Mcm4, 
the phosphorylation of which appears to relieve an auto inhibitory activity contained 
in the subunit, thereby facilitating Mcm2-7 activation (Masai et al., 2006, Sheu and 
Stillman, 2006, Randell et al., 2010, Sheu and Stillman, 2010). However, in human 
cells, the predominant target appears to be Mcm2, although Mcm2, 4 and 6 were 
all implicated as targets in both systems (Montagnoli et al., 2006, Tsuji et al., 2006, 
Charych et al., 2008, Chuang et al., 2009). To confirm known and identify potential 
novel Cdc7-dependent phosphorylation sites in the human replicative helicase, we 
used a library of synthetic peptides spanning the N-terminal 240 amino acids of 
MCM2, 4 and 6. The libraries were synthesised by the Peptide Synthesis Facility 
(London Research Institute, London) immobilised on a membrane support. 
 
5.2.1 Peptide arrays of the N-terminal tails of Mcm2, 4 and 6 highlight 
numerous potential Cdc7 phosphorylation sites 
Peptide arrays were used for radioactive kinase assays utilising a recombinant 
preparation of Cdc7(ΔN)-Dbf4(MC) kinase. A detailed description of the peptide 
array kinase assay is given in 2.4.5.1. In brief, the membrane was hydrated and 
equilibrated with kinase buffer in the presence of blocking agent to prevent non-
specific binding of the kinase. Following incubation in the presence of [γ-32P]ATP 
and recombinant kinase, the membrane was washed, and incorporated 
radioactivity was quantified by phosphor imaging (Figure 5-1). A number of Cdc7 
phosphorylation sites were identified as part of the array (Table 5-1), and some of 
these were synthesised in various forms for co-crystallisation trials (Table 5-2).  
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Figure 5-1 A peptide array kinase assay revealed a number of potential target 
sites for Cdc7-Dbf4 
Each dot represents a 20-mer peptide from N-terminal portions of human Mcm2, 4 
or 6 shifting one amino acid residue along the protein sequence with each dot. 
Peptides containing potential CDK2-primed Cdc7 phosphorylation sites (Ser-Ser-
Pro) sites were synthetized with phosphoserine residues to mimic priming by 
CDK2. Rows of dark dots represent single phosphorylation sites. Example sites are 
indicated for Mcm2 in red boxes. A comprehensive list of sites is given in table 5-1. 
Mcm2	Mcm4	Mcm6	
  
 
 
Ser5 
Ser53 
S108 Ser12 
Ser40 
 Mcm2 Mcm4 Mcm6 
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Table 5-1 Table of Cdc7 phosphorylation sites identified using peptide arrays 
Mcm2 Mcm4 Mcm6 
S5 - SE S31- SSp S40 - SD 
S12 – SSp S70- SS S76- ST 
S40 – SSp S87- SSp S153- SG 
S53 - SE S131- SD  
S108 - SQ S142- SE  
S139 - SD T189- TE  
S187 - SM S228 -SY  
S229 - SL T236- TF  
* The target and P+1 residues are shown for each site (Sp = phosphor-serine). 
Sites highlighted in red do not follow the expected consensus sequence of Cdc7. 
 
 
Table 5-2 Table of peptides used for crystallography trials 
Peptide Name Target Site Residues Modification 
Mcm2(34-46) S40 34-46 S41-P 
Mcm2(36-44) S40 36-44 S41-P 
Mcm2(37-43) S40 37-43 S41-P 
Mcm2(33-47) S40 33-47 S41-P 
Mcm2(49-57) S53 49-57 n/a 
Mcm2(50-56) S53 50-56 n/a 
S53(19) S53 44-62 n/a 
S5(9) S5 1-9 n/a 
S40-ATPγS(9) S40 36-44 ATPγS/S41-P 
S40-ATPγS(15) S40 33-47 ATPγS/S41-P 
S53-ATPγS(9) S53 49-57 ATPγS 
S53-ATPγS(15) S53 46-60 ATPγS 
S5-ATPγS(9) S5 1-9 ATPγS 
S5-ATPγS(15) S5 1-15 ATPγS 
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5.3 Production of complexes of peptides with Cdc7 
(ΔN/2aq/3e)-Dbf4 (MC) 
5.3.1 Crystal screening of transition complexes using peptides with ADP-
AlF4- and ADP-BeF3- 
Crystal screening for substrate-bound Cdc7 (ΔN/2aq/3e)-Dbf4 (MC) was carried out 
with microseeding using Cdc7 (ΔN/2aq/3e)-Dbf4 (MC)XL413 crystals as a seed stock. 
Complexes of Cdc7-Dbf4 were made in multiple combinations with different 
peptides and equimolar concentrations of ADP-BeF3- or AlF4-. Each transition 
complex was also screened in the presence or absence of MgCl2 (2.5-20 mM). 
 
A number of conditions yielded good quality crystals, allowing for acquisition of X-
ray diffraction data on synchrotron sources. However, upon data processing and 
phasing by molecular replacement, electron density that could be attributed to the 
bound peptide was not observed. Following multiple failed attempts, it was 
hypothesized that the peptides did not bind the kinase tightly enough, resulting in 
low occupancy. The length of the peptide seemed to have little effect on crystal 
formation, and increasing the peptide length to potentially enhance affinity did not 
yield substrate bound crystals. Cdc7-Dbf4 displays a high affinity for ATP, 
displaying a Km of 2-4 µM (Masai et al., 2000). We reasoned that covalently 
attaching a substrate peptide to the nucleotide would improve the chances of 
visualising a bound substrate. Indeed, such an approach proved successful in the 
crystallisation of the insulin receptor protein Tyr kinase (IRK) (Hines et al., 2005). 
This structure was useful in establishing important features in substrate binding and 
possible considerations for designing inhibitors. Substrates for both Ser/Thr and 
Tyr kinases have been produced with considerably improved affinities through 
tethering of nucleotide analogues and ATP-competitive inhibitors to kinase 
substrate peptides. In one of the early attempts, the affinity of one such bisubstrate 
ligand of PKA was shown to be 67-fold greater than of the ATP analogue alone 
(Ricouart et al., 1991). More recently, a similar approach was used to tether an 
ATP competitive small molecule to a substrate peptide of PKC, leading to improved 
affinity and selectivity for specific PKC isoforms relative to the inhibitor or peptide 
alone (van Ameijde et al., 2010). Success was also achieved through covalently 
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linking of inhibitors to peptides designed for binding of substrate docking sites away 
from the active site. When applied to the MAPK c-Jun N-terminal kinase 1 (JNK1) 
this approach created a bisubstrate inhibitor for the kinase with a 20,000-fold higher 
affinity than the small molecule alone (Stebbins et al., 2011). 
 
5.3.2 Design and production of ATPγS conjugated peptides. 
Modified peptides were synthesised by the LRI Peptide Synthesis Facility. Full 
details for the production of the ATPγS conjugated peptides can be found in section 
2.4.5. In brief, peptides were produced by solid phase peptide synthesis using 
standard Fmoc chemistry with an aminoalanine in place of the target Ser residue. 
The non-standard residue was bromoacetylated post-synthetically by incubating 
the peptide with bromoacetic acid. The ATPγS conjugates were then made by 
reacting the sulfhydryl group of ATPγS to the bromoacetyl moiety. The procedure 
produced a covalent bond linking the nucleotide analogue and the peptide, creating 
a bi-substrate ligand (Figure 5-2). 
 
 
 
Figure 5-2 Generalised structure of a bi-substrate inhibitor peptide 
R1 and R2 represent N- and C- portions of the substrate peptide.   
 
 
 
 
Chapter 5. Results 
 
147 
 
5.4 Crystal screens optimisation and freezing of (ΔN/2aq/3e)-
Dbf4 (MC) ATPγS-Mcm2-S40(15) 
 
Cdc7 (ΔN/2aq/3e)-Dbf4 (MC) supplemented with 1-2.5 mM nucleotide-peptide 
conjugate was subjected to microseed matrix screening using crystals of 
Cdc7(ΔN/2aq/3e)-Dbf4 (MC)XL413 as a seed stock. A number of hits were obtained 
in the initial screens using the ATPγS-Mcm2-S40(15) peptide. The most promising 
condition contained 25% PEG 1500 in 0.1 M propionic acid/cacodylate/BisTris 
propane (PCTP) buffer, pH 7. Manually setup grids and streak microseeding was 
used to optimise the pH of PCTP buffer against the precipitant concentration. 
Additive screens were employed at later stages, and the additive concentration 
(MPD) was optimised against the precipitant concentration. The final optimised 
condition contained 18% PEG 1500, 8% MPD in 0.1 M PCTP buffer, pH 6.5. 
Crystals were grown by vapour diffusion in hanging drops at 18°C and typically 
appeared within 16 h (Figure 5-3). Crystals were harvested within 16-24 h and 
snap-frozen in liquid nitrogen using the cryo-conditions described in 5.4.1. 
 
           
Figure 5-3 Optimised crystals of Cdc7 (ΔN/2aq/3e)-Dbf4 (MC) grown in the 
presence of ATPγS-Mcm2-S40(15). 
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5.4.1 Cryo-condition optimisation for data collection 
Crystals, harvested from mother liquor were incubated in 5-µl drops containing 1 
mM ATPγS-Mcm2-S40(15), 75 mM NaCl and 80 mM PCTP pH6.5  with stepwise 
increases in PEG 1500 (17-21% in 1% steps) and the cryo-protectant MPD (10-
25% in 5% steps). An optimal freezing condition was achieved in the presence of 
19% PEG1500 and 20% MPD, whereby no crystalline ice was observed.  
 
5.5 Data collection and structure refinement of Cdc7 
(ΔN/2aq/3e)-Dbf4(MC) ATPγS-Mcm2-S40(15) 
5.5.1 Data collection for Cdc7 (ΔN/2aq/3e)-Dbf4 (MC) ATγS-Mcm2-S40(15) 
The optimised crystallisation and cryo-cooling conditions allowed for data to be 
obtained at a resolution of 1.67 Å on the beamline I03 of the Diamond Light Source 
(Didcot, UK) (Figure 5-4). I03 is macromolecular crystallography beamline with a 
tuneable working wavelength range of 0.6-2.48 Å, equipped with a Pilatus3-6M 
direct detector. All data were collected at the standard working wavelength of 0.976 
Å (12.7 keV). Crystals from similar conditions diffracted in the range of 1.8-2.5 Å. 
The dataset at 1.67 Å was considered to be of the best quality and was 
subsequently processed and used to solve the structure of Cdc7 (ΔN/2aq/3e) - 
Dbf4 (MC) ATPγS-Mcm2-S40(15). 
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Figure 5-4 A sample X-ray diffraction pattern collected from a crystal of 
(ΔN/2aq/3e)-Dbf4(MC) ATPΥS-Mcm2-S40(15) 
 
5.5.2 Structure refinement of Cdc7 (ΔN/2aq/3e)-Dbf4 (MC) ATPγS-Mcm2-S40(15) 
The collected X-ray diffraction data was processed using XDS (Kabsch, 2010b) 
and Scala (Evans, 2006b) via the Xia2 automatic data reduction pipeline (Winter, 
2010b). The structure was solved by molecular replacement in Phaser (McCoy et 
al., 2007), and built using Phenix Autobuild (Adams et al., 2010a). The previous 
crystal structure of Cdc7 (ΔN/2aq/3e)-Dbf4 (MC) ADP-BeF3 was used as a molecular 
replacement model. The structure was refined using phenix.refine. (Adams et al., 
2010a) and Refmac (Murshudov et al., 1997)  with manual model building in Coot 
(Emsley and Cowtan, 2004a). The structure was refined to 1.67 Å. X-ray data 
collection and refinement statistics are given in Table 5-3. 
 
  
   
 
1.6Å 
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Table 5-3 Data collection and refinement statistics for Cdc7(ΔN/2aq/3e)-Dbf4(MC) 
bound to ATPγS-Mcm2-S40(15) 
 
  *Data for the highest resolution shell is given in parentheses. 
  
    ATPγS-Mcm2-S40(15) 
Data collection *   
Beamline DLS I03 
Space group P 41 21 2 
Unit cell parameters  
a, b, c (Å) 62.28, 62.28, 234.79 
α, β, γ (o) 90, 90, 90 
Wavelength (Å) 0.9796 
Resolution range (Å) 58.7 -1.67 (1.71 -1.67) 
Average multiplicity 12.1 (8.5) 
Completeness (%) 100.0 (99.8) 
CC1/2 0.999 (0.81) 
Rmerge 
 
 
0.90 (0.724) 
Rmeas 
 
0.097 (0.821) 
<I>/<sig(I)> 19.4 (3.3) 
Wilson <B> (Å2) 17.23 
Solvent content (%)                     42.5 
Refinement   
Resolution 58.7 -1.67 
Reflections (total/free) 665576 (55037) 
Rwork/Rfree 0.1602/0.1847 
No. Atoms 4043 
Protein 3653 
Ligand/ion 36 
Water 354 
Average B-factors 
(Å2) 
23.84 
Protein 22.97 
Ligand/ion 30.13 
       Water 32.21 
R.m.s. deviations   
Bond lengths (Å) 0.006 
Bond angles (°) 1.08 
Ramachandran (%)   
Favoured 97 
Outliers 2.6 
Number of TLS groups 6 
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5.6 Structure of (ΔN/2aq/3e)-Dbf4 (MC) ATPγS-Mcm2-S40(15) 
5.6.1 Substrate binds in the peptide-binding platform created by the Zn 
binding domain in Cdc7 
 
Cdc7 (ΔN/2aq/3e)-Dbf4 (MC) ATPγS-Mcm2-S40(15) crystallised in the space group P41212 
with one molecule of the kinase-substrate complex in asymmetric unit. The overall 
structure of the Cdc7-Dbf4 construct is very similar to that observed in complex 
with XL413, with r.m.s. deviations for common Cα atom positions of 0.345 Å 
(Figure 5-5). The initial difference Fo-Fc map revealed a pronounced additional 
density, which could be unambiguously interpreted as the peptide moiety of the 
chimeric ligand (Figure 5-6). In total, 9 residues of the peptide (corresponding to 
Mcm2 residues 38-46), including the aminoalanine mimicking the target Ser40 
could be built (Figure 5-6A).  
 
While the peptide and nucleotide are both bound in the active site as expected, it 
can be seen that hydrolysis of the bi-substrate inhibitor has occurred during the 
crystallisation process (Figure 5-6B). The hydrolysis left ADP in the active site with 
the peptide containing a sulfhydryl group which both interact with a metal atom in 
the active site. The metal atom was interpreted as Zn, which was present in the 
protein sample.  
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Figure 5-5 Overall structure of Cdc7-Dbf4 bound to ATPγS-Mcm2-S40(15) 
ADP and the Mcm2-derived peptide are shown as sticks in orange and magenta 
respectively. All non-carbon atoms are shown by standard colouration. Zinc atoms 
are shown as grey spheres. 
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Figure 5-6 Electron density reveals successful substrate binding 
A) The Mcm2-derived peptide binds in the cleft between the N- and C-lobe of Cdc7. 
B) The ATPγS-conjugated peptide appears to be hydrolysed during crystallisation. 
The ligand was therefore modelled as ADP and an SH-conjugated peptide held 
together by interaction with a metal atom (modelled as Zn), as suggested by the 
density. Residues discussed in the text are shown as sticks. Weighted 2Fo-Fc 
electron density of the bound nucleotide and the peptide is shown as blue chicken 
wire, contoured at 1.0σ. 
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5.6.2 Arg373 and Arg380 interact with the pre-phosphorylated serine of the 
peptide required for substrate specificity 
As hypothesized based on modelling in Chapter 4 (Figure 4-8), Arg373 and Arg380 
make favourable interactions with the phosphate group of the P+1 residue of the 
peptide (Figure 5-7) This pre-phosphorylated or negatively charged P+1 residue 
constitutes the entire consensus sequence for Cdc7 phosphorylation sites (Cho et 
al., 2006, Montagnoli et al., 2006). The importance of this interaction in the 
structure is also in excellent agreement with mutagenesis analysis (Figure 4-9). 
 
 
Figure 5-7 The structure confirms the recognition of the P+1 residue by Cdc7 
Arg373 and Arg380 and suggests a possible role for Thr376 
Residues discussed in the text are shown as sticks and indicated. Yellow dashes 
represent hydrogen bonds and salt bridge interactions involving Arg residues of 
Cdc7 and the phosphate group of the peptide. 
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5.6.3 Cdc7 contains a binding pocket for the P+4 residue of the target 
suggesting a co-evolution with CDK2 
The P+4 position in the S40(15) model substrate is occupied by an Arg residue, 
corresponding to Arg44 of Mcm2. In the structure, the guanidinium side chain of 
Arg44 stacks against Cdc7 Phe69 and forms hydrogen bonds with carbonyl groups 
of Cdc7 Ser96 and Gly198 and a salt bridge with Dbf4 Glu297 (Figure 5-8). These 
Cdc7 and Dbf4 residues form a favourable pocket for a positively charged side 
chain at the substrate P+4 position. Intriguingly, the target site consensus of CDK2, 
the kinase proposed to prime Ser40 for recognition by Cdc7 by pre-phosphorylating 
Ser41, features an Arg or a Lys residue at P+3 position (Stevenson-Lindert et al., 
2003). Therefore, it appears that Cdc7 is specifically adapted to act upon sites 
primed by CDK2, suggesting a co-evolution of the S-phase kinases (Nougarede et 
al., 2000). It is however worth noting that not all Cdc7 sites are primed sites, and a 
range of residues can be present at the P+4 position of any site. This was 
confirmed by in vitro kinase assays performed on peptides with various 
substitutions at the P+4 residue, in which mutation of the arginine residue has 
minimal effects on activity in many cases (Figure 5-9). The decrease in activity 
seen for some mutants is also significantly less than the decrease observed upon 
removal of the primed Ser41, highlighting how the P+1 residue is the essential 
requirement for substrate specificity and full activity. It is however important to 
consider that such activity assays as a method of inferring affinity does not dissect 
the relative on and off rates of the kinase-peptide interaction. It is possible that 
peptides that appear to have less affinity actually have a higher affinity for the 
kinase and are therefore released more slowly leading to slower turnover. To 
assess the affinity of the various mutant peptides for the kinase, biophysical studies 
such as ITC or SPR would be required. 
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Figure 5-8 An arginine binding pocket allows for favourable interactions between 
the P+4 residue of the peptide and Cdc7-Dbf4. 
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Figure 5-9 Arg44 of Mcm2 is not essential for phosphorylation of Ser41 by Cdc7-
Dbf4 in vitro 
Peptides with indicated substitutions of the P+4 residue were used as substrates 
for phosphorylation by Cdc7(ΔN)-Dbf4(MC) in vitro. The activity relative to that 
observed with WT Mcm2 peptide is shown in form of a bar chart. Error bars 
represent standard deviations calculated from a single experiment performed in 
triplicate. No-Phosph peptide contained Arg44 but no phosphorylation onf Ser41.  
 
 
5.6.4 A possible role for Thr376 in kinase regulation 
Activities of CDKs and numerous other kinases are regulated by phosphorylation of 
their activation loops by priming kinases leading to conformational changes 
required for kinase activation (Adams, 2003). In the case of CDK2-Cyclin A, 
phosphorylation of Thr160 allows the residue to contribute to a hydrogen bond 
network that facilitates interactions between the kinase and the activating cyclin. 
Phosphorylation moreover leads to a significant movement of the Thr residue, 
which opens the active site for substrate binding (Russo et al., 1996). The mitiotic 
kinase Aurora A also has a conserved threonine which is phosphorylated as part of 
its activation (Thr288) which forms important interactions with the αC helix upon 
binding of the activator TPX2. Binding of TPX2 induces a 10-Å movement of the 
phospho-Thr residue in order for the active conformation to be formed. In the 
absence of TPX2, Thr288 is solvent-exposed and available for phosphorylation. 
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Binding of TPX2 appears to enhance auto-phosphorylation and protect the 
phospho-Thr from phosphatases. This is in contrast to CDK2 which requires cyclin 
binding to facilitate Thr160 phosphorylation (Bayliss et al., 2003). Phosphorylation 
also plays an important role in the activation of Tyr kinases, with all MAP kinases 
requiring phosphorylation at two sites for full activation (Canagarajah et al., 1997, 
Bellon et al., 1999). In contrast, the lymphocyte tyrosine kinase (Lck) kinase 
requires a single phosphorylation at Tyr394 for activation, while a second 
phosphorylation event at Tyr505 inhibits the kinase activity (Yamaguchi and 
Hendrickson, 1996).  
 
Masai and colleagues suggested that Cdc7 may similarly depend on 
phosphorylation of its activation loop and implicated a number of kinases including 
CDK2 as the possible priming kinase with Cdc7 Thr376 as the target (Masai et al., 
2000). Mutagenesis confirmed that Thr376 is critical to Cdc7 activity, and it was 
shown to be a substrate for phosphorylation by a number of kinases in vitro. 
However, superposition of Cdc7 and phosphorylation-activated kinase structures 
revealed that Cdc7 Thr376 is unlikely to function as the activating Thr residue 
(Hughes et al., 2012), suggesting an alternative mode of regulation. Due to its 
proximity both to the γ-phosphate of the nucleotide and the negatively charged P+1 
residue of the substrate, phosphorylation of Thr376 is likely to inhibit peptide 
binding and subsequent activity (Figure 5-7). It is therefore possible that 
phosphorylation of Thr376 acts as an off-switch for the kinase. This idea is 
supported by recent data from Lee and colleagues, who showed that 
phosphorylated Cdc7 has limited affinity for replication origins, and de-
phosphorylation of a number of sites by PP1 may be required for DNA replication. 
They furthermore suggested that phosphorylation of Cdc7 by mitotic CDK1 serves 
to prevent DNA re-replication in mitosis (Knockleby et al., 2016).   
 
Inhibitory phosphorylation of kinases is more commonly associated with the P-loop 
in the active site, with phosphorylation of residues in this glycine-rich region 
preventing proper alignment of ATP in the active site (Morgan, 1995). However, 
there are examples of inhibitory phosphorylation in the activation loop of kinases. 
The activity of CDK9 has been shown to be reliant on the dephosphorylation of 
Ser175 by PP1. Presence of a phosphate at this residue has been shown to be 
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inhibitory for the kinases ability to phosphorylate RNAPolII and promote HIV-1 
transcription. This was further confirmed by a total loss of in vitro activity upon 
phosphomimetic mutation of this residue. Conversely, an alanine mutation of 
Ser175 did not lead to a reduction in CDK9 activity (Ammosova et al., 2011). A 
recent interesting example of inhibitory phosphorylation of the activation loop is 
ERK1. An initial phosphorylation event is required at the conserved TEY for 
activation of ERK1. However, the increase in its catalytic activity leads to steady 
auto-phosphorylation of the kinase at Thr207, which reduces its activity towards 
other substrates. This serves as a mechanism to gradually switch off kinase activity 
after the initial activation event (Lai and Pelech, 2016). This appears to be a 
mechanism of regulation that is conserved across a number of kinases, with the 
checkpoint kinase Chk2 and the centrosomal kinase Nek2 both containing 
activating phosphorylation sites and inhibitory auto-phosphorylation sites in the 
activation loop (Schwarz et al., 2003, Rellos et al., 2007). This kind of regulation is 
also seen with microtubule-associated protein (MAP)-microtubule affinity regulating 
kinase (MARK) which contains both an activation phosphorylation site in its 
activation loop (Thr208) alongside an inhibitory site (Ser212) (Timm et al., 2003). 
However, in the case of MARK, the inhibitory phosphorylation is executed by 
glycogen synthase kinase 3β (GSK3 β) (Timm et al., 2008). Whether such a 
method of regulation is relevant in the case of Cdc7 is not currently clear but it 
could offer an intriguing possibility for fine-tuning the activity of Cdc7 as it moves 
through the cell cycle. 
 
5.7 Conclusions 
 
This chapter describes a method for obtaining crystals of a peptide-bound form of 
Cdc7-Dbf4. Successful co-crystallization of a model target peptide was achieved 
through the use of a chimeric bi-substrate ligand, in which the nucleotide analogue 
and the peptide were covalently linked to increase the affinity of the initial binding to 
the kinase. Crystals of Cdc7-Dbf4 were obtained in the presence of a number of 
different peptides, designed based on previously known and newly identified Cdc7 
target sites. However, most of the crystallization conditions did not reveal electron 
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density for the peptide. A single structure was obtained of the previously 
crystallised Cdc7-Dbf4 construct (Chapter 4) in the presence of an Mcm2-derived 
15-mer peptide conjugated to ATPγS at the Mcm2 Ser40 Cdc7 target site with the 
priming phosphorylation at the P+1 site. The structure revealed a number of 
important features for substrate binding and kinase activation despite apparent 
hydrolysis of the peptide-ATPγS linkage. The hydrolysis was not entirely 
unexpected, as the chimeric molecule spontaneously hydrolyses over time. This 
problem was more pronounced with more acidic peptides, and the hydrolysis could 
have been increased by the slightly acidic pH required for crystallisation. 
 
The newly obtained structure confirms the importance of Cdc7 Arg373 and Arg380 
for the recognition of the negatively charged P+1 residue in Cdc7 target site 
consensus. Crucially, Arg373 and Arg380 are conserved across all known Cdc7 
orthologs, and the P+1 residue is the entirety of the Cdc7 consensus sequence. 
The importance of the P+1 substrate residue is further shown by in vitro kinase 
assays in which a substantial loss of activity in the absence of Ser41 
phosphorylation is observed. Further to this, the unexpected interaction involving 
the side chain of the P+4 residue of Mcm2 (Arg44), which becomes buried in a 
pocket at the Cdc7-Dbf4 interface. This Arg residue is also a part of the consensus 
of CDK2, which prefers an Arg or a Lys residue at the corresponding P+3 position. 
The structure therefore suggests that the pocket has evolved to facilitate Cdc7-
Dbf4 to act in tandem with CDK2 during DNA replication initiation. However, in vitro 
kinase assays using peptides containing mutants of the P+4 residue revealed 
limited importance of an Arg at this position in the kinase, with mutation of the P+1 
residue proving to be much more detrimental to kinase activity. While the 
interactions are well-defined in the structure, it is not unexpected that the pocket 
would able to accommodate a number of different residues as the P+4 residue is 
not an arginine in many of the S(D/E) sites that Cdc7 also phosphorylates. 
 
Another important feature of the structure is the proximity of Thr376 relative to the 
γ-phosphate of the nucleotide and the negatively charged P+1 residue of a bound 
substrate. The position of Thr376 is incompatible with the hypothesis of it being a 
phosphorylation-priming site for Cdc7 activation. Conversely, our structure appears 
more consistent with a mechanism, in which phosphorylation would switch off 
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kinase activity. The crystal structure reveals a number of previously unseen 
features of Cdc7-Dbf4 and how it engages its substrates. Further work will focus on 
the importance of such features in a more physiological setting (Chapter 6).  
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Chapter 6. Results 4 - Functional characterisation of 
Cdc7 mutants in cellula using a conditional 
knockout cell line 
 
6.1 Aims 
 
Having gained significant insights into the structural features of Cdc7 required for 
its activation and substrate recognition, a logical next step in the project was to 
establish the relevance of these features in a more physiological setting. Until this 
point, the functionality of Cdc7-Dbf4 mutants could only be tested using in vitro 
kinase assays. Such experiments gave valuable insight into whether the kinase, 
acting in isolation, is capable of phosphorylating a simple Mcm-derived substrate 
peptide. However, in the context of a cell, there are numerous further requirements 
for Cdc7 function, such as the ability to interact with target protein-DNA complexes 
and numerous further layers of regulation beyond Dbf4 binding.  
 
In this chapter the production of a conditional CDC7 knockout cell, which can be 
used as a system to study the kinase mutants in cellula is presented. Through 
utilising retroviral transduction and the bacteriophage P1 Cre-Lox recombination 
system, Cdc7 mutants could be expressed in the cells in the absence of the WT 
kinase to test their ability to support Mcm phosphorylation and cell cycle 
progression. This system is used to validate the importance of structural features 
described in Chapter 4 and 5, and investigate the possible roles of Cdc7 KI2 and 
KI3, which appear to be largely dispensable for the in vitro activity of the kinase. 
 
6.2 Production of an inducible CDC7 knockout cell line 
 
To investigate the effect of mutations in CDC7 on the cell cycle, a conditional 
knockout cell line, with the endogenous CDC7 alleles disrupted was created. The 
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cell line was supported by an artificial CDC7 allele flanked with LoxP recombination 
sites. This design allows removal of the artificial allele by the action of 
bacteriophage P1 Cre recombinase, which can be conveniently expressed from an 
adenoviral vector (Anton and Graham, 1995). Epithelial HT1080 cells (Rasheed et 
al., 1974) were chosen as the parental cell line because of the ease of 
maintenance, high permissivity to adenoviral vectors and the diploid karyotype. 
 
6.2.1 Production of the lentiviral vector containing expressing mCherry-
tagged Cdc7 Cdc7 
 
To monitor expression of the artificial (excisable) CDC7 allele in the presence of 
endogenous Cdc7, it was modified by an N-terminal fusion to mCherry. This 
allowed the expression of the transgene to be detected easily and simultaneously 
with endogenous Cdc7 by Western blotting. It also provided a simple way of 
monitoring the loss of mCherry-Cdc7 expression upon excision of the artificial 
CDC7 allele. The N-terminal residues of Cdc7 were predicted to be disordered, and 
are not essential for the kinase function in vitro (Hughes et al., 2012). Therefore, 
the addition of an N-terminal tag was deemed less likely to affect the structure and 
the activity of the kinase. To ensure that the excisable allele is stable in the 
presence of CRISPR-Cas9 constructs targeting endogenous CDC7 alleles, the 
artificial gene was made using a codon-shuffled sequence, originally designed for 
expression of Cdc7 in bacteria (Hughes et al., unpublished).  Full description of the 
production of the cell line can be found in section 2.2.2. 
 
The mCherry tag adds 29 kDa to the mass of the fusion protein allowing 
simultaneous detection of the endogenous and ectopically expressed proteins. 
Approximately 100 clones were tested for mCherry-Cdc7 expression, of which 
many appeared to overexpress the construct relative to endogenous Cdc7. Clones 
with relatively low expression were expanded and re-blotted (Figure 6-1A), of which 
one (clone 110), with the closest expression level to endogenous Cdc7 was 
selected for the next steps in cell line production. Before disruption of the 
endogenous CDC7, the cell line was tested to ensure the LoxP sites had not been 
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mutated, and that the mCherry-Cdc7 expression could be successfully depleted 
upon adenoviral transduction (Figure 6-1B). This new cell line was designated 
HT1080 mCherry-Cdc7(LoxP) and used for further steps in production of the 
conditional knockout system. 
 
 
 
 
Figure 6-1 Expression and depletion of mCherry-Cdc7 in HT1080 cells 
A) Cells were infected with a lentiviral vector expressing pWPT-mCherry-Cdc7 and 
diluted for single colonies before expanding for several weeks. Individual clones 
were harvested and lysed prior to Western blotting. 
B) Cells from clone 110 were infected with Ad-GFP or Ad-Cre-GFP and grown for 3 
d before harvesting and lysis prior to Western blotting. All blots contained 10 µg of 
cell lysate per well and were probed with an anti-Cdc7 antibody and an anti-β-
tubulin antibody as a loading control. 
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6.2.2 Disruption of the endogenous CDC7 alleles in HT1080 mCherry-
Cdc7(LoxP) cells 
 
To disrupt the endogenous CDC7 gene the CRISPR/Cas9 system was used. 
CRISPR is a genome editing technique that has been developed from an adaptive 
bacterial immune system (Barrangou et al., 2007). The CRISPR system requires 
two components in the form of a guide RNA and a CRISPR associated 
endonuclease in the form of Cas9.  The guide RNA (gRNA) is a sequence 
comprising a  ‘scaffold sequence’ required for Cas9 binding and a 20-nucleotide 
sequence complimentary to the genome to be altered (Jinek et al., 2012). In order 
to produce a successful knockout, the gRNA must be upstream of a protospacer 
adjacent motif (PAM) required for Cas9 binding and contain a unique guide 
sequence. The PAM sequence is essential to binding and specific to each 
endonuclease (Sternberg et al., 2014). The gRNA sequence can be cloned into 
specially designed vectors that are then transfected into target cells. Upon 
expression the Cas9 forms a riboprotein complex with the gRNA, inducing a 
conformational change in Cas9 that allows it to bind DNA. The complex is then able 
to bind any PAM sequence in the genome. The affinity for sites in the genome is 
dictated by the guide sequence and influences how likely Cas9 is to cut at that 
position in the genome. Cas9 will only cut when the guide sequence is successfully 
annealed to the genomic sequence. Successful binding leads to a further 
conformational change in Cas9 that allows it to cut both sides of the DNA resulting 
in a double strand break 3-4 bp upstream of the PAM sequence. A knockout is 
achieved when the break is repaired by the error-prone non-homologous end 
joining mechanism (Jinek et al., 2012). Transfection of the Cas9-gRNA constructs 
leads to a mixed population of cells containing a range of indels or more complex 
chromosomal rearrangements. Individual clones can be isolated by limited dilution 
of the heterogeneous population for detailed genetic and phenotypic 
characterisations. After transfecting with CRISPR/Cas9 constructs cells were 
diluted for single colonies, which, after expansion, were tested for Cdc7 expression 
by Western blotting. Western blots indicated a lack of endogenous Cdc7 
expression in the clone 47 (Figure 6-2A and B). The chromosomal region targeted 
by the gRNA construct in this clone was PCR-amplified, and the product was 
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cloned into the Topo-TA cloning vector (Life Technologies). Sequencing of 4 
individual clones revealed a single frame shift mutation (Figure 6-2C). It seems 
unlikely that both alleles in the cell clone sustained identical mutations. Given that 
no WT sequence was detected in this clone, the second allele may have suffered a 
sufficiently large deletion to prevent amplification with the primers used for PCR 
amplification of the genomic region.This clone was designated HT1080 CDC7(-/-) 
mCherry-Cdc7(LoxP) and was used for the complementation experiments. 
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Figure 6-2 Identification of a double Cdc7 knockout after transfection of HT1080 
mCherry-Cdc7(LoxP) cells with CRISPR/Cas9 constructs 
A) HT1080-mCherry-Cdc7(LoxP) cells were transfected with CRISPR/Cas9 
constructs designed to disrupt the CDC7 gene. Cells were diluted for single 
colonies before expanding for several weeks. Individual clones were harvested and 
lysed prior to Western blotting using an anti-Cdc7 antibody. 
B) Clones 110 and 47 were blotted for a second time to confirm the full knockout of 
endogenous Cdc7 expression in clone 47. 
C) The region of the genome targeted for disruption by the gRNA was PCR 
amplified and cloned into a Topo-TA cloning vector. Sequencing of 4 clones using 
the BigDye Terminator 3.1 sequencing kit revealed that a G-insertion  (highlighted 
in yellow) lead to a frame shift in the endogenous CDC7 gene. Sequencing was 
carried out at the in-house sequencing facility.  
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6.2.3 Expression of FLAG-tagged Cdc7 mutants in CDC7(-/-) mCherry-Cdc7 
cells 
DNA constructs for expression of WT and mutant versions of FLAG-Cdc7 were 
made on the basis of the pBabe-puro vector (Morgenstern and Land, 1990) (2.2.2). 
The vector contains a puromycin resistance gene allowing for quick selection of 
stably transduced cells. Retroviral vector particles were produced by co-
transfection of pBabe-FLAG-Cdc7 vectors with the packaging vectors pCG-GagPol 
and pMDG (Naldini et al., 1996) into HEK-293T cells. Cell-free supernatants 
containing vector particles were used to infect the CDC7(-/-) mCherry-Cdc7(LoxP) 
cells, and stably transduced cells were selected in the presence of puromycin. 
Western blot analysis was used to verify expression of FLAG-Cdc7 (Figure 6-3). 
Near-endogenous expression was achieved for all but the constructs carrying the 
Δ2aq deletion in KI2, which were all highly over expressed. Attempts were made to 
reduce the expression of these constructs by detuning the Kozak consensus 
sequence and using alternative expression vectors. However, Δ2aq Cdc7 was 
overexpressed in all cases (data not shown), and the original overexpressing cell 
line was used for further experiments.  
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Figure 6-3 Expression of FLAG-Cdc7 mutants in CDC7(-/-) mCherry-Cdc7(LoxP) 
cells after infection with pBabe(puro) expression constructs 
CDC7(-/-) mCherry-Cdc7 (LoxP) cells were stably transduced with retroviral vectors 
expressing a range of FLAG-Cdc7 variants. Total cell extracts (10 µg protein per 
lane) were analysed by Western blotting with an anti-Cdc7 (top) and an anti-β-
tubulin (bottom) antibody. 
 
6.2.4 Depletion of mCherry-Cdc7 following the treatment of CDC7(-/-) 
mCherry-Cdc7 cells with Ad-GFP-Cre 
To excise the ectopic mCherry-Cdc7(LoxP) allele, the cells were incubated with 
adenoviral vector particles expressing P1 phage Cre recombinase and GFP from 
two separate promoters (Ad-GFP-Cre, Vector Biolabs). Cre recombinase catalyses 
site-specific recombination between two 34-bp DNA sequences called LoxP sites. 
Recombination between a pair of directly repeated LoxP sites leads to excision of 
the intervening sequence, leaving a single LoxP sites (Nagy, 2000). The adenoviral 
system used in this assay leads to excision of the transgene without replication of 
the virus and subsequent cell death. This is due to a deletion in the E1 gene in the 
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vector genome, which prevents virus replication in normal cells. Adenoviruses are 
able to infect a wide range of cells making them an excellent vector for protein 
expression in human cells (Anton and Graham, 1995). As a control, adenoviral 
vector expressing GFP alone was used (Ad-GFP). The amount of virus is 
expressed in plaque forming units (PFUs), determined by infection of cells 
permissive for lytic replication of the vector.   
 
Cells were harvested and 70,000 cells infected with 2.5x106 or 5x106 PFU/ml Ad-
GFP-Cre or Ad-GFP in 12-well plates for 24 h. At this stage, all cells expressed 
GFP, as judged by epifluorescence microscopy (data not shown). Cells were 
expanded into 10-cm dishes for 3 days prior to lysis and analysis by Western 
blotting with antibodies to Cdc7 and β-tubulin, as a loading control (Figure 6-4). 
 
 
 
 
 
 
 
Chapter 6. Results 
 
171 
 
 
Figure 6-4 Removal of mCherry-Cdc7(LoxP) by Cre recombinase 
HT1080 and CDC7(-/-) mCherry-Cdc7 (LoxP) cells were infected with 2.5x106 and  
5x106 PFUs of Ad-GFP or Ad-Cre-GFP and grown for 3 d prior to harvesting and 
lysis; 10 µg of total protein was separated in SDS-PAGE gels and analysed by 
Western blotting using anti-Cdc7 and anti-β-tubulin antibodies. 
 
 
 
6.3 Complementation of cell cycle profiles and Mcm2 
phosphorylation by mutants of Cdc7 
 
For the cell cycle assays, each cell line was infected with 5x106 PFU of Ad-GFP or 
Ad-GFP-Cre and expanded for 5 d prior to cell cycle analysis and Western blotting 
with antibodies specific to Mcm2 phosphorylated at Ser40. Excision of the 
transgene was also verified using an anti-Cdcy antibody (Figure 6-5). 
 
Chapter 6. Results 
 
172 
 
 
Figure 6-5 Depletion of mCherry-Cdc7 following infection with Ad-GFP-Cre 
Cells infected with Ad-GFP or Ad-GFP-Cre were expanded for 5 days prior to 
Western blotting with anti-Cdc7 antibodies; each lane contained 10 µg of total cell 
extract. 
 
 
6.3.1 Cell cycle assay following depletion of mCherry-Cdc7 in the 
conditional knockout cell line 
 
Because Cdc7 is essential for cell proliferation, its depletion or inhibition leads to a 
cell cycle arrest and eventual cell death (Ito et al., 2012). Furthermore, infection of 
cells with adenoviral vectors or expression of Cre recombinase could in principle 
affect cell growth. For this reason, the conditional knockout CDC7(-/-) mCherry-
Cdc7(LoxP) cells transduced with pBabe-FLAG-Cdc7(WT) or pBabe-FLAG-
Cdc7(D196N) were used to validate downstream analyses. Cdc7 Asp196 is part of 
the essential DFG kinase motif, mutations of which are incompatible with the 
kinase activity. Cells were expanded for 5 d prior to harvesting and cell cycle 
analyses by flow cytometry (2.5). At this time, cell lysates were also prepared for 
Western blotting with phosphospecific antibodies to detect Cdc7-specific 
phosphorylation of Mcm2 Ser40. 
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Addition of the FLAG-Cdc7(WT) construct displayed cell cycle profiles similar to the 
GFP expressing cells upon mCherry-Cdc7 removal (Figure 6-6A). The Cre 
recombinase expressing cells also maintained normal levels of Mcm2 Ser40 
phosphorylation, when compared to the GFP transduced control cells (Figure 6-7). 
Visualising the cells 7 days after excision also revealed that cells proliferate at a 
similar rate to control cells after transgene excision, and these cells exhibit a 
normal morphology (Figure 6-6A). Therefore, as expected, FLAG-Cdc7(WT) is able 
to support normal cell cycle. In contrast, upon infection with Ad-GFP-Cre, the cells 
expressing FLAG-Cdc7(D196N) displayed an accumulation in G2/M with 
concomitant reductions in S and G1 populations (Figure 6-6B) and a near total loss 
of Mcm2 Ser40 phosphorylation (Figure 6-7). Considerably fewer cells were seen 
when visualised after 7 days and many of the remaining cells exhibited an unusual 
morphology consistent with a failure to perform successful mitosis. As expected, 
the cells maintained normal cell cycle profile upon infection with the control Ad-GFP 
vector (Figure 6-6B).  
 
Chapter 6. Results 
 
174 
 
 
Figure 6-6 Cell cycle analysis of CDC7(-/-) mCherry-Cdc7(LoxP) cells  expressing 
WT or kinase dead D196N FLAG-Cdc7 after mCherry-Cdc7 excision 
A) Cell cycle profile and photographs of cells transduced containing FLAG-
Cdc7(WT) B) Cell cycle profile and photographs of cells transduced containing 
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FLAG-Cdc7(D196N). Cells were stained for total DNA with propidium idodide 
(detected in FL3 channel) and nascent actively replicating DNA (Alexa Fluor 647, 
FL4 channel). Cells were then analysed by flow cytometry (for details see Materials 
and methods 2.5) Cells were analysed 5 days post infection with Ad-GFP or Ad-
Cre-GFP. Cells were photographed 7 days post infection. 
 
 
 
 
               
 
 
Figure 6-7 Western blot of Mcm2-S40 phosphorylation 
CDC7(-/-) mCherry-Cdc7(LoxP) cells expressing FLAG-Cdc7 and its mutant forms 
(as labelled) were infected with Ad-GFP or Ad-GFP-Cre and allowed to expanded 
for 5 d before harvesting and Western blotting with anti-Mcm2 Ser40 and anti-
Mcm2 antibodies; each lane contained 10 µg of total cell protein. 
 
 
6.3.2 Point mutations of the Cdc7 Zn-binding domain, Arg373 or Arg380 
affect Mcm2 phosphorylation and cell cycle progression 
 
The experiments described above established that mCherry-Cdc7 fusion can be 
successfully depleted from CDC7(-/-) mCherry-Cdc7(LoxP) cells, and that the 
survival of the cells upon the depletion depends on complementation with a 
functional Cdc7 variant. The system was then applied to test functionality of a 
range of FLAG-Cdc7 mutants (Figure 6-5). Cell cycle profiles and the 
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phosphorylation status of Mcm2 Ser40 were monitored following infection of the 
cell lines with Ad-GFP-Cre, relative to control cells infected with Ad-GFP.  
 
Mutation of the invariant Cdc7 Cys353 involved in metal coordination within the Zn-
binding domain (C353A) lead to an accumulation of cells in G2/M phase of the cell 
cycle (Figure 6-8), albeit less pronounced than with the D196N mutant. Near total 
loss of Mcm2 Ser40 phosphorylation was also observed (Figure 6-7). The 
difference in cell number and morphology between Cre and control treated cells is 
also similar to that of the D196N mutant, with a significant reduction in surviving 
cells and a significant number of cells exhibiting unusual morphology. This is in 
excellent agreement with in vitro kinase assays (Figure 3-5) and confirms the 
critical importance of the Zn-binding domain in a physiological setting.  
 
Mutation of Arg380 to Ala leads to an accumulation of cells in G2/M and a 
significant decrease in Mcm2 Ser40 phosphorylation (Figure 6-9 and 6-7). In the 
case of the double mutant R373A/R380A, a more pronounced accumulation of 
cells in G2/M of the cell cycle was observed, alongside the same significant 
decrease in steady-state levels of MCM2 Ser40 phosphorylation (Figure 6-9 and 6-
7)). The number of surviving cells and cell morphology of Cre treated cells also 
mirror that of the D196N mutant cells line. However, in the case of the single 
R380A mutant this is much less pronounced than the double mutant. This data is in 
excellent agreement with in vitro kinase data, in which the double mutant had 
significantly reduced activity relative to R380A alone (Figure 3-9). The ability of the 
R380A single mutant to survive to a greater extent than other mutants may be due 
to its ability to still successfully target a number of other Mcm2-7 phosphorylation 
sites as well as its slightly increased ability to phosphorylate Mcm2-S40. To test 
this, it would be possible to use antibodies specific to phosphorylation of other 
Mcm2-7 target sites to see if the R380A mutant significantly affects them. 
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Figure 6-8 Cell cycle analysis of CDC7(-/-) mCherry-Cdc7(LoxP) cells  expressing 
FLAG-Cdc7 (C353A) infected with Ad-GFP-Cre or Ad-GFP 
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Figure 6-9 Cell cycle analysis of CDC7(-/-) mCherry-Cdc7(LoxP) cells expressing 
R380A or R373A/R380A mutants of FLAG-Cdc7 after infection with Ad-GFP-Cre 
or Ad-GFP 
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6.3.3 Deletions in KI2 and KI3 have a minimal affect on Mcm2 
phosphorylation and cell cycle progression 
 
To determine if the regions of Cdc7 KI2 and KI3 deleted in the crystallized 
construct are essential for its functionality in cellula, we tested the ability of Δ2aq 
and Δ3e mutants of Flag-Cdc7 to complement the depletion of mCherry-Cdc7 in 
the conditional knockout cell line. Surprisingly, despite its extent, the Δ2aq deletion 
had relatively modest effect, with 13% of the cells undergoing active S-phase 
(Figure 6-10A). Consistent with these observations, the steady-state levels of 
Mcm2 Ser40 phosphorylation were comparable to the control condition (Figure 6-
7); moreover, the cells continued to proliferate for at least 2 passages. Differences 
in cell number and morphology between the Cre treated and control cells are also 
minimal when compared to the previous mutants. Although these results indicate 
that a large section of KI2 may be dispensable both in vitro and in cellula, 
overexpression of the Δ2aq mutant may compensate for the defect in its activity.  
 
FLAG-Cdc7(Δ3e), harboring the KI3 deletion used for crystallization was capable of 
supporting normal cell cycle, with 18.5% of the cells in active S-phase (Figure 6-
10B), and normal steady-state levels of Mcm2 Ser40 phosphorylation (Figure 6-7). 
In contrast to Δ2aq, this mutant was expressed at near endogenous levels, arguing 
that the removed segment of KI3 may be indeed dispensable for cell cycle 
progression. The number and morphology of cells observed at 7 days, in which the 
control and Cre treated cells appear similar. This is in agreement with in vitro 
kinase assays (Figure 3-6). 
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Figure 6-10 Cell cycle analysis of CDC7(-/-) mCherry-Cdc7(LoxP) cells  
expressing Δ2aq orΔ3e deletion mutants of FLAG-Cdc7 after mCherry-Cdc7 
excision 
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6.4 Conclusions 
 
In this chapter the production of a conditional Cdc7 knockout cell line is described 
for investigating the importance of a number of structural features of Cdc7 in a 
physiological context. By introduction of a tagged Cdc7 transgene flanked by LoxP 
sites and subsequent removal of endogenous Cdc7 expression, it was possible to 
construct an assay system, in which mutants of Cdc7 could be introduced into the 
cell and tested for their ability to support cell cycle progression. Point mutations in 
structural features described in Chapter 4 and Chapter 5 produced outcomes in 
agreement with previously used in vitro kinase assays. Disruption of the Zn-binding 
domain through mutation of the invariant Cys353 residue almost phenocopied the 
kinase dead mutant D196N, confirming importance of the Zn-binding domain for 
the core Cdc7 functions in the cell. Mutation of the conserved residues Arg373 and 
Arg380 also lead to reduced Mcm2 Ser40 phosphorylation and a reduction in cell 
cycle progression, with a more pronounced phenotype when both residues were 
mutated simultaneously. These results further highlight the importance of the 
interactions between Cdc7 and the P+1 residue of the target site in ensuring full 
kinase activity.  
 
The Δ2aq and Δ3e FLAG-Cdc7 mutants were capable of supporting cell 
proliferation with minimal effects on steady state levels of Mcm2 Ser40 
phosphorylation. Therefore, KI2 and KI3 residues deleted in the crystallized 
construct may not be strictly essential for the cell cycle related functions of Cdc7. 
However, it is important to note that overexpression of FLAG-Cdc7(Δ2aq) mutant 
could compensate a partial loss of function.  
 
As deletions in KI2 appeared to have limited affect on cell cycle progression, it was 
hypothesized that this region may be important for other roles Cdc7 plays in the cell. 
As discussed in the introduction section, Cdc7 interacts with a number of different 
proteins and acts in various capacities in the cell, including the DNA damage 
response and meiosis. (Tsuji et al., 2008, Sheu and Stillman, 2010, Lee et al., 
2012). This represents a future and potentially interesting avenue for investigation. 
However it is important to consider such conclusions as preliminary as the 
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presented data is representative of a single experiment. To fully confirm the effect 
of such mutants it is necessary to perform the experiment a number of times to 
account for the inherent variability in assays utilizing live cells. While there appears 
to be a reduction in active S-phase for a number of mutants, these reductions are 
often relatively small so replicates are required to confirm their significance. 
However, the accumulation of cells in G2/M, when combined with the difference in 
the number of cells and cellular morphology of a number of Cre treated cells does 
suggest an effect on cell viability and cell cycle progression for a number of 
mutants identified in the obtained structures. Interestingly, the accumulation of cells 
in G2/M is not in agreement with previous studies, which suggest cells with a 
functional allele of p53 should arrest and die during an abberant S-phase (Ito et al., 
2012). It is possible that accumulation may be an artifact of the system due to the 
very slow degradation of the mCherry-Cdc7 transgene. Development of a system 
with a faster knockout or production of a similar system in cell lines both positive 
and negative for p53 could shed light onto this unexpected outcome. A further 
important avenue of investigation would be to ascertain whether the cells have 
simply ceased to proliferate or have died through apoptosis. This could be 
investigated with simple apoptosis assays in which caspase activity can be 
measured. 
 
Collectively, the results described in this chapter suggest that the features identified 
in the crystal structure of Cdc7 may be physiologically important. The conditional 
Cdc7 knockout cell line represents a potential tool for understanding the various 
currently unexplained features of Cdc7 in the future. In particular, the potential roles 
of the extended KI2 in other cellular processes, such as the response to replication 
stress, warrant further investigations.
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Chapter 7. Discussion 
 
7.1 Introduction 
The S-phase kinase Cdc7-Dbf4 has a range of critical cellular functions and has 
attracted a lot of attention in recent years, not least because of its potential as a 
target for cancer therapeutics (Sawa and Masai, 2009). Overexpression of Cdc7 
and Dbf4 is common in transformed cell lines and primary cancer samples 
(Nambiar et al., 2007, Bonte et al., 2008, Kaufmann et al., 2008, Clarke et al., 2009, 
Kulkarni et al., 2009, Hou et al., 2012, Cheng et al., 2013, Melling et al., 2015, 
Ghatalia et al., 2016). Moreover, selective inhibition was claimed to kill transformed 
cells, while leaving regular tissues unharmed (Ito et al., 2012). A number of Cdc7 
inhibitors have already been developed with some success (Zhao et al., 2009, 
Koltun et al., 2012, Sasi et al., 2014, Li et al., 2015b), however, the design of future 
more potent and selective inhibitors could be greatly helped by better 
understanding of its structure. 
 
Cdc7-Dbf4 structural data has so far been mostly limited to conserved domains 
common to all kinases and a small fragment of Dbf4 minimally required for kinase 
activation (Hughes et al., 2012). The original structure revealed that Dbf4 uses its 
conserved motif-M to tether itself to the C-lobe of kinase subunit and stabilized the 
Cdc7 αC in its active “in” conformation using motif-C. However, deletions in the 
kinase insert sequences of Cdc7 (KI2 and KI3) were required for crystallisation. 
Deletions in KI2 also lead to a significant decrease in in vitro kinase activity, 
suggesting essential features of the kinase were missing from the construct 
(Hughes et al., 2012).  
 
Until now a structure of Cdc7-Dbf4 construct with activity similar to that of WT 
heterodimer has not been reported, and no structural information on how the 
kinase engages its target substrates is available. The main focus of this project was 
to fill this gap in our understanding of Cdc7-Dbf4 by determining crystal structures 
of the kinase with a more complete KI2 and hopefully improved levels of activity. 
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Such structures are presented in chapters 4 and 5, with the rationale for the 
construct design described in chapter 3. Further to this, the structure was validated 
both in vitro and in cellula using a conditional knockout cell line designed as part of 
the study  (chapter 6). This not only confirmed the importance of the structural 
features of Cdc7-Dbf4 revealed in this study, but also opened an avenue for 
functional analyses of the poorly understood insert sequences of Cdc7. 
 
7.2 Key findings 
7.2.1 New insights into the structure of Cdc7-Dbf4 
A key finding of this study was the identification of a novel Zn-binding domain in 
Cdc7 KI2 (Figure 4-5). A single Zn atom is coordinated by four Cys residues, which 
are invariant across all metazoan orthologues of Cdc7. This feature was shown to 
be critical for the kinase activity in vitro and essential for the ability of the kinase to 
support cell proliferation. Mechanistically, the interaction between the Zn-binding 
domain and Dbf4 pins back the activation loop of Cdc7, which is extended by KI2, 
fully opening up the active site of the kinase (Figure 3-5, 4-4 and 6-8). The pinning 
back of the loop creates a substrate peptide-binding platform that was partially 
occluded by a disordered portion of KI2 in the previously reported crystal structure. 
Interestingly, the invariant KI2 Cys residues that coordinate Zn are not conserved in 
lower eukaryotes, suggesting an alternative mechanism for maintaining an open 
conformation in yeast systems. Structures of Cdc7-Dbf4 were obtained bound to a 
potent Cdc7 inhibitor (XL413) and an ATP mimic (ADP-BeF3-). In the latter structure, 
the BeF3 moiety that mimics the γ-phosphate of the nucleotide could be visualised 
alongside the two Mg2+ ions involved in the catalysis. 
7.2.2 Substrate binding of Cdc7-Dbf4  
The fully open conformation of Cdc7-Dbf4 in the new structure allowed for 
crystallisation of the heterodimer in complex with an Mcm2-derived substrate 
peptide that had been covalently attached to ATPγS (referred to as bi-substrate 
ligand). This approach allowed successful co-crystallization of the kinase with an 
analogue of a substrate peptide, which could be visualised in the structure, despite 
the apparent hydrolysis of the chimeric bond. The newly obtained structure 
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confirmed the importance of the conserved Arg373 and Arg380 residues that had 
been hypothesised to interact with the negatively charged P+1 residue of the 
substrate (Figure 5-7). The importance of this feature was again validated both in 
vitro and in cellula highlighting their importance for kinase function (Figure 4-9, 
Figure 6-9). Further to this, an unexpected role for the P+4 residue of the peptide 
was observed in the structure. This residue, corresponding to Mcm2 Arg44, is 
involved in a network of interactions with both Cdc7 and Dbf4 in a binding cleft 
formed between the kinase and activating subunit. Intriguingly, the P+4 position of 
such a pre-phosphorylated Cdc7 target site also represents the P+3 residue of the 
consensus sequence of CDK2 that primes this site for Cdc7 targeting (Stevenson-
Lindert et al., 2003). This observation suggests that Cdc7 is optimized to act in 
tandem with CDKs regulating DNA replication. However, while this pocket makes 
favourable interactions with the given substrate, it is important to recognise that the 
P+4 position of a Cdc7 target site can be occupied by a number of different 
residues, and the pocket therefore must therefore be able to accommodate a range 
of amino acids side chains. This was confirmed in vitro with peptides containing 
substitutions at the P+4 position (Figure 5-9). 
 
7.2.3  A possible role for Thr376 in kinase regulation 
Many protein kinases require phosphorylation of their activation loops at one or 
more Thr, Ser, and/or Tyr residue(s) for full activation (Adams, 2003). These 
phosphorylation events induce considerable conformational rearrangements, such 
as those seen in CDK2-CyclinA, where phosphorylation of CDK2 Thr160 induces 
the formation of a hydrogen-bonding network resulting in opening of the catalytic 
cleft (Russo et al., 1996, Brown et al., 1999a). In a previous study, it was proposed 
that Cdc7 may be regulated by a similar mechanism, whereby conserved Cdc7 
Thr376 residue was proposed to act as an activation Thr (Masai et al., 2000). 
However, structural data obtained in this study argue that the location of Thr376 
would be incompatible with an active kinase conformation due to the close 
proximity to the negative charges of the γ-phosphate and the negatively charged 
P+1 substrate residue. These negative charges would likely lead to charge 
repulsion that would prevent the binding of the substrate. Furthermore, the 
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interaction between KI2 Zn-binding domain and Dbf4 that orders the activation loop 
of Cdc7 appears to be functionally analogous to the effect of activation loop 
phosphorylation in other kinases.  
 
Intriguingly, the location of Cdc7 Thr376 suggests that its phosphorylation could act 
as an off switch for Cdc7, and removal of the phosphate by a protein phosphatase 
could lead to re-activation of the kinase. This idea has received some support in 
the form of a recent study, in which phosphorylation of numerous sites of Cdc7 
(including Thr376) by CDK1 led to its dissociation from chromatin to prevent DNA 
re-replication in mitosis. Substitution of Cdc7 Thr376 for Ala conferred a reduction 
in kinase activity in vitro (Knockleby et al., 2016). Furthermore, PP1 was implicated 
as the phosphatase required for removal of the phosphorylation to facilitate re-
loading of Cdc7-Dbf4 onto chromatin in the next cell cycle. These data support a 
model, in which de-phosphorylation of the activation loop of Cdc7 is necessary for 
the full activity of the kinase. Further to this, our immunoprecipitation experiments 
and mass spectrometry identified an additional protein phosphatase, PP6 as a 
binding partner of Cdc7-Dbf4 in cells (data not shown). Intriguingly, this 
heterotrimeric phosphatase has been implicated in regulation of other kinases as 
well as roles in the cell cycle and DNA damage response (Stefansson and 
Brautigan, 2007, Zeng et al., 2010, Zhong et al., 2011, Hosing et al., 2012).  
 
7.2.4 Functional importance of Cdc7 KI2 and KI3 
Previous to this study, the only method for assessing Cdc7 mutants in the lab had 
been through the use of in vitro kinase assays. While these types of experiments 
are informative, they only reveal how well the kinase, acting in isolation, can 
phosphorylate a simple substrate. In the cell, Cdc7-Dbf4 relies on a number of 
protein-protein interactions for correct targeting and activation, which may be 
impossible to recapitulate in an in vitro system. Development of an inducible Cdc7 
knockout cell line as part of this study allowed for testing of such mutants in cellula 
(Chapter 6), revealing how modifications in Cdc7 may affect a number of its cellular 
functions. The system was used to further validate point mutations of Cdc7 based 
on structural features observed in this study, and these experiments were largely in 
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agreement with what had previously been seen in vitro. An important observation 
from experiments using the conditional knockout cell line was that the extended 
portions of KI2 and KI3 do not appear to be strictly required for the function of Cdc7 
in cell proliferation and maintaining the steady state levels of Mcm2 
phosphorylation (Figure 6-7, 6-10). This was particularly surprising in the case of 
KI2 due to the extent of the deletion and the fact that KI2 extends the activation 
loop of Cdc7. It is possible that this large, apparently disordered domain mediates 
interactions between Cdc7 and its functional partners in the cell. For example, KI2 
contains the nuclear localisation sequence for Cdc7 and an interaction between 
this region of the protein and importin-β has been proposed to facilitate Cdc7 entry 
into the nucleus. Further to this, a nuclear retention sequence is also present in KI2, 
which is required to maintain the presence of Cdc7 in the nucleus (Kim and Lee, 
2006, Kim et al., 2007). It is important to consider that the KI2 deletion mutant of 
Cdc7 was overexpressed, and this overexpression could have masked a stronger 
phenotype. Further to this, this data should be considered as preliminary and 
requires a number of replicates as well as fine-tuning of the system.  However, 
should the lack of requirement for KI2 and KI3 be confirmed, it is possible that the 
insert sequences are involved in cellular roles of Cdc7 that have yet to be identified. 
An interesting idea is that the inserts may be involved in the functions of Cdc7-Dbf4 
in meiosis and/or DNA damage response, and these represent interesting avenues 
for future studies. 
 
7.3 Future directions 
7.3.1 Structural characterisation of Cdc7-Dbf4 
While my work revealed a number of new Cdc7-Dbf4 features that are critical to 
kinase activation and substrate specificity, substantial deletions in KI2 and KI3 
required for crystallisation mean large sections of the kinase along with the bulk of 
the Dbf4 structure remain uncharacterized. Future work in this respect should focus 
on attempting to gain structural data on more complete constructs of Cdc7. Despite 
the lack of predicted secondary structure and sequence conservation in these 
sections of the protein, their existence across all eukaryotes suggests an important 
cellular role. It is likely that a structure amenable to crystallisation is only likely to be 
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achieved in the presence of a binding partner. My attempts to identify such a 
partner using immunoprecipitation experiments and mass spectrometry highlighted 
one interesting candidate, PP6 (data not shown). The newly developed cell line in 
this study represents a new avenue for identifying proteins in the cell that may 
interact with Cdc7 in a KI2- and/or KI3- dependent manner. Performing similar 
immunoprecipitation/mass spectrometry experiments utilising deletion mutants of 
Cdc7 could identify proteins that require either insert to interact. All constructs of 
Cdc7 utilised in the conditional knock out cell line were made with an N-terminal 
FLAG tag to facilitate efficient pull down of the mutants with commercially available 
antibodies. 
 
Attempts at crystallisation of Cdc7-Drf1 in this study were unsuccessful despite the 
production of constructs with significant activity in vitro (Figure 3-8). Future work 
should look to obtain a structure of this complex, which could reveal features that 
explain the requirement for two different activation subunits in the cell. Constructs 
in this study were designed solely based on homology to Dbf4 and secondary 
structure predictions. Limited proteolysis of a full Cdc7-Drf1 complex should be 
performed to better inform a construct design more relevant to the complex. It 
seems likely that Cdc7-Dbf4 and Cdc7-Drf1 have some degree of redundancy in 
their functions (Montagnoli et al., 2002), and as potential cancer therapeutics Cdc7 
inhibitors may or may not need to target both types of complexes.  
 
Further to this, the structural differences required for binding of different substrate 
peptides should be further investigated to see how the binding of substrates with 
Asp or Glu at P+1 position differs from that of the primed phosphorylation sites as 
well as how different P+4 residues are accommodated in the identified binding 
pocket. My attempts to crystallise bi-substrate ligands of alternative Cdc7 target 
peptides have so far been unsuccessful. This is likely due to hydrolysis of the 
substrate as seen in the structure (Figure 5-6B). Bi-substrate ligands have been 
designed in other studies, where the peptide or a small protein fragment is 
covalently linked to a small molecule inhibitor rather than a nucleotide, sometimes 
leading to further increases in affinity (Schneider et al., 2005, Stebbins et al., 2011). 
In principle, this approach allows for a wider range of chemistries for constructing 
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more stable chimeric ligands, which are less likely to undergo hydrolysis during 
crystallisation. 
 
Lastly, recent developments in cryo-electron microscopy have allowed the 
replisome and its components to be visualised at a level of detail that was 
previously impossible (Li et al., 2015a, Abid Ali et al., 2016). A previous issue of 
crystallising Cdc7-Dbf4 bound to its main substrate (Mcm2-7) was the requirement 
that the helicase be loaded on DNA for Cdc7-Dbf4 to show maximum affinity for its 
substrate (Francis et al., 2009). Potentially, cryo-electron microscopy may allow to 
obtain high-resolution structures of replication origin-loaded Mcm2-7 in complex 
with the kinase. 
 
7.3.2 Phosphorylation as a mechanism of Cdc7-Dbf4 regulation 
Data presented in this thesis suggest a role for phosphorylation of Thr376 of Cdc7 
in regulation of kinase activity. Analysis of Thr376 phosphorylation throughout the 
cell cycle was complicated by the inability to reproducibly detect the 
phosphorylated peptide by mass spectrometry without overexpressing Cdc7. In this 
study, a modest reduction in Thr376 phosphorylation was observed in S-phase 
synchronised cells relative to asynchronous (data not shown). Unfortunately, it was 
not possible to perform this experiment with endogenous Cdc7 due to the low 
efficiency of available antibodies for immunoprecipitation of Cdc7 from the cell. 
However, the conditional knockout cell line produced as part of this study offers the 
possibility to use efficient affinity tag antibodies to pull down stably expressed 
FLAG-Cdc7, which may allow for enough material to be obtained for successful 
analysis. A method has also been optimised by our mass spectrometry facility to 
facilitate reliable detection of the phosphorylated peptide. These experiments allow 
for analysis of the phosphorylation state of Thr376 throughout the cell, as well as in 
the context of various phosphatase knockouts to identify the key player in kinase 
regulation. The cell line presented in this study could also be used in conjunction 
with alanine substitution and phosphomimetic mutants of Thr376 to validate the 
possible roles of this modification in a physiological setting. 
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The identification of PP6 as a potential interactor is also an intriguing one, and 
future work should focus on recombinant expression of the complex to validate the 
interaction in vitro. Work in this study suggests that this is not possible in bacteria 
(data not shown) and expression will likely need to be performed in a eukaryotic 
system.  
 
7.3.3 Future functional characterisation of Cdc7-Dbf4 
The conditional Cdc7 knockout system presented here can be used in a number of 
ways to validate the importance of KI2 and KI3 in various cellular contexts, and will 
allow testing of an array of point and deletion mutants of Cdc7, and screen for 
potential loss of function in cell cycle or recovery from DNA damage response. 
Future work should therefore focus on detection of phenotypes in cells under 
genotoxic stress when supported by Cdc7 containing a deletion in an insert 
sequence. KI2 and KI3 could be important for interactions in the context of the intra 
S-phase checkpoint and this would be revealed using the presented system when 
cells have been treated with DNA damaging agents. Phosphoproteomics 
experiments could also be performed using the conditional knockout cell line 
complemented with various Cdc7 deletion mutants. Using stable isotope labelled 
amino acid culture (SILAC), it may be possible to accurately identify and quantify 
Cdc7 target sites, which are affected by KI2 and 3 deletions. This would not only 
give further clues as to the functional relevance of the insert sequences, but also 
could serve as a method for identifying binding partners of Cdc7 for future studies. 
One limitation of the current system was the overexpression of the mCherry-Cdc7 
construct. This meant that depletion of intracellular levels of the fusion protein took 
several days. This is theorised to be the possible cause of the G2/M accumulation 
of cells when supported by kinase dead mutants of Cdc7. The expected phenotype 
for HT1080 cells would be accumulation and cell death in S-phase due to the 
presence of functioning p53 (Ito et al., 2012). A quick way to confirm whether this 
phenotype is due to an unexpected change in the HT1080 cells or the slow 
reduction in mCherry-Cdc7 would be to treat the cells with a potent Cdc7 inhibitor 
(such as XL413) and see if a rapid inactivation gives a similar phenotype in the 
newly created cell line.To improve the efficiency of the mCherry-Cdc7 depletion, 
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the construct could also be tagged with a degron, which can be used to induce 
rapid degradation of the protein upon treatment with a small molecule such as 
auxin (Natsume et al., 2016).  
 
 
7.4 Final conclusions 
The data presented in this study provides previously unknown information about 
the structure and function of Cdc7-Dbf4. The structural bases of its activation and 
substrate recognition have been substantially clarified. Importance of the features 
revealed by the crystal structures have been validated in vitro and investigated in 
the context of the cell. However, a number of questions have been raised as part of 
this study, the biggest of which being the physiological roles of KI2 and KI3. While 
sequence conservation in theses inserts is limited, and there is little predicted 
secondary structure, the presence of such insert sequences across eukaryotes 
suggesting they fulfil important functions in the cell. The inducible Cdc7 knockout 
cell line produced as part of this study provides a tool to further dissect the roles of 
these inserts in the cell, as well as offering an avenue for identification of novel 
interactors and targets of Cdc7-Dbf4. The data presented here provides insights 
into the structural features required for Cdc7 activation and substrate recognition. 
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Chapter 8. Appendix 
Figure 8-1 Amino acid alignments of distal Cdc7 orthologs (pg172) 
The amino acid sequences were from Homo sapiens (mammalian), Gallus gallus (avian), Anolis carolinensis (reptile), Xenopus 
laevis (amphibian), Danio rerio (fish), Danaus plexippus (insect) and Saccharomyces cerevisiae (yeast). Secondary structure 
elements are indicated atop the alignment. Portions of the protein sequence not present in the crystallized construct are highlighted 
in gray (1–36, 228–345 and Δ467–533); the kinase insert sequences (black boxes). Invariant kinase residues are highlighted in red 
and labelled. Features discovered in this study are indicated with red boxes and labelled. Conserved amino acid residues are 
shown in bold print and those invariant within the alignment are highlighted in yellow (Adapted from Hughes et al. 2012) 
 
Figure 8-2 Amino acid alignments of the motifs-M and C of distal orthologs Dbf4 orthologs (pg173) 
(Adapted from Hughes et al., 2012) 
 
Figure 8-3 Amino acid sequence alignment of the M- and C-motifs of human Dbf4 and Drf1 (pg174) 
(Adapted from Hughes et al.). 
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                                                                                                                                  Hum 
                                                                                                                                  Hum 
                                                                                                                                  Hum 
                                                                                                                                  Hum 
                                                                                                                                  Hum 
   1       10        20        30        40        50        60        70                   80        90       100       110      
Mammal                                                  L    P          KIGEGTFSSVY                         A K    T  P RI  EL  L    G   Q V DI  Y  QL NVF I            LA L  L HLIP SH   AA  QC VAG DN...MEASLGIQMDEPMAFSP RDRFQAEGSLKKNEQNFKLAG KK EK EAV S K ED TAQ........... QVGPEEKI I T Q
Bird                                                   L    P          KIGEGTFSSVY                         A K    T  P RI  EL  L    G   E I DI  Y  QL NVF I            LA L  L HLIP SH   AA  QC VAG DN..........METESKSHCD QHPHQAEDTSRKHMQSSKLSG KK EK EAV V K KE TAQ........... QTGCEEKM L T Q
lizard                                                  L    P          KIGEGTFSSVY                         A K    T  P RI  EL  L    G   E DI  Y  QL N F I            LA  L HLIP SH   AA  QC VAG DN.............MEASHQI HPPLHGEDPCKKYSQNKKLSGAST EK EAV G L K KG VAQ...........GRGNQEEKV V I Q
frog                                                   L    P          KIGEGTFSSVY                         A K    T  P RI  EL  L    G   V EI  Y  QL NIF I            A L  L HLIP SH   AA  QC VAG DN..................................MSSGDNSG AK EK AAV H Y KS F IGR........... RSGEDAKF T S E
Fish                                                   L    P          KIGEGTFSSVY                         A K    T  P RI  EL  L    G   Q V EI  Y  QL IF I            LA M  L HLIP SH   AA  QC VAG EN.............MEEANTV RSSHRSVEKGR..SRHKISRD ET AY EVL SR R ID EAQ........... TDSSRRLF V T T
Insect                                                  L    P          KIGEGTFSSVY                         A K    T  P RI  EL  L    G   N QI   L IF V            L L   HLVP H     C G DMSRIRGIEAKVQKEIEENLE RRNKYKEVIKKKNDICTKVDSEKL VE LYKL K DK D HR GSLKQ.......HAQ PDDQKRWF I A A EH R QDI K Y
yeast                                                  L    P          KIGEGTFSSVY                         A K    T  P RI  EL  L    G   I E  Y  N Y            A  L  S      N  I  ............................MTSKTKNIDDIPPE KE MIQ HDL GIE E KLID K KDITGKITKKFASHFWNYGSNYV KIYV S Q YN L Y MT SSR
 120       130       140       150       160       170       180       190       200       210       220       230       240      
Mammal V       R         PY  H  F              Y   L  AL   H  G  HRD KP NFL         LVDFGLA                                               MGV CF DHVVI M  LE E  DI LSFQEV  M N K  I F IV   V  S   YNR L YA       QGT DTKIELLKKY KN A S L LNS RE L F KR Q R KK H FVQSEAQQERCSQNKSHIITGNKIPLSGPVPKEL
Bird  V       R         PY  H  F              Y   L  AL   H  G  HRD KP NFL         LVDFGLA                                               MGV CF DHVVIVM  LE E  DI LSFEEV  M N K  I F IV   V  S   YNR L YA       QGT DTKIELLKKY KN S L LNS KE F F RR H R KQ P TAHSEGQQGSYSQSNPNIALGNGVSVGVTAPKQI
lizard V       R         PY  H  F              Y   L  AL   H  G  HRD KP NFL         LVDFGLA                                               MGV CF DHVVIVM  LE E  DI LSFEEV  M N LK  I F IV   V  S   YN L YA       QGT ETKIELLKKC KN S L LNS RD F KR H QQ KQ P VIQSEAPQGSCTYTKPQITLGSQVSVTSTAPRHS
frog  V       R         PY  H  F              Y   L  AL   H  G  HRD KP NFL         LVDFGLA                                               MGV CF DHVVIVM  LE E  DI LSFEE  M N LK  I F IV   V  S   FNR L FA       QGT DTKIDLLKKY NK C A LHS TKE F RH S S KK S VLQP...............K..............
Fish  V       R         PY  H  F              Y   L  AL   H  G  HRD KP NFL         LVDFGLA                                               MGV CF HVVIVM  ME Q  DI LSFEDV   LK  I F II   I     FNR YA       QGT DT IELLKTY KEH T V VGL RH IYH KH K T QKRE P Q GLLS..............................
Insect V       R         PY  H  F              Y   L  AL   H  G  HRD KP NFL         LVDFGLA                                               GV C  D IV VM    E M EEV  M  L   V F VI   V  S   YDR Y        QI DL L HL T F IP RK S YVGD DA RC RA V RH S ENRR L RVVSDGPSPPVPPPAHAN...........................
yeast V       R         PY  H  F              Y   L  AL   H  G  HRD KP NFL         LVDFGLA                                                D VI VL   E  L I  E L   V  II   I     FN L        E D KAPLCDAK VR Q A YP E RTFYRD PIKG KK IW R KF SK T LE GRGV AQM Y SMISSQNDYDN............................
 250       260         270       280       290       300       310       320       330       340       350       360       370    
Mammal                                                                           R                                              R    A RAE K  M K LTCDCY D VC ICL  QV P  DQQSTTKASVKRPYTN..AQIQIKQGKDGKEGSVGLSVQRSVFGERNFNIHSSISH SPAVKLMKQS TVDVLS KLATKKKAISTKV NSAVMR TASSCPAS AT K S S RQ
Bird                                                                            R                                              R    A RAE K  K LTCNCY D VC VCL  QV P  AQQLASRATDKSSHSSSHSKIQIKQGRGGKEDSVHHSAQRSVFGERNFNIYCSTYQ NLNTKLIKQS MIDVSS KLITKKKIISTKAVNNGMGR AASGCPSN AT R S S CQ
lizard                                                                           R                                              R    A RAD K  L K LTCDCY D VC ICL  QV P  THQSATKTANKRPCSAS..QTQIKEGHKRKEGQECFAHQRSVFGERNFNVRSPAFQ RSTVKLVKQP VTDIPS KLSAKKKATST.. NNGLAK AASSCPAN AK R S S RQ
frog                                                                            R                                              R    A RAD K  K LTCDCY D VC ICL  QV P  ...KQ.........................DGLVGSSTQRSVFGERNFNVHSAVTI NTTLKAAKPS TIDVTT KLATRKTVSTKS.TSSAVPK AASTCQTS AK Q N A TR
Fish                                                                            R                                              R    A RAK  L LTCNCY D VC ICL  QV P  .........................................................KPKKEEVIPR IVSAKH SVPVRAPLNQKQK PAESQKPKPAAVNPL MT R N S KQ
Insect                                                                           R                                              R    A RAD  L K C C VC C   P  ...........................................SLKR.....PREE ENIQSEKRFALDLSTRS STSSAAQSPKKVS PKVQIS QKLPKVSPGV S SNAGS SP GA AAAR
yeast                                                                           R                                              R    A RA M K N     ..................................................YAN.TNHDGGYSMRNHEQFCPCIM NQYSPNSHNQTPP VTIQNG ....VVHLNNV GVDLTKGYPKNET RIKR N
   380       390       400       410       420       430       440       450             460       470       480       490        
Mammal GT GFRAPEVL K   Q    D W  G    S L  R       DD   L       G           G                   L      L                                   P         CP  TAI  SA VI L L S  YPFY A   L A AQIMTIR S ETIQAA F KSI CS D R LCE  RGT N T M F G K S T R KT L KEVPA......Q K R MDSSTPKLTSDIQGHASHQPAISEKTDHKAS
Bird  GT GFRAPEVL K   Q    D W  G    S L  R       DD   L       G           G                   L      L                                   P         CP  TAI  SA IV L L S  YPFY A   L A AQIMTVR S ETIQAA F KSV C N R LCE  RGT T T M F G K S T R KT L TQVVPA......Q T K TNGSCNRSHGDVPSKSGDESALPVEADKQCA
lizard GT GFRAPEVL K   Q    D W  G    S L  R       DD   L       G           G                   L      L                                   P         CP  TAI  SA II L L S  YPFY A   L A AQIMTIR S ETIQAA F KSI CS D R LCE  RGI H S I F D K G T R RT L KEIVA......Q K R NSTSFDNSTGDVQIKP.QESALPAEISNAFE
frog  GT GFRAPEVL K   Q    D W  G    S L  R       DD   L       G           G                   L      L                                   P         CP  TAI  SA II L L S  Y FF A   M A AQIMTIR S ETIQA F KSV CS D R LCE  RT H T M F G H N A N K SKC L KELPS......K T G SAIVLPNGNQHDIQKQR..AALQ.MRIMENQD
Fish  GT GFRAPEVL K   Q    D W  G    S L  R       DD   L       G           G                   L      L                                   P         CP  TAI  SA VI L L S  YPFF A   L A QIMTIR S ETIEAA F KSI CS D R LCE  RGT N G M L G K S I T K KT V RELPR......L I T .............LRSWDDASLPAEFQASHN
Insect GT GFR PEVL K   Q    D W  G    S L  R       DD   L       G           G                   L      L                                           P  AV  A VV  M  YPFF A   A AE  A  S  R L  RGQ P L S R GP T A LA TA R S AS LADLL TLPLQRT ASL RRMVT QPRRG......LC K AAR ..............GAP..PGPPPPALPACE
yeast GT GFRAPEVL K   Q    D W  G    S L  R       DD   L       G           G                   L      L                                            C  T I  S  VI L L  FP F    E TI  E A  S   R M GA S K I V L GR M QSL ADS L LC F WK LRKC ALH LGFEA GLIWDKPNGYSNG KEFVYD LN...........KECTIGTFPEYSVAFETFGF
500       510       520       530       540       550       560       570                                                          
Mammal                                                        P  R  A   L  P                                                             GWN VPDEAYDLLD LLDLN A  IT EA H FF DMCLVQTPPGQYSGNSFKKGDSNSCEHCFDEYNTNLE E K S E L K SL.................................
Bird                                                         P  R  A   L  P                                                             GWD VPDEAYDLLD LLDLN A  IT DA H FF DMPVTLRKEIQHLKSCQEDDGAS......ENKAADMK Q K T K L K RL.................................
lizard                                                        P  R  A   L  P                                                             GWD VPDEAYDLLD LLDLN A  IT DA H FF NMASLQGPQKHIHYQKQHHHGGDGRDVRITEKGADPK N K T K L R KQ.................................
frog                                                         P  R  A   L  P                                                             GWD VPNEAY LLD LLDMN A  IT EA H F NMGWFLPESPDITPDSPAVVRSSCVSTPDNMEQSNHN R H R T E I L K R..................................
Fish                                                         P  R  A   L  P                                                             GWD VPDE YDLLD LLDLN A  IT A H F DLPAEEKEE.....AESPALKSTGSRLCRSSAELKEI R V K T ST Q L K SE.................................
Insect                                                        P  R  A   L  P                                                             PDEAF L LLD D  T DA H F DHCHLPLPHCLCRDETVKATSITP.......N..LT.IAGF S AAR P RA A Q T LA ....................................
yeast                                                        P  R  A   L  P                                                             FQ LE EMD   D   FF ELLQQELHDRMSIEPQLPDPKTNMDAVDAYELKKYQEEIWSDHYWC V QCF QK SS E L KT N NENTYLLDGESTDEDDVVSSSEADLLDKDVLLISE
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 8-2 Amino acid alignments of the motifs-M and C of distal orthologs Dbf4 orthologs (pg173) 
 
                                                   human_MC   
    220       230       240         250            
human_MC       P     D      P                   P             K  FVKVE YR Y L N  S PFRL K MSQL F LQ TNMP.FI YS.IQK C ........ D
gallus_MC      P     D      P                   P             K  FVKVE YR Y L N  S PFRL N RSRS F LQ PSFP.SL YC.VPK C ........ E
Anolis_MC      P     D      P                   P             K  F KVE YR Y L N  S PFKL N L RRCH F IQ SSFP.VI YS.NPR C ........ D
Xlaevis_MC     P     D      P                   P             K  YIKVE YR Y L N  SKL S CSCQ L LV PQFRSFQ ...... V ......NYSVE
Daniorer_MC     P     D      P                   P              FVKVE YR Y L  S PFRIRR SSRH I LP SNMPVCNLRS..FP C ........ L
Scer_MC        P     D      P                   P             K  V   N  PFYF Y H YLY LWQTWA IITLEWKPQELT LDELPY ILKIGSFGRC I
                                                  human_MC   
    300       310       320        330       340  
human_MC   GYCE C  K   L  H  S  H  F          D                  C  YED E   EQ  Q S YQVV V D ELQ T LL RN A . NQ DI SKLVF FV YE
gallus_MC  GYCE C  K   L  H  S  H  F          D                  C  YED Q   EQ  Q S YQVV I E EGK T LE KN A . AQ DI SKFVY FV YK
Anolis_MC  GYCE C  K   L  H  S  H  F          D                  C  YDD Q   EQ  Q S YQVV I D ELK A VE QN A . LH DI SKVSC FL FR
Xlaevis_MC GYCE C  K   L  H  S  H  F          D                  C  YDD E   Q  E S YQVV I D DLK S IL P KN S . AY DL STFDF FV WS
Daniorer_MC GYCE C  K   L  H  S  H  F          D                  C  FEN   EQ  S Y VV D NEV KA LD QA SK. NE G RVTAGLTC LV IS
Scer_MC    GYCE C  K   L  H  S  H  F          D                    YE  E   E   E FE I I QN RV S Q IV K LS A NDLN A SL ENLRF I....
  
Mammal (H. sap. 214-254)
Avian (G. gal. 238-278)
Reptile (A. car. 218-258)
Amphibian (X. lae. 194-232)
Fish (D. rer. 209-249)
Yeast (S. cer. 260-310)
  
Mammal (H. sap. 294-342)
Avian (G. gal. 319-367)
Reptile (A. car. 298-346)
Amphibian (X. lae. 274-322)
Fish (D. rer. 292-340)
Yeast (S. cer. 659-704)
β1 β2
β3 β4 α1 α2 α3
Dbf4 Motif-
Dbf4 Motif-C
C296/299 H309/315
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Amino acid sequence alignment of the M- and C- motifs of human Dbf4 and Drf1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8-3 Amino acid sequence alignment of the M- and C-motifs of distal Dbf4 
orthologues 
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Table 8-1 Table of plasmids used for protein expression in E.coli. 
Plasmid Name Use/Description Reference 
pRSFDuet1 Vector for protein co-expression in E.coli Novagen 
pCDFDuet1 Vector for protein co-expression in E.coli Novagen 
pRSF-Cdc7 (ΔN) Expression of human Cdc7  (Δ1-36) Hughes et al. 2012 
pRSF-Cdc7 (ΔN/C345A) Expression of human Cdc7  (Δ1-36/C345A) This study 
pRSF-Cdc7 (ΔN/C351A) Expression of human Cdc7  (Δ1-36/C351A) This study 
pRSF-Cdc7 (ΔN/C353A) Expression of human Cdc7  (Δ1-36/C353A) This study 
pRSF-Cdc7 (ΔN/C360A) Expression of human Cdc7  (Δ1-36/C360A) This study 
pRSF-Cdc7 (ΔN/C363A) Expression of human Cdc7  (Δ1-36/C363A) This study 
pRSF-Cdc7 (ΔN/R373A) Expression of human Cdc7  (Δ1-36/R373A) This study 
pRSF-Cdc7 (ΔN/R380A) Expression of human Cdc7  (Δ1-36/R380A) This study 
pRSF-Cdc7 (ΔN/R373A/R380A) Expression of human Cdc7  (Δ1-36/C345A) This study 
pRSF-Cdc7 (ΔN/2n/3b) Expression of human Cdc7  (Δ1-36/ Δ228-343/ Δ484-529) Hughes et al. 2012 
pRSF-Cdc7 (ΔN/2o/3b) Expression of human Cdc7  (Δ1-36/ Δ228-349/ Δ484-529) Hughes et al. 2012 
pRSF-Cdc7 (ΔN/2q/3b) Expression of human Cdc7  (Δ1-36/ Δ228-359/ Δ484-529) Hughes et al. 2012 
pRSF-Cdc7 (ΔN/2z/3b) Expression of human Cdc7  (Δ1-36/ Δ228-305/ Δ484-529) Hughes et al. 2012 
pRSF-Cdc7 (ΔN/2ad/3b) Expression of human Cdc7  (Δ1-36/ Δ228-282/ Δ484-529) Hughes et al. 2012 
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pRSF-Cdc7 (ΔN/2ag/3b) Expression of human Cdc7  (Δ1-36/ Δ228-337/ Δ484-529) Hughes et al. 2012 
pRSF-Cdc7 (ΔN/2ah/3b) Expression of human Cdc7  (Δ1-36/ Δ228-275/ Δ484-529) Hughes et al. 2012 
pRSF-Cdc7 (ΔN/2ai/3b) Expression of human Cdc7  (Δ1-36/ Δ228-285/ Δ484-529) Hughes et al. 2012 
pRSF-Cdc7 (ΔN/2ak/3b) Expression of human Cdc7  (Δ1-36/ Δ228-295/ Δ484-529) This study 
pRSF-Cdc7 (ΔN/2al/3b) Expression of human Cdc7  (Δ1-36/ Δ231-285/ Δ484-529) This study 
pRSF-Cdc7 (ΔN/2am/3b) Expression of human Cdc7  (Δ1-36/ Δ231-382/ Δ484-529) This study 
pRSF-Cdc7 (ΔN/2an/3b) Expression of human Cdc7  (Δ1-36/ Δ228-288/ Δ484-529) This study 
pRSF-Cdc7 (ΔN/2ai/3c) Expression of human Cdc7  (Δ1-36/ Δ228-285/ Δ467-AGAG-532) This study 
pRSF-Cdc7 (ΔN/2o/3c) Expression of human Cdc7  (Δ1-36/ Δ228-349/ Δ467-AGAG-532) This study 
pRSF-Cdc7 (ΔN/2y/3c) Expression of human Cdc7  (Δ1-36/ Δ228-265/ Δ467-AGAG-532) This study 
pRSF-Cdc7 (ΔN/2z/3c) Expression of human Cdc7  (Δ1-36/ Δ228-305/ Δ467-AGAG-532) This study 
pRSF-Cdc7 (ΔN/2o/3d) Expression of human Cdc7  (Δ1-36/ Δ228-349/ Δ467-AGAGA-532) This study 
pRSF-Cdc7 (ΔN/2n/3e) Expression of human Cdc7  (Δ1-36/ Δ228-343/ Δ467-AGAG-533) This study 
pRSF-Cdc7 (ΔN/2o/3e) Expression of human Cdc7  (Δ1-36/ Δ228-349/ Δ467-AGAG-533) This study 
pRSF-Cdc7 (ΔN/2r/3e) Expression of human Cdc7  (Δ1-36/ Δ234-343/ Δ467-AGAG-533) This study 
pRSF-Cdc7 (ΔN/2ao/3e) Expression of human Cdc7  (Δ1-36/ Δ234-301/ Δ467-AGAG-533) This study 
pRSF-Cdc7 (ΔN/2ap/3e) Expression of human Cdc7  (Δ1-36/ Δ234-326/ Δ467-AGAG-533) This study 
pRSF-Cdc7 (ΔN/2aq/3e) Expression of human Cdc7  (Δ1-36/ Δ228-345/ Δ467-AGAG-533) This study 
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pRSF-Cdc7 (ΔN/2ar/3e) Expression of human Cdc7  (Δ1-36/ Δ228-347/ Δ467-AGAG-533) This study 
pRSF-Cdc7 (ΔN/2as/3e) Expression of human Cdc7  (Δ1-36/ Δ232-349/ Δ467-AGAG-533) This study 
pRSF-Cdc7 (ΔN/2at/3e) Expression of human Cdc7  (Δ1-36/ Δ230-349/ Δ467-AGAG-533) This study 
pRSF-Cdc7 (ΔN/2o/3f) Expression of human Cdc7  (Δ1-36/ Δ228-349/ Δ466-AGA-533) This study 
pCDF-His-Dbf4 (MC) Expression of human Dbf4 (210-350) with an N-terminal His6ttag Hughes et al. 2012 
pCDF-His-Dbf4 (MC2) Expression of human Dbf4 (214-344) with an N-terminal His6ttag This study 
pCDF-His-Drf1 (141-348) Expression of human Drf1 (141-348) with an N-terminal His6ttag This study 
pCDF-His-Drf1 (165-348) Expression of human Drf1 (165-348) with an N-terminal His6ttag This study 
pCDF-His-Drf1 (178-348) Expression of human Drf1 (178-348) with an N-terminal His6ttag This study 
pCDF-His-Drf1 (211-348) Expression of human Drf1 (211-348) with an N-terminal His6ttag This study 
pCDF-His-Drf1 (211-345) Expression of human Drf1 (211-345) with an N-terminal His6ttag This study 
pCDF-His-Drf1 (214-345) Expression of human Drf1 (214-345) with an N-terminal His6ttag This study 
pCDF-His-Drf1 (214-348) Expression of human Drf1 (214-348) with an N-terminal His6ttag This study 
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Table 8-2 Plasmids used for retrovirus and lentivirus production for expression in mammalian cells.. 
Plasmid Name Use/Description Reference 
pWPT-GFP Lentiviral vector expressing GFP Addgene ♯1225 
Didier Trono 
pBABE (puro) Retroviral vector Morgensten et al. 
(1990) 
pWZL (hygro) Retroviral vector Addgene plasmid 
#18750 Scott Lowe 
pCG-GagPol Retroviral packaging vector. Ulm et al. 2007 
p8.2 Lentiviral packaging vector Naldini et al. 1996 
pMD.G Lentiviral envelope vector Zufferey et al. 
1997 
pX459 Mammalian expression vector for CRISPR/Cas9  Addgene ♯62988 
Feng Zhang 
pQ-FLAG-Cdc7 Retroviral vector used for stable expression of human Cdc7 with an N-
terminal FLAG tag 
Hughes et al.  
pWPT-mCherry-Cdc7 Lentiviral vector for stable expression of human Cdc7 with an N-
terminal mCherry fusion. 
This study 
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pBABE-FLAG-Cdc7 (WT) Retroviral vector for stable expression of human Cdc7 with an N-
terminal FLAG tag 
This study 
pBABE-FLAG-Cdc7 (D196N) Retroviral vector for stable expression of human Cdc7 (D196N) with 
an N-terminal FLAG tag 
This study 
pBABE-FLAG-Cdc7 (C353A) Retroviral vector for stable expression of human Cdc7 (C353A) with 
an N-terminal FLAG tag 
This study 
pBABE-FLAG-Cdc7 (C360A) Retroviral vector for stable expression of human Cdc7 (C360A) with 
an N-terminal FLAG tag 
This study 
pBABE-FLAG-Cdc7 (R380A) Retroviral vector for stable expression of human Cdc7 (R380A) with 
an N-terminal FLAG tag 
This study 
pBABE-FLAG-Cdc7 (R373A/R380A) Retroviral vector for stable expression of human Cdc7 
(R373A/R380A) with an N-terminal FLAG tag 
This study 
pBABE-FLAG-Cdc7 (Δ2aq) Retroviral vector for stable expression of human Cdc7 (Δ2aq) with an 
N-terminal FLAG tag 
This study 
pBABE-FLAG-Cdc7 (Δ2aq/3e) Retroviral vector for stable expression of human Cdc7 (Δ2aq/3e) with 
an N-terminal FLAG tag 
This study 
pWZL-FLAG-Cdc7 (Δ2aq) Retroviral vector for stable expression of human Cdc7 (Δ2aq) with an 
N-terminal FLAG tag 
This study 
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pWZL-FLAG-Cdc7 (Δ2aq/3e) Retroviral vector for stable expression of human Cdc7 (Δ2aq/3e) with 
an N-terminal FLAG tag 
This study 
 
pBABE-FLAG-Cdc7 (Δ2aq/Kz1) 
 
Retroviral vector for stable expression of human Cdc7 (Δ2aq) with an 
N-terminal FLAG tag and a single point mutation in the Kozak 
consensus sequence. 
 
This study 
pBABE-FLAG-Cdc7 (Δ2aq/Kz2) Retroviral vector for stable expression of human Cdc7 (Δ2aq) with an 
N-terminal FLAG tag and a double point mutation in the Kozak 
consensus sequence. 
This study 
pBABE-FLAG-Cdc7 (Δ2aq/3e/Kz1) Retroviral vector for stable expression of human Cdc7 (Δ2aq/3e) with 
an N-terminal FLAG tag and a single point mutation in the Kozak 
consensus sequence. 
This study 
pBABE-FLAG-Cdc7 (Δ2aq/3e/Kz2) Retroviral vector for stable expression of human Cdc7 (Δ2aq/3e) with 
an N-terminal FLAG tag and a double point mutation in the Kozak 
consensus sequence. 
This study 
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Table 8-3 Cell lines produced and used as part of this study. 
Cell Line Name Description Reference 
HT1080 mCherry-Cdc7(LoxP) HT1080 cells stably expressing human Cdc7 with an N-terminal mCherry 
fusion with LoxP site. 
This study 
HT1080 CDC7(-/-) mCherry-
Cdc7(LoxP) 
HT1080 (Cdc7-/-) cells stably expressing human Cdc7 with an N-terminal 
mCherry fusion with LoxP site. 
This study 
HT1080 CDC7(-/-) mCherry-
Cdc7(LoxP) + FLAG-Cdc7 
HT1080 (Cdc7-/-) cells stably expressing human Cdc7 with an N-terminal 
mCherry fusion with LoxP site and FLAG-Cdc7. 
This study 
HT1080 CDC7(-/-) mCherry-
Cdc7(LoxP) + FLAG-Cdc7 (D196N) 
HT1080 (Cdc7-/-) cells stably expressing human Cdc7 with an N-terminal 
mCherry fusion with LoxP site and FLAG-Cdc7 (D196N) 
This study 
HT1080 CDC7(-/-) mCherry-
Cdc7(LoxP) + FLAG-Cdc7 (C353A) 
HT1080 (Cdc7-/-) cells stably expressing human Cdc7 with an N-terminal 
mCherry fusion with LoxP site and FLAG-Cdc7 (C353A). 
This study 
HT1080 CDC7(-/-) mCherry-
Cdc7(LoxP) + FLAG-Cdc7 (R373A) 
HT1080 (Cdc7-/-) cells stably expressing human Cdc7 with an N-terminal 
mCherry fusion with LoxP site and FLAG-Cdc7 (R373A). 
This study 
HT1080 CDC7(-/-) mCherry-
Cdc7(LoxP) + FLAG-Cdc7 
(R373A/R380A) 
HT1080 (Cdc7-/-) cells stably expressing human Cdc7 with an N-terminal 
mCherry fusion with LoxP site and FLAG-Cdc7 (R373A/R380A). 
This study 
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HT1080 CDC7(-/-) mCherry-
Cdc7(LoxP) + FLAG-Cdc7 (Δ2aq) 
(pBABE) 
HT1080 (Cdc7-/-) cells stably expressing human Cdc7 with an N-terminal 
mCherry fusion with LoxP site and FLAG-Cdc7 (Δ2aq). 
This study 
 
HT1080 CDC7(-/-) mCherry-
Cdc7(LoxP) + FLAG-Cdc7 (Δ2aq/3e) 
(pBABE) 
 
HT1080 (Cdc7-/-) cells stably expressing human Cdc7 with an N-terminal 
mCherry fusion with LoxP site and FLAG-Cdc7 (Δ2aq/3e). 
 
This study 
HT1080 CDC7(-/-) mCherry-
Cdc7(LoxP) + FLAG-Cdc7 (Δ2aq) 
(pBABE/Kz1) 
HT1080 (Cdc7-/-) cells stably expressing human Cdc7 with an N-terminal 
mCherry fusion with LoxP site and FLAG-Cdc7 (Δ2aq) with a single point 
mutation in the Kozak consensus sequence. 
This study 
HT1080 CDC7(-/-) mCherry-
Cdc7(LoxP) + FLAG-Cdc7 (Δ2aq) 
(pBABE/Kz2) 
HT1080 (Cdc7-/-) cells stably expressing human Cdc7 with an N-terminal 
mCherry fusion with LoxP site and FLAG-Cdc7 (Δ2aq) with a double point 
mutation in the Kozak consensus sequence. 
This study 
HT1080 CDC7(-/-) mCherry-
Cdc7(LoxP) + FLAG-Cdc7 (Δ2aq/3e) 
(pBABE/Kz1) 
HT1080 (Cdc7-/-) cells stably expressing human Cdc7 with an N-terminal 
mCherry fusion with LoxP site and FLAG-Cdc7 (Δ2aq/3e) with a single point 
mutation in the Kozak consensus sequence. 
This study 
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HT1080 CDC7(-/-) mCherry-
Cdc7(LoxP) + FLAG-Cdc7 (Δ2aq/3e) 
(pBABE/Kz2) 
HT1080 (Cdc7-/-) cells stably expressing human Cdc7 with an N-terminal 
mCherry fusion with LoxP site and FLAG-Cdc7 (Δ2aq/3e) with a double point 
mutation in the Kozak consensus sequence. 
This study 
HT1080 CDC7(-/-) mCherry-
Cdc7(LoxP) + FLAG-Cdc7 (Δ2aq) 
(pWZL) 
HT1080 (Cdc7-/-) cells stably expressing human Cdc7 with an N-terminal 
mCherry fusion with LoxP site and FLAG-Cdc7 (Δ2aq) 
This study 
HT1080 CDC7(-/-) mCherry-
Cdc7(LoxP) + FLAG-Cdc7 (Δ2aq/3e) 
(pWZL) 
HT1080 (Cdc7-/-) cells stably expressing human Cdc7 with an N-terminal 
mCherry fusion with LoxP site and FLAG-Cdc7 (Δ2aq/3e)  
This study 
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Table 8-4 Oligos used in this study. 
Oligo Sequence 5’-3’ Description Restriction 
site 
Reference 
SH78 GCCAGCCCATGGGACTTGCAGGTGTTAAAAAAGATATTG pRSF-Cdc7 (Δ1-36) 
construction 
NcoI Hughes et al. 
(2012) 
SH81 GGAGCCTCGAGTCACAAGCTCATATCTTTAAAAAATGGATGC 
 
pRSF-Cdc7 (C-terminus) XhoI Hughes et al. 
(2012) 
SD1 GAAAACTGCCAGTTCTGCCCCAGCTAGCCTGAC Cdc7 C345A mutation n/a This study 
SD2 GTCAGGCTAGCTGGGGCAGAACTGGCAGTTTTC Cdc7 C345A mutation n/a This study 
SD3 CAGCTAGCCTGACCGCTGACTGCTATGCAAC Cdc7 C351A mutation n/a This study 
SD4 GTTGCATAGCAGTCAGCGGTCAGGCTAGCTG Cdc7 C351A mutation n/a This study 
SD5 CTAGCCTGACCTGTGACGCCTATGCAACAGATAAAG Cdc7 C353A mutation n/a This study 
SD6 CTTTATCTGTTGCATAGGCGTCACAGGTCAGGCTAG Cdc7 C353A mutation n/a This study 
SD11 CTATGCAACAGATAAAGTTGCCAGTATTTGCCTTTCAAGGCG Cdc7 C360A mutation n/a This study 
SD12 CGCCTTGAAAGGCAAATACTGGCAACTTTATCTGTTGCATAG Cdc7 C360A mutation n/a This study 
SD13 GATAAAGTTTGTAGTATTGCCCTTTCAAGGCGTCAGC Cdc7 C363A mutation n/a This study 
SD14 GCTGACGCCTTGAAAGGGCAATACTACAAACTTTATC Cdc7 C363A mutation n/a This study 
SD84 TCAGCAGGTTGCCCCTGCAGCAGGTACACCAGGAT Cdc7 R373A mutation n/a This study 
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SD85 ATCCTGGTGTACCTGCTGCAGGGGCAACCTGCTGA Cdc7 R373A mutation n/a This study 
SD86 GTACACCAGGATTCGCAGCACCAGAGGTC Cdc7 R380A mutation n/a This study 
SD87 GACCTCTGGTGCTGCGAATCCTGGTGTAC Cdc7 R380A mutation n/a This study 
SH119 GGTGTTCACAAAACAAATCTTGCCCAGCTAGCCTG Cdc7 2n deletion n/a This study 
SH120 CAGGCTAGCTGGGCAAGATTTGTTTTGTGAACACC Cdc7 2n deletion n/a This study 
SH121 GGTGTTCACAAAACAAAACCTGTGACTGCTATGC Cdc7 2o deletion n/a This study 
SH122 GCATAGCAGTCACAGGTTTTGTTTTGTGAACACC Cdc7 2o deletion n/a This study 
SH125 GGTGTTCACAAAACAAATGTAGTATTTGCCTTTCAAG Cdc7 2q deletion n/a This study 
SH126 CTTGAAAGGCAAATACTACATTTGTTTTGTGAACACC Cdc7 2q deletion n/a This study 
SH141 GGTGTTCACAAAACAAACAGATTAAACAAGGAAAAG Cdc7 2y deletion n/a This study 
SH142 CTTTTCCTTGTTTAATCTGTTTGTTTTGTGAACACC Cdc7 2y deletion n/a This study 
SH127 CCCACATAATCACAGGATCTTGCCCAGCTAGCCTG Cdc7 2r deletion n/a This study 
SH128 CAGGCTAGCTGGGCAAGATCCTGTGATTATGTGGG Cdc7 2r deletion n/a This study 
SH159 GGTGTTCACAAAACAAAAAACTCATGAAGCAGTC Cdc7 2z deletion n/a This study 
SH160 GACTGCTTCATGAGTTTTTTGTTTTGTGAACACC Cdc7 2z deletion n/a This study 
SH197 GGTGTTCACAAAACAAACAGCGCTCTGTTTTTGG Cdc7 2ad deletion n/a This study 
SH198 CCAAAAACAGAGCGCTGTTTGTTTTGTGAACACC Cdc7 2ad deletion n/a This study 
SH203 GGTGTTCACAAAACAAAATGAGGAAAACTGCCAG Cdc7 2ag deletion n/a This study 
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SH204 CTGGCAGTTTTCCTCATTTTGTTTTGTGAACACC Cdc7 2ag deletion n/a This study 
SH205 GGTGTTCACAAAACAAAGGATCTGTAGGCCTTTCTG Cdc7 2ah deletion n/a This study 
SH206 CAGAAAGGCCTACAGATCCTTTGTTTTGTGAACACC Cdc7 2ah deletion n/a This study 
SH207 GGTGTTCACAAAACAAAGTTTTTGGAGAAAGAAATTTC Cdc7 2ai deletion n/a This study 
SH208 GAAATTTCTTTCTCCAAAAACTTTGTTTTGTGAACACC Cdc7 2ai deletion n/a This study 
SH209 GGTGTTCACAAAACAAAAGCTCCATTTCACATGAG Cdc7 2ak deletion n/a This study 
SH210 CTCATGTGAAATGGAGCTTTTGTTTTGTGAACACC Cdc7 2ak deletion n/a This study 
PC795 GTGTTCACAAAACAAATCCCACATAGTTTTTGGAGAAAGAAATTT
CAATATAC 
Cdc7 2al deletion n/a This study 
PC796 GTATATTGAAATTTCTTTCTCCAAAAACTATGTGGGATTTGTTTTG
TGAACAC 
Cdc7 2al deletion n/a This study 
PC797 GTGTTCACAAAACAAATCCCACATACAGCGCTCTGTTTTTGGA Cdc7 2am deletion n/a This study 
PC798 GTGTTCACAAAACAAATCCCACATACAGCGCTCTGTTTTTGGA Cdc7 2am deletion n/a This study 
PC799 GGTGTTCACAAAACAAAGAAAGAAATTTCAATATACAC Cdc7 2an deletion n/a This study 
PC800 GTGTATATTGAAATTTCTTTCTTTGTTTTGTGAACACC Cdc7 2an deletion n/a This study 
SD34 CACATAATCACAGGAAACAGCCCTGCAGTGAAAC Cdc7 2ao deletion n/a This study 
SD35 GTTTCACTGCAGGGCTGTTTCCTGTGATTATGTG Cdc7 2ao deletion n/a This study 
SD36 CACATAATCACAGGAAACGCTATTTCTACAAAAG Cdc7 2ap deletion n/a This study 
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SD37 CTTTTGTAGAAATAGCGTTTCCTGTGATTATGTG Cdc7 2ap deletion n/a This study 
SD45 GGTGTTCACAAAACAAACCAGCTAGCCTGACCTGTGACTGCT Cdc7 2aq deletion n/a This study 
SD46 AGCAGTCACAGGTCAGGCTAGCTGGTTTGTTTTGTGAACACC Cdc7 2aq deletion n/a This study 
SD47 GGTGTTCACAAAACAAAAGCCTGACCTGTGACTGCTATGC Cdc7 2ar deletion n/a This study 
 
SD48 
 
GCATAGCAGTCACAGGTCAGGCTTTTGTTTTGTGAACACC 
 
Cdc7 2ar deletion 
 
n/a 
 
This study 
SD49 TGTTCACAAAACAAATCCCACATAATCACCTGTGACTGCTATGCA Cdc7 2as deletion n/a This study 
SD50 TGCATAGCAGTCACAGGTGATTATGTGGGATTTGTTTTGTGAAC Cdc7 2as deletion n/a This study 
SD51 GTGTTCACAAAACAAATCCCACACCTGTGACTGCTATGCA Cdc7 2at deletion n/a This study 
SD52 TGCATAGCAGTCACAGGTGTGGGATTTGTTTTGTGAACAC Cdc7 2at deletion n/a This study 
SH62 GATATACAAGGGCATGCTACCAATTTAGAAGGCTGG Cdc7 3b deletion n/a This study 
SH63 CCAGCCTTCTAAATTGGTAGCATGCCCTTGTATATC Cdc7 3b deletion n/a This study 
SD7 TGTGAGAGACTCAGGGGTGCAGGTGCAGGTGAAGGCTGGAAT
GAGGTA 
Cdc7 3c deletion n/a This study 
SD8 TACCTCATTCCAGCCTTCACCTGCACCTGCACCCCTGAGTCTCT
CACA 
Cdc7 3c deletion n/a This study 
SD9 GAGAGACTCAGGGGTGCAGGTGCAGGTGCAGAAGGCTGGAAT
GAGGTA 
Cdc7 3d deletion n/a This study 
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SD10 TACCTCATTCCAGCCTTCTGCACCTGCACCTGCACCCCTGAGTC
TCTC 
Cdc7 3d deletion n/a This study 
SD21 GAGAGACTCAGGGGTGCAGGTGCAGGTGGCTGGAATGAGGTA Cdc7 3e deletion n/a This study 
SD22 TACCTCATTCCAGCCACCTGCACCTGCACCCCTGAGTCTCT Cdc7 3e deletion n/a This study 
SD23 TGTGAGAGACTCAGGGCAGGTGCAGGCTGGAATGAGGTACCT Cdc7 3f deletion n/a This study 
SD24 AGGTACCTCATTCCAGCCTGCACCTGCCCTGAGTCTCTCACA Cdc7 3f deletion n/a This study 
SH178 GGAC CCCGGG ACAAGAACAGGAAGACTCAAAAAGCC pCDF-His-Dbf4 210-> XmaI/SmaI This study 
SH44 GGTC CTCGAG CTATCTTTTCTTTTTAGGTGTGTCCTTTTC pCDF-His-Dbf4 ->350 XhoI This study 
SD25 GGACCCCGGGAGACTCAAAAAGCCTTTTGTAAAGG pCDF-His-Dbf4 214-> XmaI/SmaI This study 
SD20 GGTCCTCGAGCTAGTCCTTTTCATATTCCACAAAGTC pCDF-His-Dbf4 ->344 XhoI This study 
SD109 GGACCCCGGGCCTCTAAGCAGAGGGAAGGAGCTGCTGCA pCDF-His-Drf1 141-> XmaI/SmaI This study 
SD165 GGACCCCGGGGGGGGCAGCAGCAGCCTCCTGACCAATG pCDF-His-Drf1 165-> XmaI/SmaI This study 
SD141 GGACCCCGGGGGAGTGAGGATTCTGCACGT pCDF-His-Drf1 178-> XmaI/SmaI This study 
SD107 GGACCCCGGGGGAACATGTCCAGCAGCAGAGTCAAGAAC pCDF-His-Drf1 211-> XmaI/SmaI This study 
SD142 GGACCCCGGGCCAGCAGCAGAGTCAAGAACACGGA pCDF-His-Drf1 214-> XmaI/SmaI This study 
SD143 GGTCCTCGAGTGCAAAGCTGTGGCTGAGCTGAGCA pCDF-His-Drf1 ->345 XhoI This study 
SD110 GGTCCTCGAGAGGGATGTCTGCAAAGCTGTGGCT pCDF-His-Drf1 ->348 XhoI This study 
SD38 GGCGACGCGTCGCCACCATGGTGAGCAAGGGCGAGGAGGATA pWPT-mCherry-Cdc7 N- MluI This study 
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terminus 
SD16 TGAATACCCAGGCTTGCTTCCTTGTACAGCTCGTCCATGCCGCC 
 
mCherry C-terminus with 
codon optimised Cdc7 
overhang for fusion PCR 
n/a This study 
SD17 ATGGACGAGCTGTACAAGGAAGCAAGCCTGGGTATTCAGA 
 
Codon optimised Cdc7 N-
terminus with mCherry 
overhang for Fusion PCR 
n/a This study 
SD31 GGCGGTCGACTTACAGGCTCATATCTTTGAAAAACGG 
 
pWPT-mCherry-Cdc7 C-
terminus 
SalI This study 
SD105 GAC TACGTA CGCACCATGGATTACAAGGATGACG 
 
pBABE-Flag-Cdc7 N-terminus SnaBI This Study 
SD96 GGAC GTCGAC TCACAAGCTCATATCTTTAAAAA 
 
pBABE-FLAG-Cdc7 C-
terminus 
SalI This study 
SD150 GAC TACGTA ATGGAGGCGTCTTTGGGG 
 
pWZL-FLAG-Cdc7 N-terminus SnaBI This Study 
SD147 CTCACAAGCTCATATCTTTAAAAAATGGATG 
 
pWZL-FLAG-Cdc7 N-terminus BamHI This Study 
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Table 8-5 Peptides used in in vitro kinase assays 
Peptide Name Residues Modifications Use 
Mcm2-S40-assay Mcm2 35-47 N-terminal biotin, S41p Kinase assays for crystallography constructs (Hughes et al. 
2012) 
Mcm2-S40(15) Mcm2 33-47 N-terminal biotin, S41p Kinase assays for point mutants of the P+4 residue (positive 
control) 
Mcm2-S40(15)NoP Mcm2 33-47 N-terminal biotin Kinase assays for point mutants of the P+4 residue (no pre-
phosphorylation of S41) 
Mcm2-S40(15) R44A Mcm2 33-47 N-terminal biotin, S41p, R44A Kinase assays for point mutants of the P+4 residue 
Mcm2-S40(15) R44E Mcm2 33-47 N-terminal biotin, S41p, R44E Kinase assays for point mutants of the P+4 residue 
Mcm2-S40(15) R44K Mcm2 33-47 N-terminal biotin, S41p, R44K Kinase assays for point mutants of the P+4 residue 
Mcm2-S40(15) R44L Mcm2 33-47 N-terminal biotin, S41p, R44L Kinase assays for point mutants of the P+4 residue 
Mcm2-S40(15) R44F Mcm2 33-47 N-terminal biotin, S41p, R44F Kinase assays for point mutants of the P+4 residue 
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